-- Data for Name: population; Type: TABLE DATA; Schema: cpic; Owner: -
--

COPY cpic.population (id, publicationid, ethnicity, population, populationinfo, subjecttype, subjectcount, version) FROM stdin;
6721027	\N	African American/Afro-Caribbean	African American	https://uswest.ensembl.org/Homo_sapiens/Variation/Population?r=4:88130671-88131671;v=rs2231142;vdb=variation;vf=91592418#population_freq_AFR	1000 Genomes phase 3 ASW population	61	1
6721028	\N	African American/Afro-Caribbean	Afro-Caribbean	https://uswest.ensembl.org/Homo_sapiens/Variation/Population?r=4:88130671-88131671;v=rs2231142;vdb=variation;vf=91592418#population_freq_AFR	1000 Genomes phase 3 ASW population	96	1
6721029	1552823	American	American Indian	from Oklahoma center	\N	850	1
6721030	\N	Central/South Asian	South Asian	from http://gnomad.broadinstitute.org, accessed 06/15/2021	\N	15305	1
6721031	\N	East Asian	East Asian	from http://gnomad.broadinstitute.org, accessed 06/15/2021	\N	9965	1
6721032	\N	European	Non-Finnish	from http://gnomad.broadinstitute.org, accessed 06/15/2021	\N	64463	1
6721033	\N	Latino	Latino	from http://gnomad.broadinstitute.org, accessed 06/15/2021	\N	17710	1
6721034	\N	Near Eastern	Ashkenazi Jewish	from http://gnomad.broadinstitute.org, accessed 06/15/2021	\N	5182	1
6721035	1552830	Oceanian	Maori people controls	\N	\N	212	1
6721036	1552830	Oceanian	Maori people with gout	\N	\N	178	1
6721037	1552830	Oceanian	Pacific Islanders controls	\N	\N	109	1
6721038	1552830	Oceanian	Pacific Islanders with gout	\N	\N	173	1
6721039	\N	Sub-Saharan African	Esan in Nigeria	https://uswest.ensembl.org/Homo_sapiens/Variation/Population?r=4:88130671-88131671;v=rs2231142;vdb=variation;vf=91592418#population_freq_AFR	1000 Genomes phase 3 ASW population	108	1
6721040	\N	Sub-Saharan African	Luhya in Webuye, Kenya	https://uswest.ensembl.org/Homo_sapiens/Variation/Population?r=4:88130671-88131671;v=rs2231142;vdb=variation;vf=91592418#population_freq_AFR	1000 Genomes phase 3 ASW population	99	1
6721041	\N	Sub-Saharan African	Mandinka in the Gambia	https://uswest.ensembl.org/Homo_sapiens/Variation/Population?r=4:88130671-88131671;v=rs2231142;vdb=variation;vf=91592418#population_freq_AFR	1000 Genomes phase 3 ASW population	113	1
6721042	\N	Sub-Saharan African	Mende in Sierra Leone	https://uswest.ensembl.org/Homo_sapiens/Variation/Population?r=4:88130671-88131671;v=rs2231142;vdb=variation;vf=91592418#population_freq_AFR	1000 Genomes phase 3 ASW population	85	1
6721043	\N	Sub-Saharan African	Yoruba in Ibadan, Nigeria	https://uswest.ensembl.org/Homo_sapiens/Variation/Population?r=4:88130671-88131671;v=rs2231142;vdb=variation;vf=91592418#population_freq_AFR	1000 Genomes phase 3 ASW population	108	1
6721044	\N	Central/South Asian	South Asian	from http://gnomad.broadinstitute.org, accessed 10-22-2019	\N	15305	1
6721045	\N	Central/South Asian	South Asian	from http://gnomad.broadinstitute.org, accessed 10-22-2019	\N	15308	1
6721046	\N	East Asian	East Asian	from http://gnomad.broadinstitute.org, accessed 10-22-2019	\N	9197	1
6721047	\N	European	European (non-Finnish)	from http://gnomad.broadinstitute.org, accessed 10-22-2019	\N	56838	1
6721048	\N	European	European (Finnish)	from http://gnomad.broadinstitute.org, accessed 10-22-2019	\N	10820	1
6721049	\N	European	European (non-Finnish)	from http://gnomad.broadinstitute.org, accessed 10-22-2019	\N	56858	1
6721050	\N	European	European (Finnish)	from http://gnomad.broadinstitute.org, accessed 10-22-2019	\N	10824	1
6721051	\N	Latino	Latino	from http://gnomad.broadinstitute.org, accessed 10-22-2019	\N	17293	1
6721052	\N	Latino	Latino	from http://gnomad.broadinstitute.org, accessed 10-22-2019	\N	17296	1
6721053	\N	Near Eastern	Ashkenazi Jewish	from http://gnomad.broadinstitute.org, accessed 10-22-2019	\N	5037	1
6721054	\N	Near Eastern	Ashkenazi Jewish	from http://gnomad.broadinstitute.org, accessed 10-22-2019	\N	5039	1
6721055	116362	African American/Afro-Caribbean	African-American	1000 Genomes	random blood donor	85	1
6721056	116362	African American/Afro-Caribbean	African Ancestry from southwest USA	1000 Genomes	random blood donor	24	1
6721057	116365	African American/Afro-Caribbean	African, African American	AIDS Clinical Trial Group protocols 384, A5095, A5097	\N	282	1
6721058	116367	African American/Afro-Caribbean	African-American	\N	\N	70	1
6721059	116369	African American/Afro-Caribbean	African Colombian	\N	\N	27	1
6721060	\N	African American/Afro-Caribbean	African-American	ASW	1000 genomes	61	1
6721061	113537	Central/South Asian	Gujarati Indian from Houston, Texas	GIH	1000 Genomes	103	1
6721062	113537	Central/South Asian	Punjabi from Lahore, Pakistan	PJL	1000 Genomes	96	1
6721063	113537	Central/South Asian	Bengali from Bangladesh	BEB	1000 Genomes	86	1
6721064	113537	Central/South Asian	Sri Lankan Tamil from the UK	STU	1000 Genomes	102	1
6721065	113537	Central/South Asian	Indian Telugu from the UK	ITU	1000 Genomes	102	1
6721066	116377	Central/South Asian	south asia	\N	gnomAD exomes	11485	1
6721067	116379	Central/South Asian	Indians	\N	\N	63	1
6721068	113537	East Asian	Han Chinese in Bejing, China	CHB	1000 Genomes	103	1
6721069	113537	East Asian	Japanese in Tokyo, Japan	JPT	1000 Genomes	104	1
6721070	113537	East Asian	Southern Han Chinese	CHS	1000 Genomes	105	1
6721071	113537	East Asian	Chinese Dai in Xishuangbanna, China	CDX	1000 Genomes	93	1
6721072	113537	East Asian	Kinh in Ho Chi Minh City, Vietnam	KHV	1000 Genomes	99	1
6721073	116362	East Asian	Han Chinsese from Beijing	1000 Genomes	random blood donor	68	1
6721074	116362	East Asian	Han Chinese from south China	1000 Genomes	random blood donor	25	1
6721075	116362	East Asian	Japanese from Tokyo (Japan)	1000 Genomes	random blood donor	84	1
6721076	116367	East Asian	Japanese	\N	\N	50	1
6721077	116367	East Asian	Taiwanese	\N	\N	68	1
6721078	116367	East Asian	Korean	\N	\N	88	1
6721079	116379	East Asian	Chinese	\N	\N	165	1
6721080	116367	East Asian	Japanese	\N	\N	90	1
6721081	116367	East Asian	Taiwanese	\N	\N	92	1
6721082	116367	East Asian	Korean	\N	\N	96	1
6721083	116396	East Asian	Chinese	\N	\N	386	1
6721084	114023	East Asian	Japanese	\N	\N	530	1
6721085	116379	East Asian	Malay	\N	\N	196	1
6721086	113537	European	Utah Residents (CEPH) with Northern and Western Ancestry	CEU	1000 Genomes	99	1
6721087	113537	European	Toscani in Italia	TSI	1000 Genomes	107	1
6721088	113537	European	Finnish in Finland	FIN	1000 Genomes	99	1
6721089	113537	European	British in England and Scotland	GBR	1000 Genomes	91	1
6721090	113537	European	Iberian Population in Spain	IBS	1000 Genomes	107	1
6721091	116362	European	European-American	1000 Genomes	random blood donor	59	1
6721092	116362	European	Northern and Western European from UT (USA)	1000 Genomes	random blood donor	90	1
6721093	116362	European	Toscani from Italy	1000 Genomes	random blood donor	92	1
6721094	116362	European	Bristish from England and Scotland	1000 Genomes	random blood donor	43	1
6721095	116362	European	Finnish	1000 Genomes	random blood donor	36	1
6721096	116365	European	Caucasian	AIDS Clinical Trial Group protocols 384, A5095, A5097	\N	399	1
6721097	116411	European	White	\N	HIV positive	141	1
6721098	116367	European	Caucasian	\N	\N	430	1
6721099	116414	European	Caucasian	\N	\N	255	1
6721100	116416	European	Spaniard	\N	\N	180	1
6721101	116377	European	Finnish	\N	\N	11138	1
6721102	116377	European	non-Finnish	\N	\N	55856	1
6721103	116420	European	Caucasian	\N	British healthy volunteer	135	1
6721104	116422	European	Caucasian	\N	\N	215	1
6721105	113537	Latino	Mexican Ancestry from Los Angeles USA	MXL	1000 Genomes	64	1
6721106	113537	Latino	Puerto Ricans from Puerto Rico	PUR	1000 Genomes	104	1
6721107	113537	Latino	Colombians from Medellin, Colombia	CLM	1000 Genomes	94	1
6721108	113537	Latino	Peruvians from Lima, Peru	PEL	1000 Genomes	85	1
6721109	116362	Latino	Mexican ancestry from Los Angeles (CA, USA)	1000 Genomes	random blood donor	17	1
6721110	116362	Latino	Puerto Rican from Puerto Rico (USA)	1000 Genomes	random blood donor	5	1
6721111	116365	Latino	Hispanic	AIDS Clinical Trial Group protocols 384, A5095, A5097	\N	150	1
6721112	116411	Latino	Hispanic-American	\N	HIV positive	7	1
6721113	\N	Latino	Latino	\N	gnomAD exomes	13686	1
6721114	116416	Latino	Central American mestizos	\N	\N	181	1
6721115	116369	Latino	Colombian mestizo individuals	\N	\N	125	1
6721116	116435	Near Eastern	Iranian Baluchi	Sistan and Baluchistan Province, Iran	healthy, unrelated, subjects	206	1
6721117	116437	Oceanian	Papua New Guinean	\N	\N	174	1
6721118	113537	Sub-Saharan African	Yoruba in Ibadan, Nigeria	YRI	1000 Genomes	108	1
6721119	113537	Sub-Saharan African	Luhya in Webuye, Kenya	LWK	1000 Genomes	99	1
6721120	113537	Sub-Saharan African	Gambian	GWD	1000 Genomes	113	1
6721121	113537	Sub-Saharan African	Mende in Sierra Leone	MSL	1000 Genomes	85	1
6721122	113537	Sub-Saharan African	Esan in Nigeria	ESN	1000 Genomes	99	1
6721123	116362	Sub-Saharan African	Yoruba from Ibadan (Nigeria)	1000 Genomes	random blood donor	78	1
6721124	116362	Sub-Saharan African	Luhya from Webuye (Kenya)	1000 Genomes	random blood donor	67	1
6721125	116446	Sub-Saharan African	Ugandan	\N	HIV positive, no TB	106	1
6721126	116446	Sub-Saharan African	Ugandan	\N	HIV+TB positive	157	1
6721127	116449	Sub-Saharan African	South African	Bantu-speaking	HIV positive	295	1
6721128	116449	Sub-Saharan African	South African	Bantu-speaking	healthy	163	1
6721129	116452	Sub-Saharan African	Zimbabwean	HIV positve	\N	49	1
6721130	116454	Sub-Saharan African	ugandan	\N	healthy subjects	121	1
6721131	116367	Sub-Saharan African	Ghanian	\N	healthy volunteer	82	1
6721132	116367	Sub-Saharan African	Ghanian	\N	\N	64	1
6721133	116411	Sub-Saharan African	Swiss HIV cohort black	\N	HIV positive	16	1
6721134	116459	Sub-Saharan African	sub-Saharan Africa population	\N	HIV-TB coinfected	158	1
6721135	115639	African American/Afro-Caribbean	African-American	Tennessee	healthy	76	1
6721136	115641	African American/Afro-Caribbean	African-American	Kansas City	healthy subjects	100	1
6721137	115643	African American/Afro-Caribbean	African-American	Durham and Chapel Hill	healthy	108	1
6721138	115645	African American/Afro-Caribbean	African American	Los Angeles	\N	236	1
6721139	114389	African American/Afro-Caribbean	African-American	Kentucky	mentally ill patients	478	1
6721140	115648	African American/Afro-Caribbean	African-American	Kansas City	sample repository	114	1
6721141	115650	African American/Afro-Caribbean	African-American	US	n/a	149	1
6721142	115652	African American/Afro-Caribbean	African-American	New York	healthy blood donors	250	1
6721143	115656	African American/Afro-Caribbean	African-American	\N	from TRIUMPH study	670	1
6721144	115654	African American/Afro-Caribbean	African-American	\N	from PEAR and INVEST studies	181	1
6721145	115658	African American/Afro-Caribbean	African-American	Americans of African Ancestry in SW USA	1000 Genomes	61	1
6721146	115658	African American/Afro-Caribbean	African Caribbean in Barbados	1000 Genomes population (ACB)	\N	96	1
6721147	115661	American	Canadian	Native Indians	\N	159	1
6721148	115663	American	Brazilian Amerinidian	Guarani and Tupinikin, Espirito Santo State	general population	183	1
6721149	114461	American	Mexican	Purepechas , Michoacan, West Mexoco	healthy	101	1
6721150	114461	American	Mexican	Tarahumaras, Chihuahua, North Mexico	healthy	84	1
6721151	114461	American	Mexican	Tojolabales, Chiapas, Southeast Mexico	healthy	68	1
6721152	114461	American	Mexican	Tzotziles, Chiapas, Southeast Mexico	healthy	88	1
6721153	115665	American	Brazilian	Guarani Amerindians	healthy	90	1
6721154	115671	American	Native Americans	Oglala Sioux tribe	healthy controls (n=50), CAD (n=50)	100	1
6721155	114444	American	US	American Indian, Northwestern US	patients with PGx testing	113	1
6721156	115673	American	Mexican Amerindian Indigenous	\N	healthy	150	1
6721157	115676	Central/South Asian	North Indian	\N	healthy	121	1
6721158	115678	Central/South Asian	Tamilian	living in Tamilnadu and Pondicherry	healthy	112	1
6721159	115680	Central/South Asian	South Indian	Andrah Pradash	healthy	115	1
6721160	115680	Central/South Asian	South Indian	Karnataka	healthy	108	1
6721161	115680	Central/South Asian	South Indian	Kerala	healthy	118	1
6721162	115684	Central/South Asian	South Indian	Andhra pradash, Karnataka, Kerala, Tamilnadu	healthy	300	1
6721163	115686	Central/South Asian	Western India	Maharashtrian (India)	\N	139	1
6721164	115688	Central/South Asian	North Indian	\N	head and neck cancer patients, controls	600	1
6721165	115690	Central/South Asian	North Indian	\N	GI patients	91	1
6721166	115692	Central/South Asian	South Indian	Andhra Pradesh, Karnataka, Kerala, Tamilnadu, Pondicherry	healthy	50	1
6721167	115694	Central/South Asian	South Indian	Andhra/Pradesh/Karnataka/Kerala/Tamilnadu/Pondicherry	healthy	58	1
6721168	115726	Central/South Asian	Chinese	Kazakh	healthy	107	1
6721169	115700	Central/South Asian	Pakistani	\N	breast cancer	68	1
6721618	116735	American	Mexican	Maya	\N	44	1
6721170	115696	Central/South Asian	North Indian	\N	epilepsy patients, controls	457	1
6721171	115702	Central/South Asian	Tamilian	living in Pondicherry	epilepsy patients, no PHT toxicity	234	1
6721172	115698	Central/South Asian	North Indian	\N	head and neck cancer patients, controls	750	1
6721173	115704	Central/South Asian	Indian	South Indian	healthy	220	1
6721174	115706	Central/South Asian	Indian	Tamilian	healthy	206	1
6721175	115708	Central/South Asian	Indian	Singapore	ramdon subjects receiving blood counts	100	1
6721176	115710	Central/South Asian	Indian	Tamilian	91% ischemic heart disease patients	149	1
6721177	115712	Central/South Asian	North Indian	Punjab, Haryana, Delhi, Uttar Pradesh, Bihar	subjects of Indian Diabetes Consortium study	2128	1
6721178	115714	Central/South Asian	North Indian	Haryana	healthy	308	1
6721179	115716	Central/South Asian	Indian	New Delhi	ACS/CAD patients , control	144	1
6721180	115718	Central/South Asian	Indian	Mumbai	invasive fungal infections	55	1
6721181	115722	Central/South Asian	Sri Lanka	Moors	healthy	78	1
6721182	115722	Central/South Asian	Sri Lanka	Sinhalese	healthy	55	1
6721183	115722	Central/South Asian	Sri Lanka	Tamils	healthy	73	1
6721184	115720	Central/South Asian	South Indian	\N	alcohol withdrawal + healthy controls	156	1
6721185	115728	East Asian	Japanese	\N	healthy	186	1
6721186	115734	East Asian	Korean	\N	healthy	103	1
6721187	115730	East Asian	Japanese	\N	healthy	217	1
6721188	115732	East Asian	Japanese	\N	misc patients	233	1
6721189	115643	East Asian	Filipinos	living in Riyadh	\N	52	1
6721190	115643	East Asian	Japanese	Tokyo	\N	53	1
6721191	115643	East Asian	Taiwanese	\N	healthy	118	1
6721192	115736	East Asian	Bai Chinese	Yunnan	healthy	202	1
6721193	115736	East Asian	Han Chinese	Hunan	healthy	101	1
6721194	115741	East Asian	Japanese	\N	ulcer patients	62	1
6721195	115743	East Asian	Japanese	\N	healthy	140	1
6721196	115747	East Asian	Japanese	\N	epileptic patients	175	1
6721197	115745	East Asian	Japanese	\N	epilepsy patients	134	1
6721198	115749	East Asian	Chinese	Hong Kong Chinese	depressive disorder patients and healthy controls	119	1
6721199	115751	East Asian	Japanese	\N	GI patients	108	1
6721200	115755	East Asian	Japanese	\N	GI patients	101	1
6721201	115757	East Asian	Japanese	\N	Gastric ulcer patients	261	1
6721202	115759	East Asian	Japanese	\N	healty	50	1
6721203	115753	East Asian	Chinese	\N	healthy with or w/o GI problems	121	1
6721204	115753	East Asian	Japanese	\N	healthy with or w/o GI problems	96	1
6721205	115753	East Asian	Thai	\N	healthy with or w/o GI problems	121	1
6721206	115753	East Asian	Vietnamese	\N	healthy with or w/o GI problems	90	1
6721207	115762	East Asian	Japanese	\N	psychiatric patients	51	1
6721208	115768	East Asian	Japanese	\N	GI patients	65	1
6721209	115766	East Asian	Chinese	Dai	healthy	196	1
6721210	115770	East Asian	Thai	Northeastern	\N	107	1
6721211	115774	East Asian	Korean	\N	Gastric or duodenal ulcer patients	116	1
6721212	115772	East Asian	Japanese	Hokkaido	healthy	196	1
6721213	115783	East Asian	Japanese	\N	Gastric or duodenal ulcer or gastritis patients	350	1
6721214	115788	East Asian	Taiwanese	\N	epilepsy patients	169	1
6721215	115776	East Asian	Chinese	Han	healthy	70	1
6721216	115785	East Asian	Japanese	\N	healthy	80	1
6721217	115780	East Asian	Chinese	Uygur	\N	96	1
6721218	115780	East Asian	Han Chinese	\N	healthy	104	1
6721219	115778	East Asian	Chinese	Malaysia	healthy	54	1
6721220	115778	East Asian	Malay	\N	healthy	68	1
6721221	115790	East Asian	Japanese	\N	healthy and diabetics	253	1
6721222	115792	East Asian	Japanese	\N	Gastric or duodenal ulcer or gastritis patients	141	1
6721223	115794	East Asian	Japanese	\N	\N	63	1
6721224	115796	East Asian	Japanese	\N	healthy	139	1
6721225	115798	East Asian	Japanese	\N	GI patients	173	1
6721226	115800	East Asian	Japanese	\N	GI patients	426	1
6721227	115810	East Asian	Japanese	\N	healthy	54	1
6721228	113953	East Asian	Chinese	Han, living in Taiwan	healthty	180	1
6721229	115645	East Asian	East Asian	Los Angeles	healthy	161	1
6721230	115645	East Asian	Southeast Asian	Los Angeles	healthy	80	1
6721231	115812	East Asian	Japanese	\N	healthy	203	1
6721232	115804	East Asian	Burmese	\N	healthy	127	1
6721233	115804	East Asian	Korean	\N	healthy	131	1
6721234	115804	East Asian	Thai	\N	healthy	774	1
6721235	115807	East Asian	Chinese	\N	psychiatry patients	53	1
6721236	115821	East Asian	Japanese	\N	GI patients	300	1
6721237	115823	East Asian	Japanese	\N	healthy	487	1
6721238	115833	East Asian	Korean	southeast Korean peninsula	\N	377	1
6721239	115833	East Asian	Vietnamese	Kinh living in Hanoi	\N	165	1
6721240	115831	East Asian	Korean	\N	epilepsy patients	97	1
6721241	115825	East Asian	Japanese	\N	kidney transplant recipients	73	1
6721242	115827	East Asian	Japanese	\N	cancer patients	103	1
6721243	115817	East Asian	Chinese	\N	NSCLC patients	59	1
6721244	115819	East Asian	Chinese	Li living in Wuzhishan and Haikou	healthy	165	1
6721245	115829	East Asian	Japanese	\N	healthy	352	1
6721246	115836	East Asian	Chinese	Han	healthy	384	1
6721247	115842	East Asian	Korean	\N	GI patients	323	1
6721248	114092	East Asian	Russians	Tomsk	healthy	82	1
6721249	114092	East Asian	Siberian	Altaians	healthy	87	1
6721250	114092	East Asian	Siberian	Buryats	healthy	88	1
6721251	114092	East Asian	Siberian	Tuvinians	healthy	88	1
6721252	114092	East Asian	Siberian	Yakuts	healthy	88	1
6721253	114548	East Asian	Chinese	\N	healthy	101	1
6721254	114548	East Asian	Japanese (1st generation)	\N	healthy	105	1
6721255	114548	East Asian	Japanese (3rd generation)	\N	healthy	84	1
6721256	114548	East Asian	Japanese (native)	\N	healthy	100	1
6721257	114548	East Asian	Korean	\N	healthy	100	1
6721258	115802	East Asian	Japanese	\N	healthy	265	1
6721259	115852	East Asian	Japanese	\N	GERD patients	124	1
6721260	115854	East Asian	Japanese	\N	liver donors	55	1
6721261	115854	East Asian	Japanese	\N	transplant recipients	55	1
6721262	115845	East Asian	Chinese	Beijing	epilepsy patients	287	1
6721263	115865	East Asian	Korean	\N	MI patients	136	1
6721264	115867	East Asian	Korean	\N	patients with drug-induced hepatitis, controls	226	1
6721265	115869	East Asian	Korean	\N	CHD patients	386	1
6721266	115857	East Asian	Japanese	\N	breast cancer/no ADRs	140	1
6721267	115857	East Asian	Japanese	\N	breast cancer/with ADRs	76	1
6721268	115860	East Asian	Japanese	\N	breast cancer patients	173	1
6721269	115862	East Asian	Japanese	1st generation descendents, living in Brazil	\N	126	1
6721270	115862	East Asian	Japanese	native Japanese, living in Brazil	\N	200	1
6721271	115847	East Asian	Chinese	Singapore	\N	107	1
6721272	114656	East Asian	Vietnamese	\N	\N	78	1
6721273	115726	East Asian	Chinese	Han	healthy	103	1
6721274	115726	East Asian	Chinese	Uygur	healthy	149	1
6721275	114554	East Asian	Chinese	58 subjects, 42 subjects CHB HapMap Project	healthy/cell lines	100	1
6721276	115882	East Asian	Korean	\N	Cardiology patients	134	1
6721277	115884	East Asian	Korean	\N	CHD patients	126	1
6721278	115886	East Asian	Korean	\N	\N	176	1
6721279	115888	East Asian	Korean	\N	healthy	271	1
6721280	115890	East Asian	Korean	Seoul	GI patients	463	1
6721281	115872	East Asian	Chinese	\N	non-ulcer dyspepsia patients	204	1
6721282	114558	East Asian	Chinese	Han living in Singapore	\N	398	1
6721283	114558	East Asian	East Asian	Chinese, Japanese, Korean	\N	246	1
6721284	114558	East Asian	Japanese	Fukoda and Tokyo	\N	500	1
6721285	114558	East Asian	Korean	\N	\N	200	1
6721286	115880	East Asian	Japanese	\N	\N	51	1
6721287	115893	East Asian	Korean	\N	healthy	150	1
6721288	115895	East Asian	Taiwanese	\N	\N	100	1
6721289	115875	East Asian	Chinese	Uygur	CAD patients	336	1
6721290	115875	East Asian	Chinese	Uygur	controls	370	1
6721291	115904	East Asian	Korean	\N	Cardiology patients	190	1
6721292	115897	East Asian	Chinese	Han Chinese	healthy	1120	1
6721293	115897	East Asian	Chinese	Han Chinese	hypertensive patients	1249	1
6721294	115906	East Asian	Thai	\N	SLE patients, controls	71	1
6721295	115900	East Asian	Chinese	Han Chinese	healthy	200	1
6721296	115902	East Asian	Japanese	\N	CHD patients	201	1
6721297	115708	East Asian	Chinese	Singapore	ramdon subjects receiving blood counts	100	1
6721298	115708	East Asian	Malayans	Singapore	ramdon subjects receiving blood counts	100	1
6721299	115909	East Asian	Chinese	Han Chinese ( Northern, Hebei Province)	healthy	1000	1
6721300	115909	East Asian	Chinese	Han Chinese (Southern, Zhejiang Province)	healthy	1127	1
6721301	114574	East Asian	Chinese	Han Chinese	\N	214	1
6721302	114574	East Asian	Chinese	Hui Chinese	Ningxia Hui Autonomous Region of China	111	1
6721303	114574	East Asian	Chinese	Mongolian Chinese	Inner Mongolia Autonomous Region of China	129	1
6721304	114560	East Asian	Chinese	Han Chinese (Liaoning Province)	healthy	136	1
6721305	114560	East Asian	Chinese	Hui Chinese (Ningxia Province)	healthy	164	1
6721306	114560	East Asian	Chinese	Mongolian Chinese (Xinjiang Province)	healthy	158	1
6721307	114560	East Asian	Chinese	Uighur Chinese (Neimenggu Province)	healthy	214	1
6721308	115920	East Asian	Korean	\N	invasive aspergillosis	104	1
6721309	115652	East Asian	Asian	New York	healthy blood donors	250	1
6721310	113880	East Asian	Indonesians	Bandung, West Java	healthy	103	1
6721311	113880	East Asian	Indonesians	Bandung, West Java	patients (cardiavasular)	103	1
6721312	115924	East Asian	Thai	\N	not specified, n=96 with CAD	1051	1
6721313	115930	East Asian	Chinese	\N	non-small cell lung cancer	156	1
6721314	115945	East Asian	Korean	\N	acute coronary syndrome	155	1
6721315	115941	East Asian	Japanese	\N	H. pylori infection	180	1
6721316	115939	East Asian	Japanese	\N	CAD	104	1
6721317	115926	East Asian	Chinese	\N	CAD	145	1
6721318	115932	East Asian	Chinese	Han Chinese	cardiovascular and cerebrovascular disease	220	1
6721319	115932	East Asian	Chinese	Uyghur	cardiovascular and cerebrovascular disease	800	1
6721320	115937	East Asian	Japanese	\N	healthy	74	1
6721321	115943	East Asian	Japanese	\N	chronic kidney disease, controls	331	1
6721322	115947	East Asian	Thai	Bangkok	CAD	211	1
6721323	115922	East Asian	Taiwanese	\N	healthy	1038	1
6721324	115928	East Asian	Chinese	\N	CAD	840	1
6721325	115658	East Asian	Chinese	1000 Genomes population (CHB)	\N	103	1
6721326	114567	East Asian	Chinese	Han	Eastern Han	229	1
6721327	115956	East Asian	Korean	\N	ischemic stroke	76	1
6721328	115949	East Asian	Chinese	\N	coronary syndrome patients	116	1
6721329	114613	East Asian	Japanese	\N	healthy	1017	1
6721330	115934	East Asian	Chinese	\N	ischemic stroke	211	1
6721331	115951	East Asian	Chinese	Uighur	northwest China	96	1
6721332	115960	East Asian	Chinese	Tibetan	Tibet autonomous region	96	1
6721333	115958	East Asian	Chinese	Wenzhou	ischemic stroke + healthy	375	1
6721334	115971	European	German	\N	healthy	174	1
6721335	115973	European	Swedish	\N	\N	160	1
6721336	115643	European	European-American	Durham and Chapel Hill	healthy	105	1
6721337	115976	European	Portuguese	\N	healthy	153	1
6721338	115978	European	Danish	\N	very old, youny controls	303	1
6721339	115980	European	European	\N	healthy	173	1
6721340	115982	European	French	\N	control group	173	1
6721341	115986	European	Swedish	\N	GI patients	143	1
6721342	115988	European	Swedish	\N	controls	248	1
6721343	115990	European	Swedish	\N	Alzheimer disease patients, controls	110	1
6721344	115992	European	French	\N	lung cancer patients	152	1
6721345	115994	European	British	\N	leukemia, controls	952	1
6721346	114688	European	Dutch	\N	healthy	745	1
6721347	116001	European	Swiss	\N	\N	113	1
6721348	115997	European	English	\N	cancer, controls	1082	1
6721349	115999	European	Italian	\N	receiving warfarin	93	1
6721350	116003	European	Belgian	\N	\N	121	1
6721351	114674	European	Croatian	Zagreb	healthy	200	1
6721352	116012	European	Norwegian	\N	blood donors	94	1
6721971	117187	Near Eastern	Iranian	\N	\N	160	1
6721353	116005	European	Caucasian	Mayo Clinic Rochester	GI patients	60	1
6721354	114767	European	Russian	Voronezh	controls, general outpatients	290	1
6721355	116008	European	German	\N	healthy	95	1
6721356	116010	European	German	Dusseldorf, Bad Bentheim, Bad Salzschliff	psoriasis patients, controls	553	1
6721357	116015	European	German	\N	GI patients	193	1
6721358	114720	European	Italian	\N	healthy	360	1
6721359	116029	European	Spanish	Barcelona	psychiatric patients, controls	307	1
6721360	116033	European	Swiss	\N	patients on methadone	208	1
6721361	116027	European	Polish	\N	GI patients	70	1
6721362	114693	European	Faroese	\N	healthy	312	1
6721363	116031	European	Spanish	Barcelona	cancer patients, controls	672	1
6721364	116025	European	Western European	\N	GERD patients	205	1
6721365	116021	European	German	Munich	depression patients	49	1
6721366	116023	European	German	Berlin	cancer	60	1
6721367	116018	European	Dutch	\N	psychiatry patients	69	1
6721368	116046	European	Swiss	Geneva	patients on methadone	245	1
6721369	116036	European	Finnish	\N	medical autopsy	177	1
6721370	116042	European	Polish	\N	GI patients	125	1
6721371	116038	European	German	Frankfurt	healthy	51	1
6721372	115645	European	Caucasian	\N	\N	273	1
6721373	116040	European	Norwegian	\N	psychiatric patients	83	1
6721374	116044	European	Swedish	\N	\N	314	1
6721375	116051	European	German	Essen	transplant patients, controls	573	1
6721376	116057	European	Swiss	Geneva	healthy	94	1
6721377	116053	European	Italian	\N	cardiovascular patients	1419	1
6721378	114119	European	Finnish	\N	healthy	440	1
6721379	116055	European	Portuguese	\N	blood donors	126	1
6721380	116048	European	Bulgarian	\N	cardiovascular patients	96	1
6721381	116068	European	French	Eastern France	healthy	359	1
6721382	116084	European	Slovenian	\N	RA patients	105	1
6721383	116062	European	Dutch	\N	cancer patients	124	1
6721384	116064	European	Dutch	\N	cancer patients	113	1
6721385	116086	European	Swiss	Geneva	\N	81	1
6721386	116070	European	French	\N	coronary syndrome patients	601	1
6721387	116072	European	German	Tübingen	CAD, controls	423	1
6721388	116059	European	Caucasian	\N	coronary intervention patients	60	1
6721389	116082	European	Russian	\N	cancer patients	159	1
6721390	116080	European	Polish	\N	cardiovascular patients	105	1
6721391	114548	European	Caucasian	\N	\N	143	1
6721392	116076	European	Norwegian	\N	psychiatric patients	121	1
6721393	116078	European	Norwegian	\N	psychiatric patients	166	1
6721394	116066	European	Dutch	\N	psychiatry patients	181	1
6721395	116074	European	German	\N	coronary intervention	797	1
6721396	116109	European	Slovenian	Ljubljana	arthritis patients	71	1
6721397	116091	European	European-American	Virginia, USA	acute coronary syndrome, controls	186	1
6721398	114389	European	Caucasian	Kentucky	mentally ill patients	4450	1
6721399	116093	European	French	\N	acute coronary syndrome patients	598	1
6721400	116107	European	Italian	\N	cardiovascular patients	772	1
6721401	116097	European	German	Bonn	breast cancer, controls	1989	1
6721402	116089	European	Danish	Copenhagen	lichen planus patients, controls	300	1
6721403	116105	European	Greek	\N	healthy	283	1
6721404	116099	European	German	Munich	CAD	2485	1
6721405	116095	European	French	\N	\N	2178	1
6721406	116101	European	German	Kiel	adult epilepsy patients	70	1
6721407	116101	European	German	Kiel	healthy	242	1
6721408	116101	European	German	Kiel	pediatric epilepsy patients	221	1
6721409	116129	European	French	\N	coronary syndrome patients	411	1
6721410	116126	European	English	\N	cancer patients	230	1
6721411	116142	European	Polish	\N	GI patients	139	1
6721412	115984	European	Norwegian	\N	tamoxifen-treated women	90	1
6721413	116146	European	Russian	European part of Russia	healthy	352	1
6721414	116120	European	Dutch	\N	CAD	428	1
6721415	116133	European	German	Bad Krotzingen	CAD	760	1
6721416	115648	European	Caucasian	Kansas City	sample repository	107	1
6721417	116144	European	Polish	\N	cardiovascular patients	261	1
6721418	114558	European	Caucasian	\N	\N	454	1
6721419	116131	European	German	Hamburg, Karlsruhe	breast cancer, controls	8609	1
6721420	116115	European	Caucasian	\N	transplant patients	344	1
6721421	116117	European	Danish	\N	healthy	276	1
6721422	116117	European	Faroese	\N	healthy	311	1
6721423	116117	European	Norwegian	\N	healthy	309	1
6721424	115893	European	Swedish	\N	\N	185	1
6721425	116122	European	Dutch	\N	breast cancer	215	1
6721426	116148	European	Spanish	Valdecilla	Neurology patients	289	1
6721427	116124	European	Dutch	\N	psychiatry patients	178	1
6721428	116111	European	Bosnian	Tesanj	diabetic patients, nondiabetic participants	77	1
6721429	116135	European	German	Munich	CAD	986	1
6721430	116137	European	German	Munich	CAD	1524	1
6721431	116151	European	Swedish	\N	psychiatric patients, controls	1416	1
6721432	116139	European	German	Munich	CAD	928	1
6721433	114686	European	Danish	\N	cancer patients	339	1
6721434	116154	European	White	\N	cardiovascular patients	10285	1
6721435	114796	European	Swedish	\N	suicide, controls	713	1
6721436	116156	European	Dutch	\N	psychiatry patients	678	1
6721437	116160	European	White/Non-Hispanic	\N	\N	1253	1
6721438	114714	European	Hungarian	\N	\N	112	1
6721439	115663	European	Brazilian (Caucasian descent)	Brazilian urban centers across country	general population	615	1
6721440	114725	European	Italian	\N	breast cancer, controls	179	1
6721441	115650	European	White	US	n/a	357	1
6721442	116166	European	Italian	\N	controls	62	1
6721443	116168	European	Macedonian	\N	healthy	184	1
6721444	116168	European	Spanish	Northern Spain	healthy	282	1
6721445	115652	European	Caucasian	New York	healthy blood donors	250	1
6721446	116164	European	Hungarian	\N	healthy	370	1
6721447	116164	European	Roma	\N	healthy	500	1
6721972	117197	Near Eastern	Turkish	\N	\N	93	1
6721448	115146	European	Spanish	White Spanish	organ donors and recipents	570	1
6721449	115656	European	US	\N	from TRIUMPH study	2062	1
6721450	116198	European	Brazilian	European Brazilian	healthy controls	92	1
6721451	116173	European	Slovakian	\N	healthy	112	1
6721452	116178	European	Spanish	\N	healthy	362	1
6721453	116171	European	French	\N	elderly	156	1
6721454	114802	European	Swiss	\N	breast cancer	99	1
6721455	116180	European	Spanish	\N	healthy	151	1
6721456	116176	European	Spanish	Spaniards	Northern Spain	282	1
6721457	116192	European	Russian	South Ural	\N	54	1
6721458	115658	European	Caucasian	1000 Genomes population (CEU)	\N	99	1
6721459	116186	European	Lithuanian	\N	stent, but no thrombosois	456	1
6721460	116188	European	New Zealand	Whites	Wellington	232	1
6721461	116190	European	Russian	Moscow	peptic ulcer patients	971	1
6721462	116194	European	Spain	\N	patients with artery stenting	209	1
6721463	114444	European	US	Northwestern US	patients with PGx testing	621	1
6721464	116200	Latino	Bolivian	Mestizo with 82% Caucasian admixture	healthy	778	1
6721465	115645	Latino	Mexican Americans	Los Angeles	healthy	346	1
6721466	116203	Latino	Columbian	Mestizo	healthy	189	1
6721467	116205	Latino	Puerto Rican	\N	Newborn screening	122	1
6721468	115648	Latino	Hispanic	Kansas City	sample repository	108	1
6721469	115663	Latino	Brazilian Mulatto	Brazilian urban centers across country	general population	315	1
6721470	114461	Latino	Mexican	Mestizos	healthy	145	1
6721471	115650	Latino	Hispanic	US	n/a	346	1
6721472	116209	Latino	Brazilian (mixed)	Brazilians	white, brown and black skin color	1034	1
6721473	116168	Latino	Ecuadorian	Mestizo, Quito	healthy controls	297	1
6721474	115652	Latino	Hispanic	New York	healthy blood donors	250	1
6721475	116214	Latino	Puerto Ricans	\N	Newborn screening	99	1
6721476	115654	Latino	Hispanic Latinos	\N	from PEAR and INVEST studies	202	1
6721477	116219	Latino	Mexican	Mestizos, Mexico City	healthy	269	1
6721478	116176	Latino	Ecuadorian	Mestizo	healthy	297	1
6721479	116221	Latino	Mexican	Mestizos, Jalisco (Western Mexico)	healthy	238	1
6721480	116223	Latino	Mexican	Coriell	healthy	94	1
6721481	116223	Latino	Peruvian	\N	healthy	80	1
6721482	114457	Latino	Ecuadorian	\N	healthy	139	1
6721483	116226	Latino	Mexican	Mestizo	volunteers (64 epilepsy patients exluded)	300	1
6721484	116229	Latino	Mexican	\N	non-ST acute conorary syndromes	51	1
6721485	115643	Near Eastern	Saudi Arabians	\N	\N	97	1
6721486	114823	Near Eastern	Turkish	Southeastern Anatolia	various outpatients	404	1
6721487	116232	Near Eastern	Israeli	Jewish	healthy	140	1
6721488	116262	Near Eastern	Turkish	Southeastern Anatolia	healthy	96	1
6721489	116280	Near Eastern	Egyptian	Cairo	healthy	247	1
6721490	114809	Near Eastern	Bedouin	\N	\N	50	1
6721491	116264	Near Eastern	Turkish	\N	cancer patients	182	1
6721492	116266	Near Eastern	Turkish	\N	Behcet's disease, controls	169	1
6721493	116235	Near Eastern	Iranian	\N	healthy	200	1
6721494	116268	Near Eastern	Turkish	\N	cardiovascular patients, controls	198	1
6721495	116286	Near Eastern	Tunisian	\N	breast cancer patients and controls	544	1
6721496	116270	Near Eastern	Turkish	\N	endometriosis patients, controls	100	1
6721497	116272	Near Eastern	Turkish	\N	dyspeptic patients	100	1
6721498	116237	Near Eastern	Palestinian	\N	healthy	200	1
6721499	116237	Near Eastern	Palestinian	\N	hematological malignancy patients	52	1
6721500	116240	Near Eastern	Iranian	Shiraz, southern Iran	cardiovascular patients, controls	150	1
6721501	116242	Near Eastern	Iranian	\N	patients on warfarin	99	1
6721502	116274	Near Eastern	Turkish	\N	H. pylori–positive patients	105	1
6721503	116244	Near Eastern	Iranian	\N	gastroesophageal reflux disease patients	82	1
6721504	116246	Near Eastern	Lebanese	\N	healthy	161	1
6721505	116282	Near Eastern	Egyptian	Nile delta region	\N	120	1
6721506	116248	Near Eastern	Iranians	Mazandarani	healthy	103	1
6721507	114204	Near Eastern	Jordanians	\N	healthy	158	1
6721508	116251	Near Eastern	Jordanians	\N	healthy	78	1
6721509	116253	Near Eastern	Iranian	Turkman	healthy	140	1
6721510	116276	Near Eastern	Turkey	\N	colorectal cancer, controls	287	1
6721511	116257	Near Eastern	Iranian	\N	healthy	180	1
6721512	116255	Near Eastern	Iranian	Teheran	\N	691	1
6721513	116259	Near Eastern	Iranian	\N	healthy	180	1
6721514	116284	Near Eastern	Egyptian	Cairo	coronary artery disease	190	1
6721515	116278	Near Eastern	Turkey	Istanbul	non-ulcer diypepsia	200	1
6721516	116288	Oceanian	Vanuatu	Tanna and Malakula islands	malariometric survey	493	1
6721517	116290	Oceanian	Vanuatu	Malakula	malaria patients	100	1
6721518	116292	Oceanian	Aneityum	Language: Aneityum	healthy	317	1
6721519	116292	Oceanian	Aneityum	Language: Futuna-Aniwa	healthy	69	1
6721520	116292	Oceanian	Aniwa	Language: Futuna-Aniwa	healthy	346	1
6721521	116292	Oceanian	Efate	Language: Mele Fila	healthy	275	1
6721522	116292	Oceanian	Emae	Language: Emae	healthy	89	1
6721523	116292	Oceanian	Emae	Language: Namakura	healthy	84	1
6721524	116292	Oceanian	Emae	Language: North Efate	healthy	183	1
6721525	116292	Oceanian	Erromango	Language: Sie	healthy	454	1
6721526	116292	Oceanian	Futuna	Language: Futuna-Aniwa	healthy	292	1
6721527	116292	Oceanian	Gaua	Language: Lakona	healthy	149	1
6721528	116292	Oceanian	Gaua	Language: Wetamut	healthy	399	1
6721529	116292	Oceanian	Ifira	Language: Mele Fila	healthy	165	1
6721530	116292	Oceanian	Maewo	Language: Baetora	healthy	223	1
6721531	116292	Oceanian	Maewo	Language: Raga	healthy	158	1
6721532	116292	Oceanian	Malakula	Language: Big Nambas	healthy	386	1
6721533	116292	Oceanian	Malakula	Language: Lingarak	healthy	96	1
6721534	116292	Oceanian	Malo	Language: Malo	healthy	93	1
6721535	116292	Oceanian	Nguna	Language: North Efate	healthy	117	1
6721536	116292	Oceanian	Pentecost	Language: Sa	healthy	637	1
6721537	116292	Oceanian	Santo	Language: Akei	healthy	258	1
6721538	116292	Oceanian	Santo	Language: Tolomako	healthy	190	1
6721539	116292	Oceanian	Tanna	Language: Lenakel	healthy	258	1
6721540	116292	Oceanian	Tanna	Language: Southwest Tanna	healthy	57	1
6721541	116292	Oceanian	Tongoa	Language: North Efate	healthy	243	1
6721542	114839	Oceanian	Aboriginese	Western Australian	healthy	227	1
6721543	116318	Oceanian	Papua New Guinea	Jawia	healthy	75	1
6721544	116318	Oceanian	Papua New Guinea	Kiniambu	healthy	132	1
6721545	116318	Oceanian	Papua New Guinea	Witupe	healthy	194	1
6721546	116323	Oceanian	Papua New Guinea	Iruna (n=47), Tufi (n=10), Fly River (n=8)	healthy	65	1
6721547	114842	Oceanian	Maori	\N	\N	60	1
6721548	116188	Oceanian	New Zealand	Maori/Pacific Islander	ACS	70	1
6721549	116326	Sub-Saharan African	Zimbabwean	Shona	healthy	84	1
6721550	116328	Sub-Saharan African	Ethiopian	\N	healthy	114	1
6721551	116330	Sub-Saharan African	Tanzanian	Dar es Salaam	healthy	251	1
6721552	114423	Sub-Saharan African	Tanzanian	\N	\N	195	1
6721553	114425	Sub-Saharan African	South African	Venda	\N	76	1
6721554	114425	Sub-Saharan African	Tanzanian	\N	psychiatric patients and controls	192	1
6721555	114414	Sub-Saharan African	Ethiopian	Sweden	healthy	70	1
6721556	116003	Sub-Saharan African	Beninese	Zou department	healthy	111	1
6721557	116044	Sub-Saharan African	Ethiopian	Ethiopia and Sweden	\N	190	1
6721558	116338	Sub-Saharan African	Ghanaian	Accra	healthy	169	1
6721559	116340	Sub-Saharan African	Ugandan	healthy	\N	99	1
6721560	116343	Sub-Saharan African	Nigerian	95% from Southwest (Yoruba-speaking)	n=43 healthy, n=115 SCD	158	1
6721561	116345	Sub-Saharan African	South African	Xhosa	healthy	100	1
6721562	114558	Sub-Saharan African	African	\N	\N	250	1
6721563	114248	Sub-Saharan African	Black South African	Soweta, majority Zulu or Sotho-speaking	\N	985	1
6721564	115663	Sub-Saharan African	Brazilian (African descent)	Brazilian urban centers across country	general population	99	1
6721565	116348	Sub-Saharan African	South African	Black (cohort 2)	\N	70	1
6721566	116198	Sub-Saharan African	Brazilian	African Brazilian	healthy controls	87	1
6721567	115658	Sub-Saharan African	Ethiopian	\N	healthy	104	1
6721568	115658	Sub-Saharan African	Gambia	Western Divisions (GWD)	1000 Genomes	113	1
6721569	115658	Sub-Saharan African	Kenya	Luhya in Webuye (LWK)	1000 Genomes	99	1
6721570	115658	Sub-Saharan African	Nigeria	Esan (ESN)	1000 Genomes	99	1
6721571	115658	Sub-Saharan African	Nigeria	Yoruba in Ibadan (YRI)	1000 Genomes	108	1
6721572	115658	Sub-Saharan African	Sierra Leone	Mende (MSL)	1000 Genomes	85	1
6721573	116356	Sub-Saharan African	South African	representing South African population	healthy	100	1
6721574	116358	Sub-Saharan African	Ethiopian	male; residents of Addis Ababa	healthy	63	1
6721575	116697	African American/Afro-Caribbean	African-American	\N	Healthy controls	258	1
6721576	116691	African American/Afro-Caribbean	African-American	\N	\N	100	1
6721577	116681	African American/Afro-Caribbean	African-American	\N	\N	120	1
6721578	116681	African American/Afro-Caribbean	African-American	\N	\N	120	1
6721579	116699	African American/Afro-Caribbean	African-American	New Orleans, LA	Healthy controls	107	1
6721580	116699	African American/Afro-Caribbean	African-American	New Orleans, LA	Hypertensive patients	108	1
6721581	116687	African American/Afro-Caribbean	African-American	\N	\N	106	1
6721582	116702	African American/Afro-Caribbean	African-American	\N	Healthy controls	28	1
6721583	116689	African American/Afro-Caribbean	African-American	Birmingham, AL	Warfarin treated patients	226	1
6721584	116695	African American/Afro-Caribbean	African-American	\N	Warfarin treated patients	101	1
6721585	116581	African American/Afro-Caribbean	African-American	\N	\N	226	1
6721586	116678	African American/Afro-Caribbean	African-American	\N	Healthy controls	300	1
6721587	113845	African American/Afro-Caribbean	African-American	\N	Warfarin treated patients	220	1
6721588	116585	African American/Afro-Caribbean	African-American	\N	Warfarin treated patients	338	1
6721589	116248	African American/Afro-Caribbean	African-American	\N	\N	100	1
6721590	116574	African American/Afro-Caribbean	African-American	\N	IWPC; warfarin-treated African Americans	327	1
6721591	116574	African American/Afro-Caribbean	African-American	\N	UAB warfarin treated cohort	206	1
6721592	116574	African American/Afro-Caribbean	African-American	\N	replication cohort, warfarin patients from IWPC sites	432	1
6721593	116704	African American/Afro-Caribbean	African-American	\N	Pediatric sickle cell disease patients	30	1
6721594	116693	African American/Afro-Caribbean	African-American	\N	\N	264	1
6721595	113537	African American/Afro-Caribbean	African-American	Americans of African Ancestry in SW USA	\N	61	1
6721596	116570	African American/Afro-Caribbean	African-American	\N	warfarin-treated African Americans	274	1
6721597	116706	African American/Afro-Caribbean	African-American	\N	Sickle cell disease patients	165	1
6721598	116583	African American/Afro-Caribbean	African-American	\N	\N	60	1
6721599	116751	American	Canadian Inuit	\N	Unrelated individuals	88	1
6721600	116751	American	Canadian Native Indian	\N	\N	114	1
6721601	116725	American	Brazilian	\N	Warfarin treated patients	103	1
6721602	116744	American	Mexican	Tepehuano	\N	99	1
6721603	116723	American	Brazilian	Admixed population from southeast Brazil	Warfarin treated patients	780	1
6721604	116723	American	Brazilian	Guarani in Brazil	\N	90	1
6721605	116590	American	Brazilian	Guarani	\N	75	1
6721606	116590	American	Brazilian	Tupinikin	\N	147	1
6721607	115665	American	Brazilian	Guarani	\N	90	1
6721608	116728	American	Mexican	Huichol	\N	73	1
6721609	116728	American	Mexican	Mestizo	\N	947	1
6721610	116728	American	Mexican	Nahua	\N	212	1
6721611	116728	American	Mexican	Purepecha	\N	48	1
6721612	116728	American	Mexican	Tarahumara	\N	52	1
6721613	116728	American	Mexican	Teenek	\N	98	1
6721614	116708	American	American Indian and Alaska Native	Confederated Salish and Kootenai Tribes (CSKT)	\N	94	1
6721615	116735	American	Mexican	Cora	\N	81	1
6721616	116735	American	Mexican	Guarijio	\N	15	1
6721617	116735	American	Mexican	Huichol	\N	107	1
6721619	116735	American	Mexican	Mexicanero	\N	38	1
6721620	116735	American	Mexican	Seri	\N	19	1
6721621	116735	American	Mexican	Tarahumara	\N	74	1
6721622	116735	American	Mexican	Tepehuano	\N	127	1
6721623	113847	American	American Indian and Alaska Native	Center of Alaska Native Health Research cohort (CANHR)	\N	350	1
6721624	113847	American	American Indian and Alaska Native	Southcentral Foundation cohort (SCF)	\N	359	1
6721625	116746	American	Mexican	Maya	\N	184	1
6721626	116746	American	Mexican	Mixteco	\N	176	1
6721627	116746	American	Mexican	Tepehuano	\N	184	1
6721628	116746	American	Mexican	Zapoteca	\N	173	1
6721629	114444	American	American Indian and Alaska Native	\N	Pediatric patients	123	1
6721630	116714	American	Mexican	Chatino	\N	31	1
6721631	116714	American	Mexican	Chontal	\N	30	1
6721632	116714	American	Mexican	Cora	\N	30	1
6721633	116714	American	Mexican	Maya	\N	199	1
6721634	116714	American	Mexican	Mazahua	\N	47	1
6721635	116714	American	Mexican	Mixteco	\N	30	1
6721636	116714	American	Mexican	Teenek	\N	30	1
6721637	114400	American	Central Native American	Costa Rica	\N	193	1
6721638	114400	American	North Native American	Mexico	\N	823	1
6721639	114400	American	South Native American	Peru	\N	214	1
6721640	116816	Central/South Asian	Indian	Tamilian	\N	135	1
6721641	116771	Central/South Asian	Indian	Indians in Malaysia	Healthy controls	50	1
6721642	116771	Central/South Asian	Indian	Indians in Malaysia	Warfarin treated cohort	27	1
6721643	115680	Central/South Asian	Indian	South India - Andhra Pradesh, Karnataka, Kerala, Tamilnadu	\N	481	1
6721644	116809	Central/South Asian	Indian	Indians in Malaysia	\N	165	1
6721645	116826	Central/South Asian	Roma	\N	\N	465	1
6721646	116818	Central/South Asian	Indian	North Indian	\N	102	1
6721647	116820	Central/South Asian	Pakistani	Punjabi	Warfarin treated patients	120	1
6721648	116603	Central/South Asian	Indian	\N	\N	40	1
6721649	116778	Central/South Asian	Indian	\N	Epilepsy patients	402	1
6721650	116774	Central/South Asian	Indian	Indians in Malaysia	\N	76	1
6721651	116776	Central/South Asian	Indian	South Indian Tamilian	Diabetes patients	80	1
6721652	113864	Central/South Asian	North Indians	\N	\N	225	1
6721653	116824	Central/South Asian	Indian	\N	Warfarin treated patients	145	1
6721654	116782	Central/South Asian	Indian	\N	Acenocoumarol treated patients	111	1
6721655	116813	Central/South Asian	Indian	North India - Punjab, Haryana, Uttar Pradesh, New Delhi, Uttarakhand	\N	209	1
6721656	116813	Central/South Asian	Indian	South India - Tamil Nadu, Andhra Pradesh, Kerala	\N	82	1
6721657	116780	Central/South Asian	Indian	South Indian	Acenocoumarol treated patients	163	1
6721658	116807	Central/South Asian	Indian	Gujarat	Diabetic patients	109	1
6721659	115712	Central/South Asian	Indian	North Indian	\N	2128	1
6721660	115712	Central/South Asian	Indian	North Indian	\N	2120	1
6721661	113850	Central/South Asian	Indian	Bihar	\N	268	1
6721662	113850	Central/South Asian	Indian	Delhi	\N	213	1
6721663	113850	Central/South Asian	Indian	Haryana	\N	108	1
6721664	113850	Central/South Asian	Indian	Punjab	\N	225	1
6721665	113850	Central/South Asian	Indian	Uttar Pradesh	\N	1098	1
6721666	113862	Central/South Asian	South Indians	\N	\N	240	1
6721667	116811	Central/South Asian	Indian	Kerala	Cardiology patients	100	1
6721668	113537	Central/South Asian	Bangladeshi	Bengali	\N	86	1
6721669	113537	Central/South Asian	Indian	Gujarati from Houston, Texas	\N	103	1
6721670	113537	Central/South Asian	Indian	Telugu from the UK	\N	102	1
6721671	113537	Central/South Asian	Pakistani	Punjabi from Lahore	\N	96	1
6721672	113537	Central/South Asian	Sri Lankan	Tamil from the UK	\N	102	1
6721673	116786	Central/South Asian	Indian	Kashmiri	Epilepsy patients	92	1
6721674	116786	Central/South Asian	Indian	Kashmiri	Healthy controls	121	1
6721675	116784	Central/South Asian	Pakistani	\N	Warfarin treated patients	74	1
6721676	116805	Central/South Asian	Indian	North Indian	Pediatric epilepsy patients	89	1
6721677	116789	Central/South Asian	Indian	West Indian	\N	289	1
6721678	116801	Central/South Asian	Indian	South Indian	Acenocoumarol treated patients	124	1
6721679	116796	Central/South Asian	Bangladeshi	\N	Warfarin treated patients	87	1
6721680	116794	Central/South Asian	Indian	South Indian	Acenocoumarol treated patients	205	1
6721681	116791	Central/South Asian	Pakistani	\N	Warfarin treated patients	509	1
6721682	116791	Central/South Asian	Pakistani	\N	Warfarin treated patients	527	1
6721683	116798	Central/South Asian	Indian	Andhra Pradesh, South India	Diabetes patients	224	1
6721684	116798	Central/South Asian	Indian	Andhra Pradesh, South India	Healthy controls	228	1
6721685	116803	Central/South Asian	Indian	\N	Phenytoin treated patients	351	1
6721686	116828	Central/South Asian	Roma	Croatian	\N	423	1
6721687	\N	Central/South Asian	South Asian	from http://gnomad.broadinstitute.org, v2.1.1. accessed 01/27/2022	\N	15308	1
6721688	\N	Central/South Asian	South Asian	from http://gnomad.broadinstitute.org, v2.1.1. accessed 01/27/2022	\N	15307	1
6721689	\N	Central/South Asian	South Asian	from http://gnomad.broadinstitute.org, v2.1.1. accessed 01/27/2022	\N	15306	1
6721690	\N	Central/South Asian	South Asian	from http://gnomad.broadinstitute.org, v2.1.1. accessed 01/27/2022	\N	15304	1
6721691	\N	Central/South Asian	South Asian	from http://gnomad.broadinstitute.org, v2.1.1. accessed 01/27/2022	\N	15305	1
6721692	116691	East Asian	Taiwanese	\N	\N	98	1
6721693	116927	East Asian	Japanese	\N	Epilepsy patients	44	1
6721694	115743	East Asian	Japanese	\N	\N	140	1
6721695	116923	East Asian	Japanese	\N	\N	47	1
6721696	115745	East Asian	Japanese	\N	Epilepsy patients	134	1
6721697	116925	East Asian	Japanese	\N	Warfarin treated patients	86	1
6721698	116751	East Asian	Chinese	Toronto, Canada	\N	102	1
6721699	116960	East Asian	Korean	\N	\N	574	1
6721700	116843	East Asian	Korean	\N	\N	150	1
6721701	116843	East Asian	Korean	\N	\N	150	1
6721702	116851	East Asian	Japanese	\N	Warfarin treated cohort	90	1
6721703	116771	East Asian	Chinese	Chinese in Malaysia	Healthy controls	50	1
6721704	116771	East Asian	Chinese	Chinese in Malaysia	Warfarin treated cohort	46	1
6721705	116771	East Asian	Malay	\N	Healthy controls	51	1
6721706	116771	East Asian	Malay	\N	Warfarin treated cohort	27	1
6721707	115788	East Asian	Taiwanese	\N	Epilepsy patients	169	1
6721708	116853	East Asian	Japanese	\N	Epilepsy patients and healthy controls	84	1
6721709	116957	East Asian	Chinese	Changsha City, Hunan Province	Healthy controls	265	1
6721710	116957	East Asian	Chinese	Changsha City, Hunan Province	Hypertension patients	239	1
6721711	116950	East Asian	Korean	\N	\N	358	1
6721712	116858	East Asian	Chinese	\N	\N	169	1
6721713	116860	East Asian	Chinese	Taihu and Dongzhi counties	\N	1087	1
6721714	116933	East Asian	Vietnamese	Kinh	\N	157	1
6721715	116968	East Asian	Chinese	\N	\N	476	1
6721716	116836	East Asian	Japanese	\N	\N	147	1
6721717	116702	East Asian	Taiwanese	\N	Healthy controls	69	1
6721718	116702	East Asian	Taiwanese	\N	Warfarin treated patients	37	1
6721719	115810	East Asian	Japanese	\N	\N	54	1
6721720	113953	East Asian	Taiwanese	\N	\N	180	1
6721721	116865	East Asian	Japanese	\N	Diabetic patients and healthy controls	263	1
6721722	116862	East Asian	Japanese	\N	Diabetic patients	134	1
6721723	116809	East Asian	Chinese	Chinese in Malaysia	\N	165	1
6721724	116809	East Asian	Malay	\N	\N	202	1
6721725	116867	East Asian	Japanese	\N	Oncology patients	21	1
6721726	114548	East Asian	Chinese	\N	\N	200	1
6721727	114548	East Asian	Japanese	1st generation Japanese living abroad	\N	210	1
6721728	114548	East Asian	Japanese	3rd generation Japanese living abroad	\N	164	1
6721729	114548	East Asian	Japanese	Native Japanese	\N	200	1
6721730	114548	East Asian	Korean	\N	\N	200	1
6721731	116874	East Asian	Japanese	\N	Stroke and hypertension patients	724	1
6721732	116878	East Asian	Han Chinese	\N	Warfarin treated patients	235	1
6721733	116876	East Asian	Chinese	\N	\N	329	1
6721734	115862	East Asian	Japanese	1st generation Japanese living in Brazil	\N	126	1
6721735	115862	East Asian	Japanese	Native Japanese	\N	200	1
6721736	113878	East Asian	Chinese	\N	\N	222	1
6721737	116882	East Asian	Han Chinese	Southwest China	Healthy controls	133	1
6721738	116882	East Asian	Han Chinese	Southwest China	Warfarin treated patients	127	1
6721739	114558	East Asian	Han Chinese	1st generation Han Chinese living in Singapore	\N	398	1
6721740	114558	East Asian	Japanese	\N	\N	500	1
6721741	114558	East Asian	Korean	\N	\N	200	1
6721742	116880	East Asian	Han Chinese	Northern Han Chinese	Epilepsy patients	179	1
6721743	116984	East Asian	Mongolian	Mongolians in China	\N	280	1
6721744	116894	East Asian	Korean	\N	\N	1796	1
6721745	116603	East Asian	Chinese	\N	\N	93	1
6721746	116603	East Asian	Malay	\N	Warfarin treated patients	85	1
6721747	116774	East Asian	Chinese	Chinese in Malaysia	\N	76	1
6721748	116774	East Asian	Malay	\N	\N	76	1
6721749	116887	East Asian	Japanese	Warfarin treated patients and healthy controls	\N	160	1
6721750	116896	East Asian	Korean	\N	Warfarin treated patients	58	1
6721751	116898	East Asian	Korean	\N	Urticara patients and healthy controls	408	1
6721752	113884	East Asian	Indonesian	\N	\N	135	1
6721753	116952	East Asian	Han Chinese	Shanghai	\N	100	1
6721754	116952	East Asian	Han Chinese	Shantou	\N	100	1
6721755	116952	East Asian	Han Chinese	Shenyang	\N	100	1
6721756	116952	East Asian	Han Chinese	Xi'an	\N	100	1
6721757	116890	East Asian	Korean	\N	\N	177	1
6721758	116616	East Asian	Chinese	\N	Warfarin treated cohort	809	1
6721759	116892	East Asian	Han Chinese	Beijing	Warfarin treated patients	328	1
6721760	116900	East Asian	Chinese	\N	Pediatric epilepsy patients	90	1
6721761	116248	East Asian	Japanese	\N	\N	218	1
6721762	116902	East Asian	Han Chinese	Taiwanese	Epilepsy patients	269	1
6721763	116902	East Asian	Han Chinese	Taiwanese	Healthy controls	190	1
6721764	116885	East Asian	Korean	\N	\N	869	1
6721765	116944	East Asian	Han Chinese	\N	\N	839	1
6721766	116905	East Asian	Thai	\N	Epilepsy patients	75	1
6721767	113880	East Asian	Indonesian	\N	Healthy controls	103	1
6721768	113880	East Asian	Indonesian	\N	Warfarin treated patients	103	1
6721769	116907	East Asian	Cambodian	\N	Malaria patients	122	1
6721770	113872	East Asian	Chinese	\N	Warfarin treated cohort	551	1
6721771	116841	East Asian	Han Chinese	Northern Chinese - Hebei Province	\N	1000	1
6721772	116841	East Asian	Han Chinese	Southern Chinese - Zhejiang Province	\N	1127	1
6721773	116841	East Asian	Han Chinese	\N	\N	2127	1
6721774	116946	East Asian	Korean	\N	\N	250	1
6721775	116909	East Asian	Han Chinese	\N	Warfarin treated patients	101	1
6721776	113537	East Asian	Chinese Dai	Xishuangbanna, China	\N	93	1
6721777	113537	East Asian	Han Chinese	Beijing, China	\N	103	1
6721778	113537	East Asian	Han Chinese	Southern Han Chinese	\N	105	1
6721779	113537	East Asian	Japanese	Tokyo, Japan	\N	104	1
6721780	113537	East Asian	Vietnamese	Kinh in Ho Chi Minh City	\N	99	1
6721781	116964	East Asian	Chinese Li	\N	\N	100	1
6721782	116913	East Asian	Korean	\N	\N	146	1
6721783	116948	East Asian	Chinese Tibetan	\N	\N	96	1
6721784	116911	East Asian	Korean	\N	\N	358	1
6721785	113876	East Asian	Chinese	\N	Warfarin treated cohort	220	1
6721786	116915	East Asian	Chinese	\N	\N	51	1
6721787	116917	East Asian	Chinese	\N	\N	30	1
6721788	116917	East Asian	Japanese	\N	\N	30	1
6721789	116917	East Asian	Korean	\N	\N	29	1
6721790	116962	East Asian	Chinese Uyghur	\N	\N	96	1
6721791	116978	East Asian	Malay	Jahai	\N	155	1
6721792	116978	East Asian	Malay	\N	\N	183	1
6721793	116981	East Asian	Malay	Orang Asil (Bateq, Che Wong, Kanaq, Kensiu, Lanoh, Semai)	\N	61	1
6721794	116981	East Asian	Malay	Singaporean Malays	\N	96	1
6721795	113874	East Asian	Chinese	\N	Warfarin treated cohort	401	1
6721796	116583	East Asian	Chinese	\N	\N	196	1
6721797	116921	East Asian	Han Chinese	Southern Han Chinese	Epilepsy patients	254	1
6721798	116986	East Asian	Vietnamese	H'Mong	\N	40	1
6721799	116986	East Asian	Vietnamese	Kinh	\N	294	1
6721800	116986	East Asian	Vietnamese	Muong	\N	103	1
6721801	116986	East Asian	Vietnamese	Nung	\N	33	1
6721802	116986	East Asian	Vietnamese	Tay	\N	103	1
6721803	116697	European	Caucasian	\N	Healthy controls	473	1
6721804	116691	European	European American	\N	\N	100	1
6721805	117072	European	Swedish	\N	\N	430	1
6721806	116681	European	European American	\N	\N	140	1
6721807	116751	European	Caucasian	American	\N	325	1
6721808	117116	European	Spanish	\N	\N	157	1
6721809	117005	European	Italian	\N	\N	157	1
6721810	117011	European	Dutch	\N	Epilepsy patients	60	1
6721811	115999	European	Italian	\N	Warfarin-treated cohort	93	1
6721812	116843	European	Swedish	\N	\N	200	1
6721813	116843	European	Swedish	\N	\N	200	1
6721814	116003	European	Belgian	\N	\N	121	1
6721815	114674	European	Croatian	\N	\N	200	1
6721816	117015	European	Spanish	\N	\N	102	1
6721817	114767	European	Russian	Voronezh region	\N	290	1
6721818	117081	European	Italian	North Italian	Acencoumarol treated patients	125	1
6721819	116851	European	Caucasian	\N	Warfarin-treated cohort	47	1
6721820	117024	European	Spanish	\N	\N	130	1
6721821	117114	European	Spanish	\N	\N	102	1
6721822	117018	European	White European	\N	\N	64	1
6721823	117020	European	White	\N	\N	126	1
6721824	117022	European	White from Brazil	\N	\N	136	1
6721825	114693	European	Faroese	\N	\N	312	1
6721826	117074	European	Spanish	\N	\N	355	1
6721827	117085	European	Russian	\N	\N	298	1
6721828	117028	European	Italian	\N	\N	78	1
6721829	116687	European	European American	\N	Healthy controls	101	1
6721830	116687	European	European American	\N	Warfarin-treated cohort	192	1
6721831	116702	European	Caucasian	\N	Healthy controls	28	1
6721832	114132	European	Greek	\N	\N	283	1
6721833	117078	European	Italian	\N	Warfarin treated patients	147	1
6721834	117078	European	Italian	\N	Warfarin treated patients	146	1
6721835	114119	European	Finnish	\N	\N	447	1
6721836	114119	European	Finnish	\N	\N	444	1
6721837	116689	European	European American	Birmingham, AL	Warfarin treated patients	218	1
6721838	116048	European	Bulgarian	\N	Acencoumarol treated patients	96	1
6721839	116867	European	Caucasian	\N	Oncology patients	46	1
6721840	117032	European	Spanish	\N	\N	311	1
6721841	116581	European	European American	\N	\N	218	1
6721842	117035	European	Spanish	\N	\N	69	1
6721843	117037	European	Greek	\N	\N	98	1
6721844	114548	European	Caucasian	\N	\N	284	1
6721845	117118	European	Finnish	\N	Hypertension patients	217	1
6721846	117039	European	Polish	\N	\N	30	1
6721847	117042	European	Greek	\N	\N	176	1
6721848	116826	European	Hungarian	\N	\N	535	1
6721849	116635	European	Swedish	\N	Warfarin-treated cohort	1496	1
6721850	117112	European	Russian	\N	\N	352	1
6721851	113892	European	Caucasian	\N	Warfarin-treated cohort	283	1
6721852	117044	European	European Caucasian	Clinics in Austria and Germany	Phenprocoumon treated patients	185	1
6721853	116579	European	Caucasian	\N	\N	106	1
6721854	116111	European	Bosnian	\N	Diabetic patients and healthy controls	81	1
6721855	117049	European	European ancestry in Brazil	Southern Brazil	Warfarin treated patients	279	1
6721856	116744	European	Spanish	\N	\N	327	1
6721857	117046	European	Caucasian	East Westphalia, Germany	Diabetic patients	540	1
6721858	117046	European	Caucasian	East Westphalia, Germany	Healthy controls	1988	1
6721859	117054	European	Swedish	\N	Simvastatin treated patients and healthy controls	1132	1
6721860	117051	European	Czech	\N	Fluvastatin treated patients	87	1
6721861	117051	European	Czech	\N	Healthy controls	254	1
6721862	117105	European	Romanian	Transylvania	\N	332	1
6721863	117056	European	Caucasian	\N	\N	246	1
6721864	116248	European	British	\N	\N	561	1
6721865	117089	European	Bashkir	Republic of Bashkortostan	\N	144	1
6721866	117089	European	Russian	Republic of Bashkortostan	\N	319	1
6721867	117089	European	Tatar	Republic of Bashkortostan	\N	279	1
6721868	116590	European	Brazilian	White	\N	608	1
6721869	117103	European	Russian	\N	Warfarin treated patients	91	1
6721870	113897	European	Italian	\N	Warfarin-treated cohort	266	1
6721871	115146	European	Spanish	\N	Organ donors and recipients	570	1
6721872	117108	European	Greek Cypriot	\N	\N	148	1
6721873	116173	European	Slovak	\N	\N	112	1
6721874	117058	European	Cuban Caucasian	\N	\N	132	1
6721875	116178	European	Spanish	\N	\N	362	1
6721876	116998	European	Caucasian	\N	\N	852	1
6721877	116176	European	Spanish	\N	\N	282	1
6721878	117087	European	Slavic	\N	Warfarin or acencoumarol treated patients	479	1
6721879	113537	European	British	England and Scotland	\N	91	1
6721880	113537	European	European American	Utah Residents (CEPH) with Northern and Western Ancestry	\N	99	1
6721881	113537	European	Finnish	\N	\N	99	1
6721882	113537	European	Italian	Toscani	\N	107	1
6721883	113537	European	Spanish	Iberian Population	\N	107	1
6721884	117064	European	British	\N	Warfarin treated patients	152	1
6721885	116913	European	Swedish	\N	\N	148	1
6721886	117061	European	European	\N	\N	283	1
6721887	116917	European	Caucasian	\N	\N	30	1
6721888	114444	European	Caucasian	\N	Pediatric patients	688	1
6721889	117069	European	Uruguayan Caucasian	\N	Epilepsy patients	50	1
6721890	117099	European	Kosovan	\N	\N	234	1
6721891	116583	European	White	\N	\N	122	1
6721892	117067	European	Polish	\N	Surgical patients	85	1
6721893	117094	European	Avar	Dagestan Republic	\N	90	1
6721894	117094	European	Dargin	Dagestan Republic	\N	50	1
6721895	117094	European	Lak	Dagestan Republic	\N	46	1
6721896	117094	European	Russian	Moscow region	\N	580	1
6721897	114639	European	Nanai	\N	\N	70	1
6721898	114400	European	Iberian	Spain and Portugal	\N	1528	1
6721899	114400	European	Latin American	White	\N	280	1
6721900	\N	European	Non-Finnish	from http://gnomad.broadinstitute.org, v2.1.1. accessed 01/27/2022	\N	64461	1
6721973	116836	Near Eastern	Israeli	Ashkenazi	\N	100	1
6721901	\N	European	Non-Finnish	from http://gnomad.broadinstitute.org, v2.1.1. accessed 01/27/2022	\N	56868	1
6721902	\N	European	Non-Finnish	from http://gnomad.broadinstitute.org, v2.1.1. accessed 01/27/2022	\N	56839	1
6721903	\N	European	Non-Finnish	from http://gnomad.broadinstitute.org, v2.1.1. accessed 01/27/2022	\N	64544	1
6721904	\N	European	Non-Finnish	from http://gnomad.broadinstitute.org, v2.1.1. accessed 01/27/2022	\N	56820	1
6721905	\N	European	Non-Finnish	from http://gnomad.broadinstitute.org, v2.1.1. accessed 01/27/2022	\N	64503	1
6721906	\N	European	Non-Finnish	from http://gnomad.broadinstitute.org, v2.1.1. accessed 01/27/2022	\N	64482	1
6721907	\N	European	Non-Finnish	from http://gnomad.broadinstitute.org, v2.1.1. accessed 01/27/2022	\N	56789	1
6721908	\N	European	Non-Finnish	from http://gnomad.broadinstitute.org, v2.1.1. accessed 01/27/2022	\N	56798	1
6721909	\N	European	Non-Finnish	from http://gnomad.broadinstitute.org, v2.1.1. accessed 01/27/2022	\N	56719	1
6721910	\N	European	Non-Finnish	from http://gnomad.broadinstitute.org, v2.1.1. accessed 01/27/2022	\N	56790	1
6721911	\N	European	Non-Finnish	from http://gnomad.broadinstitute.org, v2.1.1. accessed 01/27/2022	\N	56776	1
6721912	\N	European	Non-Finnish	from http://gnomad.broadinstitute.org, v2.1.1. accessed 01/27/2022	\N	64491	1
6721913	\N	European	Non-Finnish	from http://gnomad.broadinstitute.org, v2.1.1. accessed 01/27/2022	\N	56863	1
6721914	\N	European	Non-Finnish	from http://gnomad.broadinstitute.org, v2.1.1. accessed 01/27/2022	\N	56815	1
6721915	\N	European	Non-Finnish	from http://gnomad.broadinstitute.org, v2.1.1. accessed 01/27/2022	\N	56800	1
6721916	\N	European	Non-Finnish	from http://gnomad.broadinstitute.org, v2.1.1. accessed 01/27/2022	\N	56779	1
6721917	\N	European	Non-Finnish	from http://gnomad.broadinstitute.org, v2.1.1. accessed 01/27/2022	\N	56846	1
6721918	\N	European	Non-Finnish	from http://gnomad.broadinstitute.org, v2.1.1. accessed 01/27/2022	\N	64487	1
6721919	\N	European	Non-Finnish	from http://gnomad.broadinstitute.org, v2.1.1. accessed 01/27/2022	\N	64481	1
6721920	\N	European	Non-Finnish	from http://gnomad.broadinstitute.org, v2.1.1. accessed 01/27/2022	\N	56794	1
6721921	\N	European	Non-Finnish	from http://gnomad.broadinstitute.org, v2.1.1. accessed 01/27/2022	\N	56757	1
6721922	\N	European	Non-Finnish	from http://gnomad.broadinstitute.org, v2.1.1. accessed 01/27/2022	\N	56785	1
6721923	117114	Latino	Mexican	Mexican Americans in Los Angeles, CA	\N	98	1
6721924	117022	Latino	Brazilian	Intermediate	\N	118	1
6721925	116200	Latino	Bolivian	\N	\N	778	1
6721926	117149	Latino	Mexican	\N	\N	100	1
6721927	117159	Latino	Brazilian	Admixed population	Warfarin treated patients	51	1
6721928	116579	Latino	Hispanic	\N	Healthy donors	101	1
6721929	117137	Latino	Hispanic	Chicago, IL	Warfarin treated patients	50	1
6721930	116744	Latino	Mexican	Mestizo from Durango	\N	102	1
6721931	117139	Latino	Brazilian	Curitiba and metropolitan area	Epilepsy patients	100	1
6721932	117144	Latino	Ecuadorian	\N	\N	194	1
6721933	114506	Latino	Chilean	Santiago	\N	253	1
6721934	117152	Latino	Argentinian	\N	\N	101	1
6721935	117141	Latino	Brazilian	\N	Warfarin treated patients	206	1
6721936	117058	Latino	Cuban	Mestizo	\N	128	1
6721937	116176	Latino	Ecuadorian	Mestizo	\N	297	1
6721938	113537	Latino	Colombian	Medellin	\N	94	1
6721939	113537	Latino	Mexican	Mexican Ancestry from Los Angeles USA	\N	64	1
6721940	113537	Latino	Peruvian	Lima	\N	85	1
6721941	113537	Latino	Puerto Rican	\N	\N	104	1
6721942	116746	Latino	Mexican	Mestizo	\N	295	1
6721943	113905	Latino	Caribbean	Hispanic	Warfarin treated patients	255	1
6721944	116226	Latino	Mexican	Mestizo	Epilepsy patients	64	1
6721945	117155	Latino	Mexican	Mestizo	\N	477	1
6721946	114400	Latino	Latin Americans	Admixed population	\N	2237	1
6721947	\N	Latino	Latino/admix american	from http://gnomad.broadinstitute.org, v2.1.1. accessed 01/27/2022	\N	17697	1
6721948	\N	Latino	Latino/admix american	from http://gnomad.broadinstitute.org, v2.1.1. accessed 01/27/2022	\N	17280	1
6721949	\N	Latino	Latino/admix american	from http://gnomad.broadinstitute.org, v2.1.1. accessed 01/27/2022	\N	17264	1
6721950	\N	Latino	Latino/admix american	from http://gnomad.broadinstitute.org, v2.1.1. accessed 01/27/2022	\N	17692	1
6721951	\N	Latino	Latino/admix american	from http://gnomad.broadinstitute.org, v2.1.1. accessed 01/27/2022	\N	17263	1
6721952	\N	Latino	Latino/admix american	from http://gnomad.broadinstitute.org, v2.1.1. accessed 01/27/2022	\N	17692	1
6721953	\N	Latino	Latino/admix american	from http://gnomad.broadinstitute.org, v2.1.1. accessed 01/27/2022	\N	17276	1
6721954	\N	Latino	Latino/admix american	from http://gnomad.broadinstitute.org, v2.1.1. accessed 01/27/2022	\N	17258	1
6721955	\N	Latino	Latino/admix american	from http://gnomad.broadinstitute.org, v2.1.1. accessed 01/27/2022	\N	17243	1
6721956	\N	Latino	Latino/admix american	from http://gnomad.broadinstitute.org, v2.1.1. accessed 01/27/2022	\N	17266	1
6721957	\N	Latino	Latino/admix american	from http://gnomad.broadinstitute.org, v2.1.1. accessed 01/27/2022	\N	17251	1
6721958	\N	Latino	Latino/admix american	from http://gnomad.broadinstitute.org, v2.1.1. accessed 01/27/2022	\N	17269	1
6721959	\N	Latino	Latino/admix american	from http://gnomad.broadinstitute.org, v2.1.1. accessed 01/27/2022	\N	17688	1
6721960	\N	Latino	Latino/admix american	from http://gnomad.broadinstitute.org, v2.1.1. accessed 01/27/2022	\N	17271	1
6721961	\N	Latino	Latino/admix american	from http://gnomad.broadinstitute.org, v2.1.1. accessed 01/27/2022	\N	17267	1
6721962	\N	Latino	Latino/admix american	from http://gnomad.broadinstitute.org, v2.1.1. accessed 01/27/2022	\N	17275	1
6721963	\N	Latino	Latino/admix american	from http://gnomad.broadinstitute.org, v2.1.1. accessed 01/27/2022	\N	17250	1
6721964	\N	Latino	Latino/admix american	from http://gnomad.broadinstitute.org, v2.1.1. accessed 01/27/2022	\N	17273	1
6721965	\N	Latino	Latino/admix american	from http://gnomad.broadinstitute.org, v2.1.1. accessed 01/27/2022	\N	17700	1
6721966	\N	Latino	Latino/admix american	from http://gnomad.broadinstitute.org, v2.1.1. accessed 01/27/2022	\N	17699	1
6721967	\N	Latino	Latino/admix american	from http://gnomad.broadinstitute.org, v2.1.1. accessed 01/27/2022	\N	17707	1
6721968	\N	Latino	Latino/admix american	from http://gnomad.broadinstitute.org, v2.1.1. accessed 01/27/2022	\N	17279	1
6721969	\N	Latino	Latino/admix american	from http://gnomad.broadinstitute.org, v2.1.1. accessed 01/27/2022	\N	17248	1
6721970	116262	Near Eastern	Turkish	South-East Anatolia	\N	96	1
6721974	116836	Near Eastern	Israeli	Libyan	\N	89	1
6721975	116836	Near Eastern	Israeli	Moroccan	\N	100	1
6721976	116836	Near Eastern	Israeli	Yementite	\N	99	1
6721977	114806	Near Eastern	Ashkenazi Jews	New York	\N	250	1
6721978	117215	Near Eastern	Omani	\N	Warfarin treated patients	189	1
6721979	116235	Near Eastern	Iranian	\N	\N	200	1
6721980	116657	Near Eastern	Ashkenazi Jews in NY	\N	\N	260	1
6721981	116657	Near Eastern	Sephardi Jews in NY	\N	\N	80	1
6721982	116240	Near Eastern	Iranian	Shiraz	\N	148	1
6721983	116660	Near Eastern	Israeli population	Arab Moslem	\N	96	1
6721984	116660	Near Eastern	Israeli population	Druze	\N	180	1
6721985	116660	Near Eastern	Israeli population	Jewish	\N	162	1
6721986	116242	Near Eastern	Iranian	\N	Warfarin treated patients	100	1
6721987	116579	Near Eastern	Ashkenazi Jews	New York	\N	502	1
6721988	116645	Near Eastern	Lebanese	\N	\N	161	1
6721989	116647	Near Eastern	Lebanese	\N	\N	231	1
6721990	117162	Near Eastern	Egyptian	\N	Warfarin treated patients	207	1
6721991	117174	Near Eastern	Egyptian	\N	\N	200	1
6721992	116248	Near Eastern	Iranian	Mazandaran	\N	103	1
6721993	113912	Near Eastern	Israeli patients	\N	Warfarin-treated cohort	210	1
6721994	113908	Near Eastern	Omani	\N	\N	220	1
6721995	117210	Near Eastern	Turkish	\N	Anticoagulant treated patients	292	1
6721996	114204	Near Eastern	Jordanian	\N	\N	263	1
6721997	116651	Near Eastern	Arabic population in Saudi arabia	\N	Healthy adults	131	1
6721998	117164	Near Eastern	Moroccan	\N	Acencoumarol treated patients	114	1
6721999	117172	Near Eastern	Egyptian	\N	Warfarin treated pediatric patients	41	1
6722000	117168	Near Eastern	Tunisian	\N	\N	258	1
6722001	117166	Near Eastern	Egyptian	\N	Warfarin treated patients	80	1
6722002	117212	Near Eastern	Turkish	\N	Behcet's disease patients	52	1
6722003	117212	Near Eastern	Turkish	\N	Healthy controls	73	1
6722004	116649	Near Eastern	Iranian	\N	\N	115	1
6722005	117199	Near Eastern	Turkish	\N	Warfarin treated pediatric patients and healthy controls	207	1
6722006	117170	Near Eastern	Moroccan	\N	\N	290	1
6722007	114837	Near Eastern	Turkish	\N	\N	160	1
6722008	117201	Near Eastern	Iranian	Birjand	\N	120	1
6722009	117203	Near Eastern	Iranian	Sistani ethnic group	\N	140	1
6722010	114400	Near Eastern	Ashkenazi Jews	Argentinian	\N	173	1
6722011	117206	Near Eastern	Ashkenazi Jews	\N	\N	5076	1
6722012	\N	Near Eastern	Ashkenazi Jewish	from http://gnomad.broadinstitute.org, v2.1.1. accessed 01/27/2022	\N	5181	1
6722013	\N	Near Eastern	Ashkenazi Jewish	from http://gnomad.broadinstitute.org, v2.1.1. accessed 01/27/2022	\N	5039	1
6722014	\N	Near Eastern	Ashkenazi Jewish	from http://gnomad.broadinstitute.org, v2.1.1. accessed 01/27/2022	\N	5037	1
6722015	\N	Near Eastern	Ashkenazi Jewish	from http://gnomad.broadinstitute.org, v2.1.1. accessed 01/27/2022	\N	5182	1
6722016	\N	Near Eastern	Ashkenazi Jewish	from http://gnomad.broadinstitute.org, v2.1.1. accessed 01/27/2022	\N	5035	1
6722017	\N	Near Eastern	Ashkenazi Jewish	from http://gnomad.broadinstitute.org, v2.1.1. accessed 01/27/2022	\N	5180	1
6722018	\N	Near Eastern	Ashkenazi Jewish	from http://gnomad.broadinstitute.org, v2.1.1. accessed 01/27/2022	\N	5038	1
6722019	\N	Near Eastern	Ashkenazi Jewish	from http://gnomad.broadinstitute.org, v2.1.1. accessed 01/27/2022	\N	5034	1
6722020	\N	Near Eastern	Ashkenazi Jewish	from http://gnomad.broadinstitute.org, v2.1.1. accessed 01/27/2022	\N	5036	1
6722021	\N	Near Eastern	Ashkenazi Jewish	from http://gnomad.broadinstitute.org, v2.1.1. accessed 01/27/2022	\N	5178	1
6722022	\N	Near Eastern	Ashkenazi Jewish	from http://gnomad.broadinstitute.org, v2.1.1. accessed 01/27/2022	\N	5183	1
6722023	\N	Near Eastern	Ashkenazi Jewish	from http://gnomad.broadinstitute.org, v2.1.1. accessed 01/27/2022	\N	5031	1
6722024	114842	Oceanian	New Zealand Maori	\N	\N	60	1
6722025	116998	Oceanian	Polynesian	Maori and pacific island	\N	1072	1
6722026	117005	Sub-Saharan African	Black from Ethiopians	\N	\N	150	1
6722027	116843	Sub-Saharan African	Ethiopian	\N	\N	150	1
6722028	116843	Sub-Saharan African	Ethiopian	\N	\N	150	1
6722029	116843	Sub-Saharan African	Tanzanian	\N	\N	183	1
6722030	116843	Sub-Saharan African	Tanzanian	\N	\N	183	1
6722031	116003	Sub-Saharan African	Beninese	Zou department of Benin	\N	111	1
6722032	117022	Sub-Saharan African	Black from Brazil	\N	\N	77	1
6722033	117236	Sub-Saharan African	Beninese	\N	\N	109	1
6722034	117232	Sub-Saharan African	Ethiopian	\N	\N	150	1
6722035	117238	Sub-Saharan African	Gambian	Farafenni and surrounding villages	\N	43	1
6722036	116338	Sub-Saharan African	Ghanaian	\N	\N	204	1
6722037	114248	Sub-Saharan African	South African	Black	\N	993	1
6722038	116723	Sub-Saharan African	Mozambican	Maputo	Warfarin treated patients and healthy controls	206	1
6722039	116248	Sub-Saharan African	Ethiopian	\N	\N	150	1
6722040	116590	Sub-Saharan African	Black from Brazil	\N	\N	117	1
6722041	116907	Sub-Saharan African	Tanzanian	\N	Malaria patients	131	1
6722042	113537	Sub-Saharan African	Gambian	Mandinka	\N	113	1
6722043	113537	Sub-Saharan African	Kenyan	Luhya in Webuye	\N	99	1
6722044	113537	Sub-Saharan African	Nigerian	Esan	\N	99	1
6722045	113537	Sub-Saharan African	Nigerian	Yoruba in Ibadan	\N	108	1
6722046	113537	Sub-Saharan African	Sierra Leonean	Mende	\N	85	1
6722047	117241	Sub-Saharan African	Ghanaian	\N	Warfarin treated patients	86	1
6722048	117241	Sub-Saharan African	Ghanaian	\N	Warfarin treated patients	84	1
6722049	114400	Sub-Saharan African	Afro-Latin Americans	\N	\N	89	1
6722050	114361	African American/Afro-Caribbean	African American	\N	healthy subjects	408	1
6722051	114363	African American/Afro-Caribbean	African American	\N	healthy subjects	246	1
6722052	114365	African American/Afro-Caribbean	African American	Southern CA	healthy subjects	154	1
6722053	114367	African American/Afro-Caribbean	African American	Atlanta	healthy subjects	251	1
6722054	114369	African American/Afro-Caribbean	African American	\N	healthy subjects	193	1
6722055	114371	African American/Afro-Caribbean	African American	\N	healthy subjects	251	1
6722056	114373	African American/Afro-Caribbean	African American	\N	healthy subjects	251	1
6722057	114375	African American/Afro-Caribbean	African American	\N	controls	131	1
6723058	\N	East Asian	East Asian	\N	\N	14834	1
6722058	114375	African American/Afro-Caribbean	African American	\N	controls+psychiatric patients	222	1
6722059	114375	African American/Afro-Caribbean	African American	\N	psychiatric	91	1
6722060	114379	African American/Afro-Caribbean	African American	\N	healthy subjects+sickle cell patients	407	1
6722061	114385	African American/Afro-Caribbean	African American	\N	healthy subjects+sickle cell patients	422	1
6722062	114381	African American/Afro-Caribbean	African American	Atlanta	healthy subjects	280	1
6722063	114381	African American/Afro-Caribbean	African American	Kansas City	sickle cell patients	125	1
6722064	114381	African American/Afro-Caribbean	African American	Milwaukee	sickle cell patients	73	1
6722065	114387	African American/Afro-Caribbean	African American	\N	healthy subjects, or with unrelated disease	272	1
6722066	114389	African American/Afro-Caribbean	African American	Kentucky	mentally ill patients	452	1
6722067	114391	African American/Afro-Caribbean	African American	Kansas City	sickle cell patients	154	1
6722068	114406	African American/Afro-Caribbean	Trinidadian	Afro-trinidadians	healthy subjects	103	1
6722069	114393	African American/Afro-Caribbean	African American	Atlanta	sickle cell patients	75	1
6722070	114402	African American/Afro-Caribbean	Costa Rican	Afro-Caribbean	healthy	49	1
6722071	114397	African American/Afro-Caribbean	Antillean	Dutch Caribbean living in the Netherlands	healthy	165	1
6722072	114397	African American/Afro-Caribbean	Antillean	Island of Curacao, mainly African decent	mentally ill	231	1
6722073	114395	African American/Afro-Caribbean	African American	self defined, living in the US	patients for which a PGx test was ordered	6762	1
6722074	114400	African American/Afro-Caribbean	Costa Rica & Cuba	Afro Latin American	Afro-descendants (Costa Rica) or 4 grandparents (Cuba)	82	1
6722075	114404	African American/Afro-Caribbean	African American	African American/Black	US military volunteers	158	1
6722076	3001761	African American/Afro-Caribbean	People with African Ancestry in Southwest United States/African Caribbean in Barbados	\N	healthy subjects	157	1
6722077	114449	American	Canadian	Inuit	healthy, unrelated in first degree	90	1
6722078	114451	American	Canadian	Native Indians, Toronto	\N	39	1
6722079	114451	American	Canadian	Native Indians, Toronto, mixed ancestry	\N	110	1
6722080	114454	American	Chilean	Mapuches, Southern Chile	healthy subjects	84	1
6722081	114477	American	Panamanian	Embera	healthy subjects	136	1
6722082	114477	American	Panamanian	Ngawbe	healthy subjects	105	1
6722083	114470	American	Mexican	Tepehuano, Guajolota Community	healthy subjects	85	1
6722084	114447	American	Argentinian+Paraguayan	Native Americans	healthy subjects	84	1
6722085	114459	American	Mexican	Amerindian (Mixtecos, Tepehuanos, Maysa, Zapotecos)	healthy subjects	120	1
6722086	114480	American	Venezuelan	Bari	healthy subjects	40	1
6722087	114480	American	Venezuelan	Bari, Panare, Pemon, Warao, Wayuu	healthy subjects	179	1
6722088	114480	American	Venezuelan	Panare	healthy subjects	46	1
6722089	114480	American	Venezuelan	Pemon	healthy subjects	40	1
6722090	114480	American	Venezuelan	Warao	healthy subjects	29	1
6722091	114480	American	Venezuelan	Wayuu	healthy subjects	24	1
6722092	114461	American	Mexican	5 Amerindian subpopulations	healthy subjects	291	1
6722093	114402	American	Costa Rican	Amerindian	healthy	197	1
6722094	114463	American	Mexican	Coras	healthy	81	1
6722095	114463	American	Mexican	Huicholes	healthy	107	1
6722096	114463	American	Mexican	Tarahumaras	healthy	74	1
6722097	114463	American	Mexican	Tepehuanos	healthy	129	1
6722098	114468	American	Mexican	Lacandones	healthy	154	1
6722099	114488	American	Venezuelan	Estado Aragua	\N	145	1
6722100	114472	American	Mexican Native	Tzotzil, Tzeltal	healthy	110	1
6722101	114457	American	Ecuadorian	\N	healthy subjects	139	1
6722102	114444	American	American Native Indian	Helena, Montana	psychiatric patients	123	1
6722103	114442	American	Alaska Native	AIAN people	\N	380	1
6722104	114442	American	American Native Indian	Kootenai	\N	187	1
6722105	114400	American	Native Americans (Central)	rural populations, locally recognized as indiginous	\N	196	1
6722106	114400	American	Native Americans (North)	rural populations, locally recognized as indiginous	\N	946	1
6722107	114400	American	Native Americans (South)	rural populations, locally recognized as indiginous	\N	214	1
6722108	114404	American	Native American/Alaska Native	\N	US military volunteers	7	1
6722109	3001761	American	American (AMR)	\N	healthy subjects	345	1
6722110	114851	Central/South Asian	Indian	West and central India	healthy	881	1
6722111	114853	Central/South Asian	Indian	living in Malaysia	healthy subjects	83	1
6722112	114878	Central/South Asian	Tamil	\N	healthy subjects	106	1
6722113	114855	Central/South Asian	Indian	Andhra Pradesh, South India	healthy	106	1
6722114	114855	Central/South Asian	Indian	Karanatka, South India	healthy	94	1
6722115	114855	Central/South Asian	Indian	Kerala, South India	healthy	107	1
6722116	114855	Central/South Asian	Indian	Tamildadu, South India	healthy	140	1
6722117	114421	Central/South Asian	South/Central Asia	\N	Human Genome Diversity Panels	210	1
6722118	114695	Central/South Asian	Indian	Ahmedabad, Gujarat, West India	healthy subjects	160	1
6722119	114861	Central/South Asian	Indian	Uttar Pradash, North India	healthy	300	1
6722120	114863	Central/South Asian	Indian	North Indians	healthy	125	1
6722121	114865	Central/South Asian	Indian	Jawaharlal, South Indians	Breast cancer	132	1
6722122	114406	Central/South Asian	Trinidadian	Indo-Trinidadians	healthy subjects	167	1
6722123	114867	Central/South Asian	Indian	Madras	hypertensive patients and controls	160	1
6722124	114874	Central/South Asian	Pakistani	Rawalpindi	breast cancer	223	1
6722125	114876	Central/South Asian	Pakistani	Pathan/Khyber, Pakhtunkhwa province	healthy volunteers	200	1
6722126	114569	Central/South Asian	Indian	Singapore	TTSH Biobank	179	1
6722127	114870	Central/South Asian	Indian	subjects of Kashmir origin	controls	200	1
6722128	114872	Central/South Asian	Indian	Western India, Mumbai	healthy volunteers	49	1
6722129	114880	Central/South Asian	Indian	South Indian	MDD patients	105	1
6722130	3001761	Central/South Asian	South Asian (SAS)	\N	healthy subjects	481	1
6722131	114580	East Asian	Japanese	\N	healthy subjects	318	1
6722132	114582	East Asian	Japanese	\N	healthy subjects	98	1
6722133	114584	East Asian	Japanese	\N	healthy subjects	162	1
6722134	114586	East Asian	Japanese	\N	healthy subjects	206	1
6722135	114632	East Asian	Malay	Kuala Lumpur	healthy subjects	107	1
6722136	114588	East Asian	Japanese	\N	healthy subjects	151	1
6722137	114540	East Asian	Chinese	\N	healthy subjects	223	1
6722138	114590	East Asian	Japanese	\N	healthy subjects	162	1
6722139	114542	East Asian	Chinese	living in Malaysia	healthy subjects+patients	236	1
6722140	114592	East Asian	Japanese	\N	healthy subjects	86	1
6722141	114594	East Asian	Japanese	\N	subjects on antiarrythmic drugs and/or beta-blockers	254	1
6722142	114596	East Asian	Japanese	\N	healthy subjects	286	1
6722143	114598	East Asian	Japanese	\N	healthy subjects	285	1
6722144	114620	East Asian	Korean	\N	anonymized subjects	400	1
6722145	114544	East Asian	Chinese	\N	healthy subjects	295	1
6722146	114546	East Asian	Chinese	Eastern Han	healthy subjects	363	1
6722147	114421	East Asian	East Asian	\N	Human Genome Diversity Panels	241	1
6722148	114548	East Asian	Chinese	Singapore	healthy subjects	100	1
6722149	114548	East Asian	Japanese	1st generation Japanese	healthy subjects	105	1
6722150	114548	East Asian	Japanese	3rd generation Japanese	healthy subjects	82	1
6722151	114548	East Asian	Japanese	Native Japanese	healthy subjects	100	1
6722152	114548	East Asian	Korean	\N	healthy subjects	100	1
6722153	114550	East Asian	Chinese	Han, Shanghai	healthy subjects	100	1
6722154	114550	East Asian	Chinese	Han, Shantou	healthy subjects	100	1
6722155	114550	East Asian	Chinese	Han, Shenyang	healthy subjects	100	1
6722156	114550	East Asian	Chinese	Han, Xi'an	healthy subjects	100	1
6722157	114603	East Asian	Japanese	\N	healthy subjects	455	1
6722158	114623	East Asian	Korean	\N	healthy subjects	758	1
6722159	114656	East Asian	Vietnamese	Kinh origin	healthy subjects	74	1
6722160	114554	East Asian	Chinese	Han, Beijing	HapMap and healthy subjects	100	1
6722161	114556	East Asian	Chinese	Han	DNA Repository of the PGRC	89	1
6722162	114556	East Asian	Korean	\N	DNA Repository of the PGRC	758	1
6722163	114556	East Asian	Vietnamese	Viet Kinh	DNA Repository of the PGRC	122	1
6722164	114607	East Asian	Japanese	\N	breast cancer	282	1
6722165	114605	East Asian	Japanese	\N	healthy subjects	98	1
6722166	114558	East Asian	Chinese	Han	healthy subjects	500	1
6722167	114558	East Asian	Japanese	\N	healthy subjects	398	1
6722168	114558	East Asian	Korean	\N	healthy subjects	200	1
6722169	114641	East Asian	Thai	\N	healthy subjects	288	1
6722170	114627	East Asian	Korean	\N	healthy subjects	49	1
6722171	114610	East Asian	Japanese	\N	breast cancer patients	98	1
6722172	114574	East Asian	Chinese	Han Chinese; across China	healthy subjects	214	1
6722173	114574	East Asian	Chinese	Hui Chinese; Ningxia Hui Autonomous Region	healthy subjects	111	1
6722174	114574	East Asian	Mongolian	China; Inner Mongolia Autonomous Region	healthy subjects	129	1
6722175	114560	East Asian	Chinese	Han	healthy subjects	136	1
6722176	114560	East Asian	Chinese	Hui	healthy subjects	164	1
6722177	114560	East Asian	Mongolian	living in China	healthy subjects	158	1
6722178	114560	East Asian	Uyghur	living in China	healthy subjects	214	1
6722179	114643	East Asian	Thai	\N	breast cancer patients	57	1
6722180	114653	East Asian	Tibetan	living in China	healthy subjects	96	1
6722181	114578	East Asian	Filipino	\N	breast cancer patients	138	1
6722182	114578	East Asian	Vietnamese	\N	breast cancer patients	86	1
6722183	114572	East Asian	Chinese	Han Chinese; northern and southern regions	healthy	1954	1
6722184	114563	East Asian	Chinese	residing in Ningxia	healthy and hyperlipidemia patients	350	1
6722185	114565	East Asian	Chinese	residing in Seoul	all male, healthy subjects	130	1
6722186	114565	East Asian	Japanese	Fukuoka	healthy subjects, 81% male	208	1
6722187	114565	East Asian	Korean	seoul or Gyeonggi-do	all male, healthy subjects	448	1
6722188	114567	East Asian	Chinese	Eastern Han	healthy	229	1
6722189	114613	East Asian	Japanese	\N	healthy	1017	1
6722190	114634	East Asian	Malay	Breat cancer	\N	52	1
6722191	312209	East Asian	Thai	\N	healthy	190	1
6722192	114647	East Asian	Thai	\N	autistic children	86	1
6722193	114569	East Asian	Chinese	Singapore	TTSH Biobank	201	1
6722194	114569	East Asian	Malay	Singapore	TTSH Biobank	126	1
6722195	114639	East Asian	Russian	Nanai, Khabarovsk territory, Russian Far East	healthy volunteers	70	1
6722196	114649	East Asian	Thai	\N	autistic children	97	1
6722197	114630	East Asian	Korean	\N	healthy subjects	3417	1
6722198	114651	East Asian	Thai	\N	healthy volunteers	721	1
6722199	114615	East Asian	Japanese	\N	controls (no methamphetamine)	567	1
6722200	114615	East Asian	Japanese	\N	methamphetamine abusers	82	1
6722201	114618	East Asian	Karen	living in Thailand/Myanmar border region	\N	70	1
6722202	114659	East Asian	Vietnamese	Kinh origin	Healthy volunteers	136	1
6722203	3001761	East Asian	East Asian (EAS)	\N	healthy subjects	502	1
6722204	114703	European	French	\N	healthy(n=144); various diseases (n=528)	672	1
6722205	114705	European	German	\N	healthy subjects	589	1
6722206	114707	European	German	\N	healthy subjects	195	1
6722207	114363	European	Caucasian	\N	healthy subjects	464	1
6722208	114736	European	North American	\N	healthy subjects	208	1
6722209	114688	European	Dutch	\N	healthy subjects	765	1
6722210	114365	European	North American	Southern CA	healthy subjects	143	1
6722211	114751	European	Norwegian	\N	healthy subjects	83	1
6722212	114755	European	Polish	\N	healthy subjects	300	1
6722213	114674	European	Croatian	\N	healthy subjects	200	1
6722214	114369	European	North American	Kansas City	healthy subjects	203	1
6722215	114767	European	Russian	Voronezh Region	71 healthy+other misc patients	290	1
6722216	114771	European	Sardinian	\N	healthy subjects	48	1
6722217	114771	European	Spanish	Southern Spain	healthy subjects	51	1
6722218	114709	European	German	\N	healthy subjects	308	1
6722219	114720	European	Italian	\N	healthy subjects	360	1
6722220	114793	European	Swedish	\N	blood donors	281	1
6722221	114793	European	Swedish	\N	fatal intoxication cases	236	1
6722222	114373	European	North American	Kansas City	healthy subjects	203	1
6722223	114693	European	Faroese	\N	healthy subjects	309	1
6722224	114681	European	Danish	\N	healthy subjects	276	1
6722225	114379	European	North American	\N	healthy subjects	209	1
6722226	114670	European	Caucasian	\N	hepatocytes	51	1
6722227	114774	European	Spanish	\N	healthy subjects	105	1
6722228	114683	European	Danish	\N	healthy controls	244	1
6722229	114683	European	Danish	\N	psychiatric patients	225	1
6722230	114711	European	German	\N	healthy subjects	308	1
6722231	114132	European	Greek	\N	healthy subjects	283	1
6722232	114776	European	Spanish	Barcelona	Trauma service patients	290	1
6722233	114385	European	North American	\N	healthy subjects	339	1
6722234	114381	European	North American	\N	healthy subjects	262	1
6722235	114421	European	European	\N	Human Genome Diversity Panels	157	1
6722236	114677	European	Czech	\N	healthy subjects	223	1
6722237	114778	European	Spanish	Barcelona	psychiatric patients (no extrapyramidal symptoms)	188	1
6722238	114778	European	Spanish	Barcelona	psychiatric patients (with extrapyramidal symptoms)	79	1
6722239	114387	European	North American	\N	healthy subjects+patients with unrelated disease	347	1
6722240	114753	European	Norwegian	\N	breast cancer patients	151	1
6722241	114548	European	Caucasian	\N	healthy subjects	142	1
6722242	114757	European	Portugese	\N	healthy subjects	100	1
6722243	114410	European	Brazilian	European descent	healthy subjects	92	1
6722244	114410	European	Brazilian	European descent	schizophrenia patients	186	1
6722245	114800	European	Swiss	\N	healthy subjects	165	1
6722246	114408	European	Brazilian	European descent, Sao Paulo	general population treated at hospital	178	1
6722247	114695	European	Finnish	Kankaanpää. West Finnish	healthy subjects	56	1
6722248	114695	European	Finnish	Suomussalami, Est Finnish	healthy subjects	86	1
6722249	114389	European	North American	Kentucky	mentally ill patients	3779	1
6722250	114722	European	Italian	\N	healthy subjects	218	1
6722251	114722	European	Italian	\N	multiple chemical sensitivity patients	110	1
6722252	114781	European	Spanish	La Alpujarra region	healthy subjects	104	1
6722253	114781	European	Spanish	\N	healthy subjects	185	1
6722254	114391	European	North American	Kansas City	healthy subjects	237	1
6722255	114391	European	Spanish	\N	healthy subjects+psychiatric patients	176	1
6722256	114558	European	North American & European	\N	healthy subjects	454	1
6722257	114686	European	Danish	\N	multiple myeloma patients	228	1
6722258	114796	European	Swedish	\N	fatal intoxication cases	239	1
6722259	114796	European	Swedish	\N	natural death cases	205	1
6722260	114796	European	Swedish	\N	suicide cases	254	1
6722261	114664	European	Austrian	\N	healthy subjects	93	1
6722262	114714	European	Hungarian	\N	healthy subjects	112	1
6722263	114725	European	Italian	\N	breast cancer, controls	300	1
6722264	114517	European	Cuban	European descent	healthy subjects	130	1
6722265	114679	European	Czech	\N	orthopedic patients (knee arthroscopy)	156	1
6722266	312282	European	Portugese	\N	healthy	1138	1
6722267	114785	European	Spanish	\N	breast cancer	133	1
6722268	114718	European	Hungarian	\N	recurrent unipolar depression patients	55	1
6722269	114746	European	North American	\N	orthopedic trauma patients	112	1
6722270	114787	European	Spanish	\N	breast cancer	90	1
6722271	114733	European	Macedonian	\N	healthy	184	1
6722272	114802	European	Swiss	\N	breast cancer	99	1
6722273	114802	European	Swiss	\N	breast cancer	99	1
6722274	114690	European	Dutch & Belgian	\N	breast cancer	196	1
6722275	114662	European	Albanian	\N	DNA bank	100	1
6722276	114662	European	Macedonian	\N	DNA bank	100	1
6722277	114662	European	Roma	\N	DNA bank	100	1
6722278	114769	European	Russian	St Petersburg	blood donors	1230	1
6722279	114716	European	Hungarian	\N	healthy	431	1
6722280	114716	European	Roma	\N	healthy	426	1
6722281	114444	European	Caucasian	Helena, Montana	psychiatric patients	688	1
6722282	114698	European	Finnish	living in Helsinki region	healthy volunteers	857	1
6722283	114789	European	Spanish	\N	first episode psychosis patients	70	1
6722284	114791	European	Spanish	Madrid	healthy subjects	148	1
6722285	114727	European	Italian	central Italy	healthy volunteers	55	1
6722286	114727	European	Italian	northern Italy	healthy volunteers	64	1
6722287	114727	European	Italian	southern Italy	healthy volunteers	55	1
6722288	114731	European	Italian	\N	patient control cohort	169	1
6722289	114395	European	North American	self defined as 'Caucasian', living in the US	patients for which a PGx test was ordered	37571	1
6722290	114400	European	Portugese & Spanish	Iberian	\N	1530	1
6722291	114700	European	Finnish	\N	female controls	597	1
6722292	114700	European	Finnish	\N	male controls	257	1
6722293	114761	European	Portugese	\N	women after giving birth	55	1
6722294	114761	European	Portugese	\N	women of child-bearing age	53	1
6722295	114404	European	White/Caucasian	\N	US military volunteers	300	1
6722296	3001761	European	European (EUR)	\N	healthy subjects	498	1
6722297	114531	Latino	Nicaraguan	\N	healthy subjects	137	1
6722298	114513	Latino	Columbian	Mestizo-prevalent	healthy subjects	121	1
6722299	114491	Latino	American	Mexican American, Southern CA	healthy subjects	349	1
6722300	114493	Latino	American	Mexican American, El Paso, TX	healthy subjects	50	1
6722301	114495	Latino	American	Mexican American, Southern CA	healthy subjects	264	1
6722302	114523	Latino	Mexican	Mestizos	healthy subjects	243	1
6722303	114470	Latino	Mexican	Mestizos, Nuevo Ideal	healthy subjects	110	1
6722304	114535	Latino	Puerto Rican	\N	random newborns	94	1
6722305	114408	Latino	Brazilian	Mulatto, Sao Paulo	general population treated at hospital	89	1
6722306	114499	Latino	Brazilian	Sao Paulo	ALL pediatric patients	95	1
6722307	114391	Latino	American	Hispanic living in Kansas City	anonymous subjects	150	1
6722308	114391	Latino	Puerto Rican	\N	psychiatric patients	50	1
6722309	114459	Latino	Mexican	6 different Mestizo subpopulations	healthy subjects	96	1
6722310	114533	Latino	Nicaraguan	Mestizos	healthy subjects	98	1
6722311	114502	Latino	Brazilian	Porto Allegre	breast cancer patients	97	1
6722312	114521	Latino	Ecuadorian	Mestizo	healthy subjects	118	1
6722313	114480	Latino	Venezuelan	urban admixed, city of Barquisimeto	healthy subjects	149	1
6722314	114517	Latino	Cuban	Mestizos	healthy subjects	126	1
6722315	114506	Latino	Chilean	Santiago de Chile, (37% Amerindian/Caucasian)	healthy subjects	253	1
6722316	114461	Latino	Mexican	Western Mestizos	healthy subjects	125	1
6722317	114402	Latino	Costa Rican	Mestizos	healthy	139	1
6722318	114504	Latino	Brazilian	North, Northeast, Southeast, South	healthy subjects	1020	1
6722319	114468	Latino	Mexican	Mestizos, Chiapas	healthy	100	1
6722320	114472	Latino	Mexican	Mestizo, Nuevo Léon, NE Mexico	healthy	102	1
6722321	114472	Latino	Mexican	Mestizo, San Critobal de las Casas	healthy	102	1
6722322	114508	Latino	Chilean	Mestizos (general population, Santiago)	healthy	321	1
6722323	114510	Latino	Chilean	Mestizos, eastern part hospital of San Jose	healthy volunteers	123	1
6722324	114510	Latino	Chilean	Mestizos, northern part of San Jose	healthy volunteers	121	1
6722325	114519	Latino	Cuban	\N	healthy subjects	174	1
6722326	114395	Latino	American	self defined as 'Hispanic', living in the US	subjects receiving PGx testing	2072	1
6722327	114400	Latino	Admixed Latin American	Mestizo	\N	1898	1
6722328	114400	Latino	Cuban	White Latin American; 4 white grandparents	\N	267	1
6722329	114404	Latino	Hispanic/LatinX	\N	US military volunteers	94	1
6722330	114818	Near Eastern	Saudi Arabian	\N	healthy subjects	101	1
6722331	114823	Near Eastern	Turkish	SE Anatolia	healthy subjects	404	1
6722332	114771	Near Eastern	Syrian	\N	healthy subjects	51	1
6722333	114809	Near Eastern	Bedouin	Israel	healthy subjects	50	1
6722334	114825	Near Eastern	Turkish	\N	healthy subjects	140	1
6722335	114827	Near Eastern	Turkish	Bursa	\N	100	1
6722336	114806	Near Eastern	Ashkenazi Jews	New York	healthy subjects	250	1
6722337	114421	Near Eastern	Middle-Eastern	\N	Human Genome Diversity Panels	148	1
6722338	114813	Near Eastern	Iranian	Eastern Azerbaijan	healthy subjects	100	1
6722339	114815	Near Eastern	Iranian	Mazandaran	healthy subjects	100	1
6722340	114811	Near Eastern	Emirati	United Arab Emirates	majority psychiatric patients	302	1
6722341	114829	Near Eastern	Turkish	Middle Black Seas area	patients with arthritis, joint/back pain	249	1
6722342	114831	Near Eastern	Turkish	\N	healthy subjects	100	1
6722343	114820	Near Eastern	Saudi Arabian	different geographic regions	healthy	192	1
6722344	114837	Near Eastern	Turkish	\N	healthy volunteers	160	1
6722345	114400	Near Eastern	Ashkenazi Jews	Argentina	\N	173	1
6722346	114835	Near Eastern	Iranian	\N	Female breast cancer patients	134	1
6722347	114833	Near Eastern	Iraqi	Mid-Euphrates	ACS patients	500	1
6722348	114839	Oceanian	Australian Aborigines	NW Australia	healthy subjects	239	1
6722349	114421	Oceanian	Oceanian	\N	Human Genome Diversity Panels	39	1
6722350	114842	Oceanian	Maori	\N	DNA Bank	60	1
6722351	114844	Oceanian	Papua New Guinean	Alexishafen	healthy subjects	84	1
6722352	114844	Oceanian	Papua New Guinean	Kunjingini	healthy subjects	88	1
6722353	114404	Oceanian	Hawaiian/Pacific Islander	\N	US military volunteers	9	1
6722354	114847	Oceanian	Melanesian/Polynesian	Ni-Vanuatu	Healthy volunteers	278	1
6722355	3002041	Oceanian	Māori and Pacific people living in Aotearoa	\N	Healthy volunteers	202	1
6722356	114412	Sub-Saharan African	Ethiopian	\N	healthy subjects	122	1
6722357	114435	Sub-Saharan African	Zimbabwean	Shona	healthy subjects	76	1
6722358	114423	Sub-Saharan African	Tanzanian	\N	healthy subjects	195	1
6722359	114417	Sub-Saharan African	Ghanaian	\N	healthy subjects	193	1
6722360	114428	Sub-Saharan African	Tanzanian	Bantu	healthy subjects	106	1
6722361	114425	Sub-Saharan African	Tanzanian	\N	healthy controls	106	1
6722362	114425	Sub-Saharan African	Tanzanian	\N	psychiatric patients	88	1
6722363	114425	Sub-Saharan African	Venda	\N	healthy subjects	76	1
6722364	114425	Sub-Saharan African	Zimbabwean	\N	healthy subjects	114	1
6722365	114430	Sub-Saharan African	Tanzanian	Bantu	healthy subjects	106	1
6722366	114414	Sub-Saharan African	Ethiopian	living in Ethopia	healthy subjects	122	1
6722367	114414	Sub-Saharan African	Ethiopian	living in Sweden	healthy subjects	69	1
6722368	114421	Sub-Saharan African	Sub-Saharan African	\N	Human Genome Diversity Panels	127	1
6722369	114410	Sub-Saharan African	Brazilian	African descent	healthy subjects	87	1
6722370	114408	Sub-Saharan African	Brazilian	African descent, Sao Paulo	general population treated at hospital	33	1
6722371	114432	Sub-Saharan African	Xhosa	South African	healthy and schizophrenia patients	104	1
6722372	114419	Sub-Saharan African	South African	Limpopo Province	patients screened for malaria	248	1
6722373	114439	Sub-Saharan African	Ethiopian	\N	Female breast cancer patients	81	1
6722374	114437	Sub-Saharan African	Kenyan	Mainly Luo and Suba ethnic groups	Healthy volunteers	195	1
6722375	3001761	Sub-Saharan African	multiple sub-Saharan African populations	\N	healthy subjects	961	1
6722376	113921	African American/Afro-Caribbean	African American	\N	Kidney transplant patients	144	1
6722377	113923	African American/Afro-Caribbean	African American	\N	Healthy individuals	25	1
6722378	113925	African American/Afro-Caribbean	African American	\N	Healthy individuals	34	1
6722379	113927	African American/Afro-Caribbean	African American	\N	Healthy individuals	15	1
6722380	113929	African American/Afro-Caribbean	African American	\N	General population	20	1
6722381	113931	African American/Afro-Caribbean	African American	\N	1000 Genomes Project	61	1
6722382	113933	African American/Afro-Caribbean	African American	\N	International HapMap Project	57	1
6722383	113935	African American/Afro-Caribbean	African American	\N	Healthy individuals and hypertensive patients	124	1
6722384	113937	Central/South Asian	Bangladeshi	\N	Healthy individuals	200	1
6722385	113939	Central/South Asian	Bangladeshi	\N	Healthy individuals	116	1
6722386	113941	Central/South Asian	Indian	\N	Healthy individuals	90	1
6722387	113943	Central/South Asian	Indian	\N	Healthy individuals	652	1
6722388	113933	Central/South Asian	Indian	Gujarati in USA	International HapMap Project	101	1
6722389	113946	Central/South Asian	Indian	\N	Kidney transplant patients	44	1
6722390	113948	Central/South Asian	Indian	North Indian	Healthy individuals	208	1
6722391	113950	Central/South Asian	Chinese	Kazakh	Healthy individuals	108	1
6722392	113950	East Asian	Chinese	Han	Healthy individuals	165	1
6722393	113953	East Asian	Chinese	Taiwanese	General population	180	1
6722394	113955	East Asian	Chinese	Han	General population	451	1
6722395	113957	East Asian	Chinese	\N	General population	302	1
6722396	113941	East Asian	Chinese	\N	Healthy individuals	108	1
6722397	113960	East Asian	Chinese	\N	Pediatric liver transplant patients	64	1
6722398	113962	East Asian	Chinese	\N	Healthy individuals	15	1
6722399	113964	East Asian	Chinese	\N	Kidney transplant patients	63	1
6722400	113966	East Asian	Chinese	\N	Kidney transplant patients	30	1
6722401	113968	East Asian	Chinese	\N	Kidney transplant patients	16	1
6722402	113970	East Asian	Chinese	\N	Kidney transplant patients	161	1
6722403	113972	East Asian	Chinese	\N	Liver transplant patients	216	1
6722404	113974	East Asian	Chinese	\N	Healthy individuals	22	1
6722405	113976	East Asian	Chinese	\N	Liver transplant patients	53	1
6722406	113978	East Asian	Chinese	\N	Kidney transplant patients	142	1
6722407	113980	East Asian	Chinese	\N	Kidney transplant patients	63	1
6722408	113982	East Asian	Chinese	\N	Kidney transplant patients	240	1
6722409	113984	East Asian	Chinese	\N	Kidney transplant patients	28	1
6722410	113986	East Asian	Chinese	\N	Liver transplant patients	70	1
6722411	113988	East Asian	Chinese	\N	Liver transplant patients	73	1
6722412	113990	East Asian	Chinese	\N	Kidney transplant patients	103	1
6722413	113992	East Asian	Chinese	\N	Liver transplant patients	50	1
6722414	113994	East Asian	Chinese	\N	Kidney transplant patients	118	1
6722415	113996	East Asian	Chinese	\N	Liver transplant patients	96	1
6722416	113998	East Asian	Chinese	\N	Healthy individuals	73	1
6722417	114000	East Asian	Chinese	\N	Liver transplant patients	53	1
6722418	114002	East Asian	Chinese	\N	Liver transplant patients	95	1
6722419	114004	East Asian	Chinese	Han in Taiwan	Healthy individuals	42	1
6722420	113931	East Asian	Chinese	Han in Beijing	1000 Genomes Project	97	1
6722421	113931	East Asian	Chinese	Southern Han	1000 Genomes Project	100	1
6722422	113933	East Asian	Chinese	Han in Beijing	International HapMap Project	137	1
6722423	113933	East Asian	Chinese	in USA	International HapMap Project	109	1
6722424	113950	East Asian	Chinese	Uygur	Healthy individuals	161	1
6722425	114011	East Asian	Chinese	Kyrgyz	Healthy individuals	100	1
6722426	114013	East Asian	Chinese	\N	Liver transplant patients	180	1
6722427	114015	East Asian	Chinese	\N	Kidney transplant patients	166	1
6722428	114017	East Asian	Chinese	\N	Liver transplant patients	96	1
6722429	114019	East Asian	Japanese	\N	General population	187	1
6722430	114021	East Asian	Japanese	\N	Healthy individuals	200	1
6722431	114023	East Asian	Japanese	\N	General population	265	1
6722432	114025	East Asian	Japanese	\N	Kidney transplant patients	97	1
6722433	114027	East Asian	Japanese	\N	Kidney transplant patients	50	1
6722434	114029	East Asian	Japanese	\N	Kidney transplant patients	72	1
6722435	114031	East Asian	Japanese	\N	Kidney transplant patients	136	1
6722436	114033	East Asian	Japanese	\N	Liver transplant patients	51	1
6722437	114035	East Asian	Japanese	\N	Kidney transplant patients	59	1
6722438	114037	East Asian	Japanese	\N	Kidney transplant patients	50	1
6722439	114039	East Asian	Japanese	\N	Liver transplant patients	60	1
6722440	114041	East Asian	Japanese	\N	Ulcerative colitis patients	45	1
6722441	114043	East Asian	Japanese	\N	Hematopoietic stem cell transplant patients	33	1
6722442	114045	East Asian	Japanese	\N	Liver transplant patients	201	1
6722443	114047	East Asian	Japanese	\N	Kidney transplant patients	39	1
6722444	114049	East Asian	Japanese	\N	Kidney transplant patients	30	1
6722445	114051	East Asian	Japanese	\N	Liver transplant patients	114	1
6722446	113931	East Asian	Japanese	in Tokyo	1000 Genomes Project	89	1
6722447	113933	East Asian	Japanese	in Tokyo	International HapMap Project	113	1
6722448	114055	East Asian	Japanese	\N	Kidney transplant patients	50	1
6722449	114057	East Asian	Korean	\N	Healthy individuals	40	1
6722450	114059	East Asian	Korean	\N	Healthy individuals	104	1
6722451	114061	East Asian	Korean	\N	Healthy individuals	46	1
6722452	114063	East Asian	Korean	\N	Healthy individuals	194	1
6722453	114065	East Asian	Korean	\N	Kidney transplant patients	129	1
6722454	114067	East Asian	Korean	\N	Liver transplant patients	58	1
6722455	114069	East Asian	Korean	\N	Kidney transplant patients	249	1
6722456	114071	East Asian	Korean	\N	Kidney transplant patients	132	1
6722457	114073	East Asian	Korean	\N	Kidney transplant patients	80	1
6722458	114075	East Asian	Korean	\N	Kidney transplant patients	62	1
6722459	114077	East Asian	Korean	\N	Healthy individuals	29	1
6722460	114079	East Asian	Korean	\N	Liver and kidney transplant patients	314	1
6722461	114081	East Asian	Korean	\N	Healthy individuals	29	1
6722462	114083	East Asian	Korean	\N	Kidney transplant patients	122	1
6722463	114085	East Asian	Korean	\N	Kidney transplant patients	70	1
6722464	113941	East Asian	Malay	\N	Healthy individuals	98	1
6722465	114088	East Asian	Taiwanese	\N	Kidney transplant patients	150	1
6722466	114090	East Asian	Thai	\N	Kidney transplant patients	33	1
6722467	114092	East Asian	Russian	Tuvinian	Healthy individuals	87	1
6722468	114092	East Asian	Russian	Buryat	Healthy individuals	87	1
6722469	114092	East Asian	Russian	Altaian	Healthy individuals	85	1
6722470	114092	East Asian	Russian	Yakut	Healthy individuals	88	1
6722471	113925	European	American	\N	Healthy individuals	23	1
6722472	113931	European	American	\N	1000 Genomes Project	85	1
6722473	113933	European	American	\N	International HapMap Project	111	1
6722474	113935	European	American	\N	Healthy individuals and hypertensive patients	166	1
6722475	114101	European	Austrian	\N	Heart transplant patients	15	1
6722476	114103	European	Belgian	\N	Kidney transplant patients	59	1
6722477	114105	European	Belgian	\N	Kidney transplant patients	50	1
6722478	114107	European	Bosnian and Herzegovinian	\N	General population	140	1
6722479	113931	European	British	\N	1000 Genomes Project	89	1
6722480	114110	European	Bulgarian	\N	Healthy individuals	160	1
6722481	114112	European	Canadian	\N	General population	77	1
6722482	114114	European	Dutch	\N	Healthy individuals	500	1
6722483	114116	European	Dutch	\N	Kidney transplant patients	49	1
6722484	113929	European	European/European American	\N	General population	27	1
6722485	114119	European	Finnish	\N	Healthy individuals	449	1
6722486	113931	European	Finnish	\N	1000 Genomes Project	93	1
6722487	114122	European	French	\N	Healthy individuals	51	1
6722488	114124	European	French	\N	Pediatric kidney transplant patients	50	1
6722489	114126	European	German	\N	Kidney transplant patients	40	1
6722490	114128	European	German	\N	Kidney transplant patients	74	1
6722491	114130	European	German	\N	Kidney transplant patients	134	1
6722492	114132	European	Greek	\N	General population	283	1
6722493	114134	European	Italian	\N	Liver and kidney transplant patients	51	1
6722494	114136	European	Italian	\N	Kidney transplant patients	143	1
6722495	114138	European	Italian	\N	Kidney transplant patients	26	1
6722496	114140	European	Italian	\N	Liver transplant patients	32	1
6722497	114142	European	Italian	\N	Kidney transplant patients	92	1
6722498	114144	European	Italian	\N	Adolescent kidney transplant patients	27	1
6722499	113931	European	Italian	Tuscan	1000 Genomes Project	98	1
6722500	113933	European	Italian	Tuscan	International HapMap Project	102	1
6722501	114148	European	Polish	\N	Healthy newborn individuals	200	1
6722502	114150	European	Polish	\N	Kidney transplant patients	241	1
6722503	114092	European	Russian	\N	Healthy individuals	83	1
6722504	114153	European	Spanish	\N	Healthy individuals	207	1
6722505	114155	European	Spanish	\N	Healthy individuals	204	1
6722506	114157	European	Spanish	\N	Healthy individuals	177	1
6722507	114159	European	Spanish	\N	Liver transplant patients	186	1
6722508	114161	European	Spanish	\N	Kidney transplant patients	206	1
6722509	114163	European	Spanish	\N	Kidney transplant patients	50	1
6722510	114165	European	Spanish	\N	Heart transplant patients	65	1
6722511	114167	European	Spanish	\N	Kidney transplant patients	103	1
6722512	114169	European	Spanish	\N	Kidney transplant patients	400	1
6722513	114171	European	Spanish	\N	Liver transplant patients	53	1
6722514	114173	European	Swedish	\N	Healthy individuals	136	1
6722515	114175	Latino	Argentinian	\N	Pediatric kidney transplant patients	48	1
6722516	114177	Latino	Brazilian	\N	Kidney transplant patients	108	1
6722517	114179	Latino	Brazilian	\N	Healthy individuals	909	1
6722518	113931	Latino	Colombian	from Medellin	1000 Genomes Project	60	1
6722519	114182	Latino	Ecuadorian Mestizo	\N	Healthy individuals	317	1
6722520	114155	Latino	El Salvadoran Mestizo	\N	Healthy individuals	112	1
6722521	114185	Latino	Mexican	\N	Kidney transplant patients	291	1
6722522	113931	Latino	Mexican	in USA	1000 Genomes Project	66	1
6722523	113933	Latino	Mexican	in USA	International HapMap Project	58	1
6722524	114155	Latino	Nicaraguan Mestizo	\N	Healthy individuals	120	1
6722525	113931	Latino	Puerto Rican	\N	1000 Genomes Project	55	1
6722526	114191	Near Eastern	Algerian	Northern Algerian	Healthy individuals	161	1
6722527	114193	Near Eastern	Moroccan	\N	Healthy individuals and kidney transplant patients	108	1
6722528	114191	Near Eastern	Moroccan	Berber	Healthy individuals	86	1
6722529	114191	Near Eastern	Sudanese	Northern Sudanese	Healthy individuals	136	1
6722530	114191	Near Eastern	Sudanese	from Kordofan	Healthy individuals	30	1
6722531	114122	Near Eastern	Tunisian	\N	Healthy individuals	36	1
6722532	114191	Near Eastern	Armenian	Southern Armenian	Healthy individuals	100	1
6722533	114200	Near Eastern	Iranian	\N	General population	112	1
6722534	114202	Near Eastern	Iranian	\N	Liver transplant patients	100	1
6722535	114204	Near Eastern	Jordanian	\N	Healthy individuals	229	1
6722536	114206	Near Eastern	Jordanian	\N	Healthy individuals	591	1
6722537	114208	Near Eastern	Jordanian	\N	Pediatric kidney transplant patients	38	1
6722538	114210	Near Eastern	Jordanian	\N	Pediatric kidney transplant patients	38	1
6722539	114191	Near Eastern	Turkish	Anatolian	Healthy individuals	74	1
6722540	114191	Near Eastern	Yemeni	from Hadramaut	Healthy individuals	82	1
6722541	114191	Near Eastern	Yemeni	from Sena and Msila	Healthy individuals	37	1
6722542	114215	Sub-Saharan African	Cabindan	\N	General population	102	1
6722543	114191	Sub-Saharan African	Cameroonian	Kotoko	Healthy individuals	40	1
6722544	114191	Sub-Saharan African	Cameroonian	Shewa Arabs	Healthy individuals	69	1
6722545	114191	Sub-Saharan African	Cameroonian	Mayo Darle	Healthy individuals	117	1
6722546	114191	Sub-Saharan African	Cameroonian	Somie, Cameroonian Grassfields	Healthy individuals	65	1
6722547	114191	Sub-Saharan African	Congolese	from Brazzaville	Healthy individuals	55	1
6722548	114122	Sub-Saharan African	Gabonese	\N	Healthy individuals	36	1
6722549	113931	Sub-Saharan African	Nigerian	Yoruban in Ibadan	1000 Genomes Project	88	1
6722550	113933	Sub-Saharan African	Nigerian	Yoruban in Ibadan	International HapMap Project	147	1
6722551	114191	Sub-Saharan African	Nigerian	Igbo	Healthy individuals	88	1
6722552	114215	Sub-Saharan African	São Toméan	\N	General population	102	1
6722553	114227	Sub-Saharan African	Ethiopian	\N	Healthy individuals	150	1
6722554	114191	Sub-Saharan African	Ethiopian	Afar	Healthy individuals	73	1
6722555	114191	Sub-Saharan African	Ethiopian	Amhara	Healthy individuals	76	1
6722637	113843	Latino	Hispanic	\N	\N	53	1
6722556	114191	Sub-Saharan African	Ethiopian	Anuak	Healthy individuals	76	1
6722557	114191	Sub-Saharan African	Ethiopian	Maale	Healthy individuals	75	1
6722558	114191	Sub-Saharan African	Ethiopian	Oromo	Healthy individuals	73	1
6722559	113931	Sub-Saharan African	Kenyan	Luhya in Webuye	1000 Genomes Project	97	1
6722560	113933	Sub-Saharan African	Kenyan	Luhya in Webuye	International HapMap Project	110	1
6722561	113933	Sub-Saharan African	Kenyan	Maasai in Kinyawa	International HapMap Project	156	1
6722562	114191	Sub-Saharan African	Southern Sudanese	\N	Healthy individuals	125	1
6722563	114173	Sub-Saharan African	Tanzanian	\N	Healthy individuals	144	1
6722564	114191	Sub-Saharan African	Tanzanian	Chagga	Healthy individuals	50	1
6722565	114191	Sub-Saharan African	Ugandan	Bantu speakers from Ssese	Healthy individuals	39	1
6722566	114191	Sub-Saharan African	Malawia	Chewa	Healthy individuals	92	1
6722567	114191	Sub-Saharan African	Malawian	Lomwe	Healthy individuals	18	1
6722568	114191	Sub-Saharan African	Malawian	Ngoni	Healthy individuals	18	1
6722569	114191	Sub-Saharan African	Malawian	Tumbuka	Healthy individuals	62	1
6722570	114191	Sub-Saharan African	Malawian	Yao	Healthy individuals	56	1
6722571	114191	Sub-Saharan African	Mozambican	Sena	Healthy individuals	85	1
6722572	114215	Sub-Saharan African	Mozambican	\N	General population	103	1
6722573	114248	Sub-Saharan African	South African	Black South Africans	Birth to Twenty (Bt20) study	980	1
6722574	114191	Sub-Saharan African	South African	Bantu speakers	Healthy individuals	41	1
6722575	114191	Sub-Saharan African	Zimbabwean	Lemba	Healthy individuals	24	1
6722576	114191	Sub-Saharan African	Zimbabwean	from Mposi	Healthy individuals	52	1
6722577	114253	Sub-Saharan African	Ghanaian	\N	Healthy individuals	204	1
6722578	114191	Sub-Saharan African	Ghanaian	Asante	Healthy individuals	35	1
6722579	114191	Sub-Saharan African	Ghanaian	Bulsa	Healthy individuals	90	1
6722580	114191	Sub-Saharan African	Ghanaian	Kasena	Healthy individuals	47	1
6722581	114191	Sub-Saharan African	Senegalese	Manjak	Healthy individuals	94	1
6722582	114191	Sub-Saharan African	Senegalese	Wolof	Healthy individuals	94	1
6722583	\N	African American/Afro-Caribbean	African-American	Americans of African Ancestry in SW USA	1000 Genomes	61	1
6722584	113839	African American/Afro-Caribbean	African-American	\N	\N	50	1
6722585	113841	African American/Afro-Caribbean	African American	\N	warfarin treated cohort	531	1
6722586	113843	African American/Afro-Caribbean	African-American	\N	\N	260	1
6722587	113845	African American/Afro-Caribbean	African-American	\N	warfarin treated cohort	220	1
6722588	113847	American	American Indian and Alaska Native	Southcentral Foundation cohort (SCF)	\N	359	1
6722589	113847	American	American Indian and Alaska Native	Center of Alaska Native Health Research cohort (CANHR)	\N	350	1
6722590	113850	Central/South Asian	Indian	Punjab	\N	226	1
6722591	113850	Central/South Asian	Indian	Haryana	\N	108	1
6722592	113850	Central/South Asian	Indian	Delhi	\N	213	1
6722593	113850	Central/South Asian	Indian	Uttar Pradesh	\N	1101	1
6722594	113850	Central/South Asian	Indian	Bihar	\N	267	1
6722595	113537	Central/South Asian	Gujarati Indian from Houston, Texas	GIH	1000 Genomes	103	1
6722596	113537	Central/South Asian	Punjabi from Lahore, Pakistan	PJL	1000 Genomes	96	1
6722597	113537	Central/South Asian	Bengali from Bangladesh	BEB	1000 Genomes	86	1
6722598	113537	Central/South Asian	Sri Lankan Tamil from the UK	STU	1000 Genomes	102	1
6722599	113537	Central/South Asian	Indian Telugu from the UK	ITU	1000 Genomes	102	1
6722600	113839	Central/South Asian	Indians	\N	\N	88	1
6722601	113862	Central/South Asian	South Indians	\N	\N	240	1
6722602	113864	Central/South Asian	North Indians	\N	\N	225	1
6722603	\N	Central/South Asian	South Asian	GnomAD v2.1.1 population SAS	\N	3028	1
6722604	113537	East Asian	Han Chinese in Bejing, China	CHB	1000 Genomes	103	1
6722605	113537	East Asian	Japanese in Tokyo, Japan	JPT	1000 Genomes	104	1
6722606	113537	East Asian	Southern Han Chinese	CHS	1000 Genomes	105	1
6722607	113537	East Asian	Chinese Dai in Xishuangbanna, China	CDX	1000 Genomes	93	1
6722608	113537	East Asian	Kinh in Ho Chi Minh City, Vietnam	KHV	1000 Genomes	99	1
6722609	113839	East Asian	Chinese	\N	\N	88	1
6722610	113872	East Asian	Chinese	\N	\N	551	1
6722611	113874	East Asian	Chinese	\N	\N	408	1
6722612	113876	East Asian	Chinese	\N	\N	220	1
6722613	113878	East Asian	Chinese	\N	\N	222	1
6722614	113880	East Asian	Indonesian	\N	warfarin treated patients	103	1
6722615	113880	East Asian	Indonesian	\N	healthy control	103	1
6722616	113839	East Asian	Malays	\N	\N	88	1
6722617	113884	East Asian	Indonesian	\N	\N	135	1
6722618	\N	East Asian	East Asian	GnomAD v2.1.1 population EAS	\N	3130	1
6722619	113537	European	Utah Residents (CEPH) with Northern and Western Ancestry	CEU	1000 Genomes	99	1
6722620	113537	European	Toscani in Italia	TSI	1000 Genomes	107	1
6722621	113537	European	Finnish in Finland	FIN	1000 Genomes	99	1
6722622	113537	European	British in England and Scotland	GBR	1000 Genomes	91	1
6722623	113537	European	Iberian Population in Spain	IBS	1000 Genomes	107	1
6722624	113839	European	Caucasians	\N	\N	141	1
6722625	113892	European	Caucasian	\N	warfarin-treated cohort	283	1
6722626	113841	European	European Americans	\N	warfarin-treated cohort	707	1
6722627	113895	European	Caucasians	\N	warfarin-treated cohort	429	1
6722628	113897	European	Italy	\N	warfarin-treated cohort	266	1
6722629	113899	European	white	\N	warfarin-treated cohort	241	1
6722630	\N	European	Finnish	GnomAD v2.1.1 population FIN	\N	10462	1
6722631	\N	European	Non-Finnish European	GnomAD v2.1.1 population NFE	\N	64492	1
6722632	113537	Latino	Mexican Ancestry from Los Angeles USA	MXL	1000 Genomes	64	1
6722633	113537	Latino	Puerto Ricans from Puerto Rico	PUR	1000 Genomes	104	1
6722634	113537	Latino	Colombians from Medellin, Colombia	CLM	1000 Genomes	94	1
6722635	113537	Latino	Peruvians from Lima, Peru	PEL	1000 Genomes	85	1
6722636	113905	Latino	Carribean hispanics	\N	warfarin treated patients	255	1
6722638	\N	Latino	Latino	GnomAD v2.1.1 population AMR	\N	13648	1
6722639	113908	Near Eastern	Omani	\N	\N	192	1
6722640	113910	Near Eastern	Moroccan patients	\N	acenocoumarol treated patients	114	1
6722641	113912	Near Eastern	Israeli patients	\N	warfarin-treated cohort	191	1
6722642	113914	Near Eastern	Kuwaiti population subgroup of inferred Saudi Arabian tribe ancestry.	\N	\N	63	1
6722643	\N	Near Eastern	Ashkenazi Jewish	GnomAD v2.1.1 population ASJ	\N	3322	1
6722644	113537	Sub-Saharan African	Yoruba in Ibadan, Nigeria	YRI	1000 Genomes	108	1
6722645	113537	Sub-Saharan African	Luhya in Webuye, Kenya	LWK	1000 Genomes	99	1
6722646	113537	Sub-Saharan African	Mandinka in the Gambia	MAG	1000 Genomes	113	1
6722647	113537	Sub-Saharan African	Mende in Sierra Leone	MSL	1000 Genomes	85	1
6722648	113537	Sub-Saharan African	Esan in Nigeria	ESN	1000 Genomes	99	1
6722649	\N	Sub-Saharan African	African/African American	GnomAD v2.1.1 population AFR	\N	41938	1
6722650	113537	African American/Afro-Caribbean	African Caribbean (ACB)	\N	\N	192	1
6722651	113537	African American/Afro-Caribbean	African Ancestry in Southwest US (ASW)	\N	\N	122	1
6722652	117252	Central/South Asian	South Asian	Retrieved from ExAC genome browser	\N	8255	1
6722653	117252	Central/South Asian	South Asian	Retrieved from ExAC genome browser	\N	8242	1
6722654	117252	Central/South Asian	South Asian	Retrieved from ExAC genome browser	\N	8254	1
6722655	117252	Central/South Asian	South Asian	Retrieved from ExAC genome browser	\N	8234	1
6722656	117252	Central/South Asian	South Asian	Retrieved from ExAC genome browser	\N	8253	1
6722657	117252	Central/South Asian	South Asian	Retrieved from ExAC genome browser	\N	8233	1
6722658	117252	Central/South Asian	South Asian	Retrieved from ExAC genome browser	\N	8251	1
6722659	117252	Central/South Asian	South Asian	Retrieved from ExAC genome browser	\N	8238	1
6722660	117252	Central/South Asian	South Asian	Retrieved from ExAC genome browser	\N	8249	1
6722661	117252	Central/South Asian	South Asian	Retrieved from ExAC genome browser	\N	7773	1
6722662	117252	Central/South Asian	South Asian	Retrieved from ExAC genome browser	\N	7455	1
6722663	117252	Central/South Asian	South Asian	Retrieved from ExAC genome browser	\N	7374	1
6722664	117252	Central/South Asian	South Asian	Retrieved from ExAC genome browser	\N	8239	1
6722665	117252	Central/South Asian	South Asian	Retrieved from ExAC genome browser	\N	8232	1
6722666	117252	Central/South Asian	South Asian	Retrieved from ExAC genome browser	\N	5348	1
6722667	117252	Central/South Asian	South Asian	Retrieved from ExAC genome browser	\N	8250	1
6722668	117252	Central/South Asian	South Asian	Retrieved from ExAC genome browser	\N	8256	1
6722669	117252	Central/South Asian	South Asian	Retrieved from ExAC genome browser	\N	8246	1
6722670	117252	Central/South Asian	South Asian	Retrieved from ExAC genome browser	\N	8245	1
6722671	117252	Central/South Asian	South Asian	Retrieved from ExAC genome browser	\N	8052	1
6722672	117252	Central/South Asian	South Asian	Retrieved from ExAC genome browser	\N	8138	1
6722673	117252	Central/South Asian	South Asian	Retrieved from ExAC genome browser	\N	8161	1
6722674	117252	Central/South Asian	South Asian	Retrieved from ExAC genome browser	\N	8230	1
6722675	117252	Central/South Asian	South Asian	Retrieved from ExAC genome browser	\N	8241	1
6722676	117252	Central/South Asian	South Asian	Retrieved from ExAC genome browser	\N	7120	1
6722677	117252	Central/South Asian	South Asian	Retrieved from ExAC genome browser	\N	8229	1
6722678	117252	Central/South Asian	South Asian	Retrieved from ExAC genome browser	\N	8240	1
6722679	117252	Central/South Asian	South Asian	Retrieved from ExAC genome browser	\N	8211	1
6722680	117252	Central/South Asian	South Asian	Retrieved from ExAC genome browser	\N	8007	1
6722681	117252	Central/South Asian	South Asian	Retrieved from ExAC genome browser	\N	8252	1
6722682	117252	Central/South Asian	South Asian	Retrieved from ExAC genome browser	\N	8192	1
6722683	117252	Central/South Asian	South Asian	Retrieved from ExAC genome browser	\N	8221	1
6722684	117252	Central/South Asian	South Asian	Retrieved from ExAC genome browser	\N	8235	1
6722685	117252	Central/South Asian	South Asian	Retrieved from ExAC genome browser	\N	4019	1
6722686	117252	Central/South Asian	South Asian	Retrieved from ExAC genome browser	\N	8210	1
6722687	117252	Central/South Asian	South Asian	Retrieved from ExAC genome browser	\N	8190	1
6722688	117252	Central/South Asian	South Asian	Retrieved from ExAC genome browser	\N	7547	1
6722689	117252	Central/South Asian	South Asian	Retrieved from ExAC genome browser	\N	7490	1
6722690	117252	Central/South Asian	South Asian	Retrieved from ExAC genome browser	\N	8243	1
6722691	113537	Central/South Asian	Bengali (BEB)	\N	\N	172	1
6722692	113537	Central/South Asian	Gujarati Indian in Houston, Texas (GIH)	\N	\N	206	1
6722693	113537	Central/South Asian	Indian Telugu in the United Kingdom (ITU)	\N	\N	204	1
6722694	113537	Central/South Asian	Punjabi in Lahore (PJL)	\N	\N	192	1
6722695	113537	Central/South Asian	Sri Lankan Tamil in the United Kingdom (STU)	\N	\N	204	1
6722696	117252	East Asian	East Asian	Retrieved from ExAC genome browser	\N	4324	1
6722697	117252	East Asian	East Asian	Retrieved from ExAC genome browser	\N	4303	1
6722698	117252	East Asian	East Asian	Retrieved from ExAC genome browser	\N	4304	1
6722699	117252	East Asian	East Asian	Retrieved from ExAC genome browser	\N	4313	1
6722700	117252	East Asian	East Asian	Retrieved from ExAC genome browser	\N	4322	1
6722701	117252	East Asian	East Asian	Retrieved from ExAC genome browser	\N	4320	1
6722702	117252	East Asian	East Asian	Retrieved from ExAC genome browser	\N	4321	1
6722703	117252	East Asian	East Asian	Retrieved from ExAC genome browser	\N	4306	1
6722704	117252	East Asian	East Asian	Retrieved from ExAC genome browser	\N	4292	1
6722705	117252	East Asian	East Asian	Retrieved from ExAC genome browser	\N	4326	1
6722706	117252	East Asian	East Asian	Retrieved from ExAC genome browser	\N	4323	1
6722707	117252	East Asian	East Asian	Retrieved from ExAC genome browser	\N	4319	1
6722708	117252	East Asian	East Asian	Retrieved from ExAC genome browser	\N	4283	1
6722709	117252	East Asian	East Asian	Retrieved from ExAC genome browser	\N	4327	1
6722710	117252	East Asian	East Asian	Retrieved from ExAC genome browser	\N	4263	1
6722711	117252	East Asian	East Asian	Retrieved from ExAC genome browser	\N	4316	1
6722712	117252	East Asian	East Asian	Retrieved from ExAC genome browser	\N	3903	1
6722713	117252	East Asian	East Asian	Retrieved from ExAC genome browser	\N	3546	1
6722714	117252	East Asian	East Asian	Retrieved from ExAC genome browser	\N	3472	1
6722715	117252	East Asian	East Asian	Retrieved from ExAC genome browser	\N	4243	1
6722716	117252	East Asian	East Asian	Retrieved from ExAC genome browser	\N	2317	1
6722717	117252	East Asian	East Asian	Retrieved from ExAC genome browser	\N	4317	1
6722718	117252	East Asian	East Asian	Retrieved from ExAC genome browser	\N	4318	1
6722719	117252	East Asian	East Asian	Retrieved from ExAC genome browser	\N	4311	1
6722720	117252	East Asian	East Asian	Retrieved from ExAC genome browser	\N	4312	1
6722721	117252	East Asian	East Asian	Retrieved from ExAC genome browser	\N	4307	1
6722722	117252	East Asian	East Asian	Retrieved from ExAC genome browser	\N	4042	1
6722723	117252	East Asian	East Asian	Retrieved from ExAC genome browser	\N	4146	1
6722724	117252	East Asian	East Asian	Retrieved from ExAC genome browser	\N	4290	1
6722725	117252	East Asian	East Asian	Retrieved from ExAC genome browser	\N	4305	1
6722726	117252	East Asian	East Asian	Retrieved from ExAC genome browser	\N	4296	1
6722727	117252	East Asian	East Asian	Retrieved from ExAC genome browser	\N	4247	1
6722728	117252	East Asian	East Asian	Retrieved from ExAC genome browser	\N	4293	1
6722729	117252	East Asian	East Asian	Retrieved from ExAC genome browser	\N	3675	1
6722730	117252	East Asian	East Asian	Retrieved from ExAC genome browser	\N	4278	1
6722731	117252	East Asian	East Asian	Retrieved from ExAC genome browser	\N	4289	1
6722732	117252	East Asian	East Asian	Retrieved from ExAC genome browser	\N	4291	1
6722733	117252	East Asian	East Asian	Retrieved from ExAC genome browser	\N	4302	1
6722734	117252	East Asian	East Asian	Retrieved from ExAC genome browser	\N	4298	1
6722735	117252	East Asian	East Asian	Retrieved from ExAC genome browser	\N	4150	1
6722736	117252	East Asian	East Asian	Retrieved from ExAC genome browser	\N	4288	1
6722737	117252	East Asian	East Asian	Retrieved from ExAC genome browser	\N	4200	1
6722738	117252	East Asian	East Asian	Retrieved from ExAC genome browser	\N	4257	1
6722739	117252	East Asian	East Asian	Retrieved from ExAC genome browser	\N	4281	1
6722740	117252	East Asian	East Asian	Retrieved from ExAC genome browser	\N	242	1
6722741	117252	East Asian	East Asian	Retrieved from ExAC genome browser	\N	4239	1
6722742	117252	East Asian	East Asian	Retrieved from ExAC genome browser	\N	3723	1
6722743	117252	East Asian	East Asian	Retrieved from ExAC genome browser	\N	3537	1
6722744	117252	East Asian	East Asian	Retrieved from ExAC genome browser	\N	4314	1
6722745	117252	East Asian	East Asian	Retrieved from ExAC genome browser	\N	4295	1
6722746	113537	East Asian	Chinese Dai in Xishuangbanna (CDX)	\N	\N	186	1
6722747	113537	East Asian	Han Chinese in Beijing (CHB)	\N	\N	206	1
6722748	113537	East Asian	Southern Han Chinese (CHS)	\N	\N	210	1
6722749	113537	East Asian	Japanese in Tokyo (JPT)	\N	\N	208	1
6722750	113537	East Asian	Kinh in Ho Chi Minh City (KHV)	\N	\N	198	1
6722751	117252	European	Finnish	Retrieved from ExAC genome browser	\N	3304	1
6722752	117252	European	Finnish	Retrieved from ExAC genome browser	\N	3280	1
6722753	117252	European	Finnish	Retrieved from ExAC genome browser	\N	3297	1
6722754	117252	European	Finnish	Retrieved from ExAC genome browser	\N	3278	1
6722755	117252	European	Finnish	Retrieved from ExAC genome browser	\N	3307	1
6722756	117252	European	Finnish	Retrieved from ExAC genome browser	\N	3305	1
6722757	117252	European	Finnish	Retrieved from ExAC genome browser	\N	3299	1
6722758	117252	European	Finnish	Retrieved from ExAC genome browser	\N	3279	1
6722759	117252	European	Finnish	Retrieved from ExAC genome browser	\N	3303	1
6722760	117252	European	Finnish	Retrieved from ExAC genome browser	\N	3272	1
6722761	117252	European	Finnish	Retrieved from ExAC genome browser	\N	3284	1
6722762	117252	European	Finnish	Retrieved from ExAC genome browser	\N	3306	1
6722763	117252	European	Finnish	Retrieved from ExAC genome browser	\N	3143	1
6722764	117252	European	Finnish	Retrieved from ExAC genome browser	\N	2778	1
6722765	117252	European	Finnish	Retrieved from ExAC genome browser	\N	2719	1
6722766	117252	European	Finnish	Retrieved from ExAC genome browser	\N	3281	1
6722767	117252	European	Finnish	Retrieved from ExAC genome browser	\N	3293	1
6722768	117252	European	Finnish	Retrieved from ExAC genome browser	\N	3300	1
6722769	117252	European	Finnish	Retrieved from ExAC genome browser	\N	1378	1
6722770	117252	European	Finnish	Retrieved from ExAC genome browser	\N	3302	1
6722771	117252	European	Finnish	Retrieved from ExAC genome browser	\N	3296	1
6722772	117252	European	Finnish	Retrieved from ExAC genome browser	\N	3295	1
6722773	117252	European	Finnish	Retrieved from ExAC genome browser	\N	3219	1
6722774	117252	European	Finnish	Retrieved from ExAC genome browser	\N	3253	1
6722775	117252	European	Finnish	Retrieved from ExAC genome browser	\N	3250	1
6722776	117252	European	Finnish	Retrieved from ExAC genome browser	\N	3277	1
6722777	117252	European	Finnish	Retrieved from ExAC genome browser	\N	3294	1
6722778	117252	European	Finnish	Retrieved from ExAC genome browser	\N	3301	1
6722779	117252	European	Finnish	Retrieved from ExAC genome browser	\N	2687	1
6722780	117252	European	Finnish	Retrieved from ExAC genome browser	\N	3287	1
6722781	117252	European	Finnish	Retrieved from ExAC genome browser	\N	3290	1
6722782	117252	European	Finnish	Retrieved from ExAC genome browser	\N	3235	1
6722783	117252	European	Finnish	Retrieved from ExAC genome browser	\N	3262	1
6722784	117252	European	Finnish	Retrieved from ExAC genome browser	\N	3268	1
6722785	117252	European	Finnish	Retrieved from ExAC genome browser	\N	3274	1
6722786	117252	European	Finnish	Retrieved from ExAC genome browser	\N	180	1
6722787	117252	European	Finnish	Retrieved from ExAC genome browser	\N	3051	1
6722788	117252	European	Finnish	Retrieved from ExAC genome browser	\N	3086	1
6722789	117252	European	Non-Finnish	Retrieved from ExAC genome browser	\N	33344	1
6722790	117252	European	Non-Finnish	Retrieved from ExAC genome browser	\N	33211	1
6722791	117252	European	Non-Finnish	Retrieved from ExAC genome browser	\N	33296	1
6722792	117252	European	Non-Finnish	Retrieved from ExAC genome browser	\N	33193	1
6722793	117252	European	Non-Finnish	Retrieved from ExAC genome browser	\N	33363	1
6722794	117252	European	Non-Finnish	Retrieved from ExAC genome browser	\N	33351	1
6722795	117252	European	Non-Finnish	Retrieved from ExAC genome browser	\N	33285	1
6722796	117252	European	Non-Finnish	Retrieved from ExAC genome browser	\N	33210	1
6722797	117252	European	Non-Finnish	Retrieved from ExAC genome browser	\N	33343	1
6722798	117252	European	Non-Finnish	Retrieved from ExAC genome browser	\N	33342	1
6722799	117252	European	Non-Finnish	Retrieved from ExAC genome browser	\N	33350	1
6722800	117252	European	Non-Finnish	Retrieved from ExAC genome browser	\N	33356	1
6722801	117252	European	Non-Finnish	Retrieved from ExAC genome browser	\N	33148	1
6722802	117252	European	Non-Finnish	Retrieved from ExAC genome browser	\N	33348	1
6722803	117252	European	Non-Finnish	Retrieved from ExAC genome browser	\N	33228	1
6722804	117252	European	Non-Finnish	Retrieved from ExAC genome browser	\N	33329	1
6722805	117252	European	Non-Finnish	Retrieved from ExAC genome browser	\N	33333	1
6722806	117252	European	Non-Finnish	Retrieved from ExAC genome browser	\N	33352	1
6722807	117252	European	Non-Finnish	Retrieved from ExAC genome browser	\N	30849	1
6722808	117252	European	Non-Finnish	Retrieved from ExAC genome browser	\N	26999	1
6722809	117252	European	Non-Finnish	Retrieved from ExAC genome browser	\N	26393	1
6722810	117252	European	Non-Finnish	Retrieved from ExAC genome browser	\N	33149	1
6722811	117252	European	Non-Finnish	Retrieved from ExAC genome browser	\N	33331	1
6722812	117252	European	Non-Finnish	Retrieved from ExAC genome browser	\N	33174	1
6722813	117252	European	Non-Finnish	Retrieved from ExAC genome browser	\N	33317	1
6722814	117252	European	Non-Finnish	Retrieved from ExAC genome browser	\N	13720	1
6722815	117252	European	Non-Finnish	Retrieved from ExAC genome browser	\N	33335	1
6722816	117252	European	Non-Finnish	Retrieved from ExAC genome browser	\N	33359	1
6722817	117252	European	Non-Finnish	Retrieved from ExAC genome browser	\N	33323	1
6722818	117252	European	Non-Finnish	Retrieved from ExAC genome browser	\N	33306	1
6722819	117252	European	Non-Finnish	Retrieved from ExAC genome browser	\N	33297	1
6722820	117252	European	Non-Finnish	Retrieved from ExAC genome browser	\N	33355	1
6722821	117252	European	Non-Finnish	Retrieved from ExAC genome browser	\N	33362	1
6722822	117252	European	Non-Finnish	Retrieved from ExAC genome browser	\N	33361	1
6722823	117252	European	Non-Finnish	Retrieved from ExAC genome browser	\N	31621	1
6722824	117252	European	Non-Finnish	Retrieved from ExAC genome browser	\N	32417	1
6722825	117252	European	Non-Finnish	Retrieved from ExAC genome browser	\N	33291	1
6722826	117252	European	Non-Finnish	Retrieved from ExAC genome browser	\N	33340	1
6722827	117252	European	Non-Finnish	Retrieved from ExAC genome browser	\N	33316	1
6722828	117252	European	Non-Finnish	Retrieved from ExAC genome browser	\N	32876	1
6722829	117252	European	Non-Finnish	Retrieved from ExAC genome browser	\N	33186	1
6722830	117252	European	Non-Finnish	Retrieved from ExAC genome browser	\N	33214	1
6722831	117252	European	Non-Finnish	Retrieved from ExAC genome browser	\N	33177	1
6722832	117252	European	Non-Finnish	Retrieved from ExAC genome browser	\N	33303	1
6722833	117252	European	Non-Finnish	Retrieved from ExAC genome browser	\N	33299	1
6722834	117252	European	Non-Finnish	Retrieved from ExAC genome browser	\N	33309	1
6722835	117252	European	Non-Finnish	Retrieved from ExAC genome browser	\N	33347	1
6722836	117252	European	Non-Finnish	Retrieved from ExAC genome browser	\N	27268	1
6722837	117252	European	Non-Finnish	Retrieved from ExAC genome browser	\N	33220	1
6722838	117252	European	Non-Finnish	Retrieved from ExAC genome browser	\N	33240	1
6722839	117252	European	Non-Finnish	Retrieved from ExAC genome browser	\N	33345	1
6722840	117252	European	Non-Finnish	Retrieved from ExAC genome browser	\N	33275	1
6722841	117252	European	Non-Finnish	Retrieved from ExAC genome browser	\N	33304	1
6722842	117252	European	Non-Finnish	Retrieved from ExAC genome browser	\N	32595	1
6722843	117252	European	Non-Finnish	Retrieved from ExAC genome browser	\N	33341	1
6722844	117252	European	Non-Finnish	Retrieved from ExAC genome browser	\N	32693	1
6722845	117252	European	Non-Finnish	Retrieved from ExAC genome browser	\N	33000	1
6722846	117252	European	Non-Finnish	Retrieved from ExAC genome browser	\N	33136	1
6722847	117252	European	Non-Finnish	Retrieved from ExAC genome browser	\N	33366	1
6722848	117252	European	Non-Finnish	Retrieved from ExAC genome browser	\N	33358	1
6722849	117252	European	Non-Finnish	Retrieved from ExAC genome browser	\N	33367	1
6722850	117252	European	Non-Finnish	Retrieved from ExAC genome browser	\N	3810	1
6722851	117252	European	Non-Finnish	Retrieved from ExAC genome browser	\N	32975	1
6722852	117252	European	Non-Finnish	Retrieved from ExAC genome browser	\N	33169	1
6722853	117252	European	Non-Finnish	Retrieved from ExAC genome browser	\N	29181	1
6722854	117252	European	Non-Finnish	Retrieved from ExAC genome browser	\N	29111	1
6722855	117252	European	Non-Finnish	Retrieved from ExAC genome browser	\N	33354	1
6722856	117252	European	Non-Finnish	Retrieved from ExAC genome browser	\N	33270	1
6722857	117252	European	Non-Finnish	Retrieved from ExAC genome browser	\N	33233	1
6722858	117252	European	Non-Finnish	Retrieved from ExAC genome browser	\N	33364	1
6722859	113537	European	Utah Residents with Northern and Western European Ancestry (CEU)	\N	\N	198	1
6722860	113537	European	Finnish (FIN)	\N	\N	198	1
6722861	113537	European	Toscani (TSI)	\N	\N	214	1
6722862	113537	European	Iberian populations (IBS)	\N	\N	214	1
6722863	113537	European	British in England and Scotland (GBR)	\N	\N	182	1
6722864	117252	Latino	Latino	Retrieved from ExAC genome browser	\N	5743	1
6722865	117252	Latino	Latino	Retrieved from ExAC genome browser	\N	5689	1
6722866	117252	Latino	Latino	Retrieved from ExAC genome browser	\N	5751	1
6722867	117252	Latino	Latino	Retrieved from ExAC genome browser	\N	5675	1
6722868	117252	Latino	Latino	Retrieved from ExAC genome browser	\N	5788	1
6722869	117252	Latino	Latino	Retrieved from ExAC genome browser	\N	5766	1
6722870	117252	Latino	Latino	Retrieved from ExAC genome browser	\N	5687	1
6722871	117252	Latino	Latino	Retrieved from ExAC genome browser	\N	5674	1
6722872	117252	Latino	Latino	Retrieved from ExAC genome browser	\N	5726	1
6722873	117252	Latino	Latino	Retrieved from ExAC genome browser	\N	5778	1
6722874	117252	Latino	Latino	Retrieved from ExAC genome browser	\N	5784	1
6722875	117252	Latino	Latino	Retrieved from ExAC genome browser	\N	5789	1
6722876	117252	Latino	Latino	Retrieved from ExAC genome browser	\N	5704	1
6722877	117252	Latino	Latino	Retrieved from ExAC genome browser	\N	5785	1
6722878	117252	Latino	Latino	Retrieved from ExAC genome browser	\N	5730	1
6722879	117252	Latino	Latino	Retrieved from ExAC genome browser	\N	5782	1
6722880	117252	Latino	Latino	Retrieved from ExAC genome browser	\N	5760	1
6722881	117252	Latino	Latino	Retrieved from ExAC genome browser	\N	5748	1
6722882	117252	Latino	Latino	Retrieved from ExAC genome browser	\N	5300	1
6722883	117252	Latino	Latino	Retrieved from ExAC genome browser	\N	4929	1
6722884	117252	Latino	Latino	Retrieved from ExAC genome browser	\N	4847	1
6722885	117252	Latino	Latino	Retrieved from ExAC genome browser	\N	5722	1
6722886	117252	Latino	Latino	Retrieved from ExAC genome browser	\N	5770	1
6722887	117252	Latino	Latino	Retrieved from ExAC genome browser	\N	5658	1
6722888	117252	Latino	Latino	Retrieved from ExAC genome browser	\N	5781	1
6722889	117252	Latino	Latino	Retrieved from ExAC genome browser	\N	5776	1
6722890	117252	Latino	Latino	Retrieved from ExAC genome browser	\N	2937	1
6722891	117252	Latino	Latino	Retrieved from ExAC genome browser	\N	5783	1
6722892	117252	Latino	Latino	Retrieved from ExAC genome browser	\N	5786	1
6722893	117252	Latino	Latino	Retrieved from ExAC genome browser	\N	5746	1
6722894	117252	Latino	Latino	Retrieved from ExAC genome browser	\N	5773	1
6722895	117252	Latino	Latino	Retrieved from ExAC genome browser	\N	5780	1
6722896	117252	Latino	Latino	Retrieved from ExAC genome browser	\N	5779	1
6722897	117252	Latino	Latino	Retrieved from ExAC genome browser	\N	5552	1
6722898	117252	Latino	Latino	Retrieved from ExAC genome browser	\N	5642	1
6722899	117252	Latino	Latino	Retrieved from ExAC genome browser	\N	5750	1
6722900	117252	Latino	Latino	Retrieved from ExAC genome browser	\N	5619	1
6722901	117252	Latino	Latino	Retrieved from ExAC genome browser	\N	5672	1
6722902	117252	Latino	Latino	Retrieved from ExAC genome browser	\N	5676	1
6722903	117252	Latino	Latino	Retrieved from ExAC genome browser	\N	5670	1
6722904	117252	Latino	Latino	Retrieved from ExAC genome browser	\N	5717	1
6722905	117252	Latino	Latino	Retrieved from ExAC genome browser	\N	5714	1
6722906	117252	Latino	Latino	Retrieved from ExAC genome browser	\N	5715	1
6722907	117252	Latino	Latino	Retrieved from ExAC genome browser	\N	5729	1
6722908	117252	Latino	Latino	Retrieved from ExAC genome browser	\N	5079	1
6722909	117252	Latino	Latino	Retrieved from ExAC genome browser	\N	5762	1
6722910	117252	Latino	Latino	Retrieved from ExAC genome browser	\N	5765	1
6722911	117252	Latino	Latino	Retrieved from ExAC genome browser	\N	5716	1
6722912	117252	Latino	Latino	Retrieved from ExAC genome browser	\N	5591	1
6722913	117252	Latino	Latino	Retrieved from ExAC genome browser	\N	5771	1
6722914	117252	Latino	Latino	Retrieved from ExAC genome browser	\N	5633	1
6722915	117252	Latino	Latino	Retrieved from ExAC genome browser	\N	5701	1
6722916	117252	Latino	Latino	Retrieved from ExAC genome browser	\N	5761	1
6722917	117252	Latino	Latino	Retrieved from ExAC genome browser	\N	5772	1
6722918	117252	Latino	Latino	Retrieved from ExAC genome browser	\N	5775	1
6722919	117252	Latino	Latino	Retrieved from ExAC genome browser	\N	5777	1
6722920	117252	Latino	Latino	Retrieved from ExAC genome browser	\N	236	1
6722921	117252	Latino	Latino	Retrieved from ExAC genome browser	\N	5703	1
6722922	117252	Latino	Latino	Retrieved from ExAC genome browser	\N	5072	1
6722923	117252	Latino	Latino	Retrieved from ExAC genome browser	\N	5763	1
6722924	117252	Latino	Latino	Retrieved from ExAC genome browser	\N	5148	1
6722925	117252	Latino	Latino	Retrieved from ExAC genome browser	\N	5709	1
6722926	117252	Latino	Latino	Retrieved from ExAC genome browser	\N	5723	1
6722927	113537	Latino	Columbian in Medellin (CLM)	\N	\N	188	1
6722928	113537	Latino	Los Angeles (MXL)	\N	\N	128	1
6722929	113537	Latino	Peruvian in Lima (PEL)	\N	\N	170	1
6722930	113537	Latino	Puerto Rican (PUR)	\N	\N	208	1
6722931	113537	Sub-Saharan African	Gambian in Western Division (GWD)	\N	\N	226	1
6722932	113537	Sub-Saharan African	Luhya in Webuye (LWK)	\N	\N	198	1
6722933	113537	Sub-Saharan African	Esan (ESN)	\N	\N	198	1
6722934	113537	Sub-Saharan African	Yoruba in Ibadan (YRI)	\N	\N	216	1
6722935	113537	Sub-Saharan African	Mende (MSL)	\N	\N	170	1
6722936	\N	African American/Afro-Caribbean	African/African American	\N	\N	18923	1
6722937	\N	African American/Afro-Caribbean	African/African American	\N	\N	19097	1
6722938	\N	African American/Afro-Caribbean	African/African American	\N	\N	12997	1
6722939	\N	African American/Afro-Caribbean	African/African American	\N	\N	18968	1
6722940	\N	African American/Afro-Caribbean	African/African American	\N	\N	13156	1
6722941	\N	African American/Afro-Caribbean	African/African American	\N	\N	30659	1
6722942	\N	African American/Afro-Caribbean	African/African American	\N	\N	18886	1
6722943	\N	African American/Afro-Caribbean	African/African American	\N	\N	13092	1
6722944	\N	African American/Afro-Caribbean	African/African American	\N	\N	19035	1
6722945	\N	African American/Afro-Caribbean	African/African American	\N	\N	13154	1
6722946	\N	African American/Afro-Caribbean	African/African American	\N	\N	13017	1
6722947	\N	African American/Afro-Caribbean	African/African American	\N	\N	13158	1
6722948	\N	African American/Afro-Caribbean	African/African American	\N	\N	18963	1
6722949	\N	African American/Afro-Caribbean	African/African American	\N	\N	18977	1
6722950	\N	African American/Afro-Caribbean	African/African American	\N	\N	13156	1
6722951	\N	African American/Afro-Caribbean	African/African American	\N	\N	18975	1
6722952	\N	African American/Afro-Caribbean	African/African American	\N	\N	18866	1
6722953	\N	African American/Afro-Caribbean	African/African American	\N	\N	19063	1
6722954	\N	African American/Afro-Caribbean	African/African American	\N	\N	13111	1
6722955	\N	African American/Afro-Caribbean	African/African American	\N	\N	13854	1
6722956	\N	African American/Afro-Caribbean	African/African American	\N	\N	18973	1
6722957	\N	African American/Afro-Caribbean	African/African American	\N	\N	18967	1
6722958	\N	African American/Afro-Caribbean	African/African American	\N	\N	13157	1
6722959	\N	African American/Afro-Caribbean	African/African American	\N	\N	13150	1
6722960	\N	African American/Afro-Caribbean	African/African American	\N	\N	5327	1
6722961	\N	African American/Afro-Caribbean	African/African American	\N	\N	13153	1
6722962	\N	African American/Afro-Caribbean	African/African American	\N	\N	19038	1
6722963	\N	African American/Afro-Caribbean	African/African American	\N	\N	13150	1
6722964	\N	African American/Afro-Caribbean	African/African American	\N	\N	13147	1
6722965	\N	African American/Afro-Caribbean	African/African American	\N	\N	13155	1
6722966	\N	African American/Afro-Caribbean	African/African American	\N	\N	19043	1
6722967	\N	African American/Afro-Caribbean	African/African American	\N	\N	13065	1
6722968	\N	African American/Afro-Caribbean	African/African American	\N	\N	13155	1
6722969	\N	African American/Afro-Caribbean	African/African American	\N	\N	13154	1
6722970	\N	African American/Afro-Caribbean	African/African American	\N	\N	19037	1
6722971	\N	African American/Afro-Caribbean	African/African American	\N	\N	19140	1
6722972	\N	African American/Afro-Caribbean	African/African American	\N	\N	27408	1
6722973	\N	African American/Afro-Caribbean	African/African American	\N	\N	18982	1
6722974	\N	African American/Afro-Caribbean	African/African American	\N	\N	13113	1
6722975	\N	African American/Afro-Caribbean	African/African American	\N	\N	18987	1
6722976	\N	African American/Afro-Caribbean	African/African American	\N	\N	19005	1
6722977	\N	African American/Afro-Caribbean	African/African American	\N	\N	18914	1
6722978	\N	African American/Afro-Caribbean	African/African American	\N	\N	13154	1
6722979	\N	African American/Afro-Caribbean	African/African American	\N	\N	13114	1
6722980	\N	Central/South Asian	South Asian	\N	\N	19079	1
6722981	\N	Central/South Asian	South Asian	\N	\N	19075	1
6722982	\N	Central/South Asian	South Asian	\N	\N	19044	1
6722983	\N	Central/South Asian	South Asian	\N	\N	19076	1
6722984	\N	Central/South Asian	South Asian	\N	\N	19080	1
6722985	\N	Central/South Asian	South Asian	\N	\N	2649	1
6722986	\N	Central/South Asian	South Asian	\N	\N	18933	1
6722987	\N	Central/South Asian	South Asian	\N	\N	19065	1
6722988	\N	Central/South Asian	South Asian	\N	\N	19075	1
6722989	\N	Central/South Asian	South Asian	\N	\N	19078	1
6722990	\N	Central/South Asian	South Asian	\N	\N	18933	1
6722991	\N	Central/South Asian	South Asian	\N	\N	19080	1
6722992	\N	Central/South Asian	South Asian	\N	\N	19080	1
6722993	\N	Central/South Asian	South Asian	\N	\N	19079	1
6722994	\N	Central/South Asian	South Asian	\N	\N	19078	1
6722995	\N	Central/South Asian	South Asian	\N	\N	19080	1
6722996	\N	Central/South Asian	South Asian	\N	\N	18953	1
6722997	\N	Central/South Asian	South Asian	\N	\N	19073	1
6722998	\N	Central/South Asian	South Asian	\N	\N	19043	1
6722999	\N	Central/South Asian	South Asian	\N	\N	19077	1
6723000	\N	Central/South Asian	South Asian	\N	\N	19077	1
6723001	\N	Central/South Asian	South Asian	\N	\N	19078	1
6723002	\N	Central/South Asian	South Asian	\N	\N	19076	1
6723003	\N	Central/South Asian	South Asian	\N	\N	19077	1
6723004	\N	Central/South Asian	South Asian	\N	\N	19077	1
6723005	\N	Central/South Asian	South Asian	\N	\N	19067	1
6723006	\N	Central/South Asian	South Asian	\N	\N	18963	1
6723007	\N	Central/South Asian	South Asian	\N	\N	19073	1
6723008	\N	Central/South Asian	South Asian	\N	\N	19074	1
6723009	\N	Central/South Asian	South Asian	\N	\N	19074	1
6723010	\N	Central/South Asian	South Asian	\N	\N	19079	1
6723011	\N	Central/South Asian	South Asian	\N	\N	18999	1
6723012	\N	Central/South Asian	South Asian	\N	\N	19076	1
6723013	\N	Central/South Asian	South Asian	\N	\N	19080	1
6723014	\N	Central/South Asian	South Asian	\N	\N	19079	1
6723015	\N	Central/South Asian	South Asian	\N	\N	19076	1
6723016	\N	Central/South Asian	South Asian	\N	\N	19078	1
6723017	\N	Central/South Asian	South Asian	\N	\N	19031	1
6723018	\N	Central/South Asian	South Asian	\N	\N	19062	1
6723019	\N	Central/South Asian	South Asian	\N	\N	19075	1
6723020	\N	Central/South Asian	South Asian	\N	\N	19050	1
6723021	\N	Central/South Asian	South Asian	\N	\N	19043	1
6723022	\N	Central/South Asian	South Asian	\N	\N	19080	1
6723023	\N	Central/South Asian	South Asian	\N	\N	19073	1
6723024	\N	East Asian	East Asian	\N	\N	14844	1
6723025	\N	East Asian	East Asian	\N	\N	14851	1
6723026	\N	East Asian	East Asian	\N	\N	13825	1
6723027	\N	East Asian	East Asian	\N	\N	14839	1
6723028	\N	East Asian	East Asian	\N	\N	13861	1
6723029	\N	East Asian	East Asian	\N	\N	3559	1
6723030	\N	East Asian	East Asian	\N	\N	14796	1
6723031	\N	East Asian	East Asian	\N	\N	13851	1
6723032	\N	East Asian	East Asian	\N	\N	14847	1
6723033	\N	East Asian	East Asian	\N	\N	13861	1
6723034	\N	East Asian	East Asian	\N	\N	13802	1
6723035	\N	East Asian	East Asian	\N	\N	13861	1
6723036	\N	East Asian	East Asian	\N	\N	14827	1
6723037	\N	East Asian	East Asian	\N	\N	14838	1
6723038	\N	East Asian	East Asian	\N	\N	13861	1
6723039	\N	East Asian	East Asian	\N	\N	14383	1
6723040	\N	East Asian	East Asian	\N	\N	14782	1
6723041	\N	East Asian	East Asian	\N	\N	14855	1
6723042	\N	East Asian	East Asian	\N	\N	13844	1
6723043	\N	East Asian	East Asian	\N	\N	13854	1
6723044	\N	East Asian	East Asian	\N	\N	14824	1
6723045	\N	East Asian	East Asian	\N	\N	14822	1
6723046	\N	East Asian	East Asian	\N	\N	13857	1
6723047	\N	East Asian	East Asian	\N	\N	13859	1
6723048	\N	East Asian	East Asian	\N	\N	14838	1
6723049	\N	East Asian	East Asian	\N	\N	13858	1
6723050	\N	East Asian	East Asian	\N	\N	14758	1
6723051	\N	East Asian	East Asian	\N	\N	13860	1
6723052	\N	East Asian	East Asian	\N	\N	13861	1
6723053	\N	East Asian	East Asian	\N	\N	13860	1
6723054	\N	East Asian	East Asian	\N	\N	14841	1
6723055	\N	East Asian	East Asian	\N	\N	13828	1
6723056	\N	East Asian	East Asian	\N	\N	13860	1
6723057	\N	East Asian	East Asian	\N	\N	13859	1
6723059	\N	East Asian	East Asian	\N	\N	14861	1
6723060	\N	East Asian	East Asian	\N	\N	13859	1
6723061	\N	East Asian	East Asian	\N	\N	14815	1
6723062	\N	East Asian	East Asian	\N	\N	13851	1
6723063	\N	East Asian	East Asian	\N	\N	14833	1
6723064	\N	East Asian	East Asian	\N	\N	14834	1
6723065	\N	East Asian	East Asian	\N	\N	14804	1
6723066	\N	East Asian	East Asian	\N	\N	13859	1
6723067	\N	East Asian	East Asian	\N	\N	13844	1
6723068	\N	European	Finnish	\N	\N	18634	1
6723069	\N	European	non-Finnish	\N	\N	92560	1
6723070	\N	European	Finnish	\N	\N	18633	1
6723071	\N	European	non-Finnish	\N	\N	92365	1
6723072	\N	European	Finnish	\N	\N	15949	1
6723073	\N	European	non-Finnish	\N	\N	80881	1
6723074	\N	European	Finnish	\N	\N	18616	1
6723075	\N	European	non-Finnish	\N	\N	92499	1
6723076	\N	European	Finnish	\N	\N	15988	1
6723077	\N	European	non-Finnish	\N	\N	81834	1
6723078	\N	European	Finnish	\N	\N	6161	1
6723079	\N	European	non-Finnish	\N	\N	52914	1
6723080	\N	European	Finnish	\N	\N	18509	1
6723081	\N	European	non-Finnish	\N	\N	91636	1
6723082	\N	European	Finnish	\N	\N	15966	1
6723083	\N	European	non-Finnish	\N	\N	81140	1
6723084	\N	European	Finnish	\N	\N	18631	1
6723085	\N	European	non-Finnish	\N	\N	92236	1
6723086	\N	European	Finnish	\N	\N	15936	1
6723087	\N	European	non-Finnish	\N	\N	81811	1
6723088	\N	European	Finnish	\N	\N	15880	1
6723089	\N	European	non-Finnish	\N	\N	81023	1
6723090	\N	European	Finnish	\N	\N	15948	1
6723091	\N	European	non-Finnish	\N	\N	81840	1
6723092	\N	European	Finnish	\N	\N	18175	1
6723093	\N	European	non-Finnish	\N	\N	92559	1
6723094	\N	European	Finnish	\N	\N	18602	1
6723095	\N	European	non-Finnish	\N	\N	92240	1
6723096	\N	European	Finnish	\N	\N	15935	1
6723097	\N	European	non-Finnish	\N	\N	81583	1
6723098	\N	European	Finnish	\N	\N	18606	1
6723099	\N	European	non-Finnish	\N	\N	92342	1
6723100	\N	European	Finnish	\N	\N	18551	1
6723101	\N	European	non-Finnish	\N	\N	91742	1
6723102	\N	European	Finnish	\N	\N	18645	1
6723103	\N	European	non-Finnish	\N	\N	92469	1
6723104	\N	European	Finnish	\N	\N	15945	1
6723105	\N	European	non-Finnish	\N	\N	81575	1
6723106	\N	European	Finnish	\N	\N	15279	1
6723107	\N	European	non-Finnish	\N	\N	81081	1
6723108	\N	European	Finnish	\N	\N	18511	1
6723109	\N	European	non-Finnish	\N	\N	92220	1
6723110	\N	European	Finnish	\N	\N	18546	1
6723111	\N	European	non-Finnish	\N	\N	92279	1
6723112	\N	European	Finnish	\N	\N	15967	1
6723113	\N	European	non-Finnish	\N	\N	81708	1
6723114	\N	European	Finnish	\N	\N	15843	1
6723115	\N	European	non-Finnish	\N	\N	81661	1
6723116	\N	European	Finnish	\N	\N	18625	1
6723117	\N	European	non-Finnish	\N	\N	92015	1
6723118	\N	European	Finnish	\N	\N	16000	1
6723119	\N	European	non-Finnish	\N	\N	81639	1
6723120	\N	European	Finnish	\N	\N	18564	1
6723121	\N	European	non-Finnish	\N	\N	91777	1
6723122	\N	European	Finnish	\N	\N	15979	1
6723123	\N	European	non-Finnish	\N	\N	81810	1
6723124	\N	European	Finnish	\N	\N	15979	1
6723125	\N	European	non-Finnish	\N	\N	81810	1
6723126	\N	European	Finnish	\N	\N	15982	1
6723127	\N	European	non-Finnish	\N	\N	81840	1
6723128	\N	European	Finnish	\N	\N	15760	1
6723129	\N	European	non-Finnish	\N	\N	81579	1
6723130	\N	European	Finnish	\N	\N	18596	1
6723131	\N	European	non-Finnish	\N	\N	92526	1
6723132	\N	European	Finnish	\N	\N	15930	1
6723133	\N	European	non-Finnish	\N	\N	81335	1
6723134	\N	European	Finnish	\N	\N	15980	1
6723135	\N	European	non-Finnish	\N	\N	81808	1
6723136	\N	European	Finnish	\N	\N	16006	1
6723137	\N	European	non-Finnish	\N	\N	81841	1
6723138	\N	European	Finnish	\N	\N	18607	1
6723139	\N	European	non-Finnish	\N	\N	92425	1
6723140	\N	European	Finnish	\N	\N	18640	1
6723141	\N	European	non-Finnish	\N	\N	92538	1
6723142	\N	European	Finnish	\N	\N	15954	1
6723143	\N	European	non-Finnish	\N	\N	81672	1
6723144	\N	European	Finnish	\N	\N	18522	1
6723145	\N	European	non-Finnish	\N	\N	92058	1
6723146	\N	European	Finnish	\N	\N	15987	1
6723147	\N	European	non-Finnish	\N	\N	81150	1
6723148	\N	European	Finnish	\N	\N	17996	1
6723149	\N	European	non-Finnish	\N	\N	91676	1
6723150	\N	European	Finnish	\N	\N	18575	1
6723151	\N	European	non-Finnish	\N	\N	92310	1
6723152	\N	European	Finnish	\N	\N	18591	1
6723153	\N	European	non-Finnish	\N	\N	91611	1
6723154	\N	European	Finnish	\N	\N	16006	1
6723155	\N	European	non-Finnish	\N	\N	81841	1
6723156	\N	European	Finnish	\N	\N	15994	1
6723157	\N	European	non-Finnish	\N	\N	81428	1
6723158	\N	Latino	Latino/Admixed American	\N	\N	28037	1
6723159	\N	Latino	Latino/Admixed American	\N	\N	28038	1
6723160	\N	Latino	Latino/Admixed American	\N	\N	27381	1
6723161	\N	Latino	Latino/Admixed American	\N	\N	28041	1
6723162	\N	Latino	Latino/Admixed American	\N	\N	27423	1
6723163	\N	Latino	Latino/Admixed American	\N	\N	10583	1
6723164	\N	Latino	Latino/Admixed American	\N	\N	27974	1
6723165	\N	Latino	Latino/Admixed American	\N	\N	27396	1
6723166	\N	Latino	Latino/Admixed American	\N	\N	28036	1
6723167	\N	Latino	Latino/Admixed American	\N	\N	27412	1
6723168	\N	Latino	Latino/Admixed American	\N	\N	27346	1
6723169	\N	Latino	Latino/Admixed American	\N	\N	27411	1
6723170	\N	Latino	Latino/Admixed American	\N	\N	28043	1
6723171	\N	Latino	Latino/Admixed American	\N	\N	28054	1
6723172	\N	Latino	Latino/Admixed American	\N	\N	27415	1
6723173	\N	Latino	Latino/Admixed American	\N	\N	28049	1
6723174	\N	Latino	Latino/Admixed American	\N	\N	27994	1
6723175	\N	Latino	Latino/Admixed American	\N	\N	28038	1
6723176	\N	Latino	Latino/Admixed American	\N	\N	27400	1
6723177	\N	Latino	Latino/Admixed American	\N	\N	27411	1
6723178	\N	Latino	Latino/Admixed American	\N	\N	28029	1
6723179	\N	Latino	Latino/Admixed American	\N	\N	28030	1
6723180	\N	Latino	Latino/Admixed American	\N	\N	27420	1
6723181	\N	Latino	Latino/Admixed American	\N	\N	27406	1
6723182	\N	Latino	Latino/Admixed American	\N	\N	28037	1
6723183	\N	Latino	Latino/Admixed American	\N	\N	27398	1
6723184	\N	Latino	Latino/Admixed American	\N	\N	27964	1
6723185	\N	Latino	Latino/Admixed American	\N	\N	27423	1
6723186	\N	Latino	Latino/Admixed American	\N	\N	27425	1
6723187	\N	Latino	Latino/Admixed American	\N	\N	27412	1
6723188	\N	Latino	Latino/Admixed American	\N	\N	28041	1
6723189	\N	Latino	Latino/Admixed American	\N	\N	27358	1
6723190	\N	Latino	Latino/Admixed American	\N	\N	27418	1
6723191	\N	Latino	Latino/Admixed American	\N	\N	27424	1
6723192	\N	Latino	Latino/Admixed American	\N	\N	28031	1
6723193	\N	Latino	Latino/Admixed American	\N	\N	28034	1
6723194	\N	Latino	Latino/Admixed American	\N	\N	27408	1
6723195	\N	Latino	Latino/Admixed American	\N	\N	27995	1
6723196	\N	Latino	Latino/Admixed American	\N	\N	27408	1
6723197	\N	Latino	Latino/Admixed American	\N	\N	28028	1
6723198	\N	Latino	Latino/Admixed American	\N	\N	28027	1
6723199	\N	Latino	Latino/Admixed American	\N	\N	27995	1
6723200	\N	Latino	Latino/Admixed American	\N	\N	27424	1
6723201	\N	Latino	Latino/Admixed American	\N	\N	27408	1
6723202	113528	African American/Afro-Caribbean	USA African American	\N	\N	252	1
6723203	113528	African American/Afro-Caribbean	USA African American Bethesda	\N	\N	187	1
6723204	113528	African American/Afro-Caribbean	USA African American pop 2	\N	\N	149	1
6723205	113528	African American/Afro-Caribbean	USA African American pop 3	\N	\N	564	1
6723206	113528	African American/Afro-Caribbean	USA African American pop 4	\N	\N	2411	1
6723207	113528	African American/Afro-Caribbean	USA African American pop 8	\N	\N	605	1
6723208	113528	African American/Afro-Caribbean	USA NMDP African American	\N	\N	416581	1
6723209	113528	African American/Afro-Caribbean	USA NMDP Caribbean Black	\N	\N	33328	1
6723210	113537	African American/Afro-Caribbean	Americans of African Ancestry in SW USA	ASW	\N	112	1
6723211	113539	African American/Afro-Caribbean	Costa Ricans of Afro-Caribbean descent	\N	\N	102	1
6723212	113528	American	Argentina Gran Chaco Eastern Toba	\N	\N	135	1
6723213	113528	American	Chile Mapuches	\N	\N	104	1
6723214	113528	American	Ecuador Cayapa	\N	\N	183	1
6723215	113528	American	Mexico Oaxaca Mixtec	\N	\N	103	1
6723216	113528	American	Peru Titikaka Lake Uro	\N	\N	105	1
6723217	113528	American	USA Alaska Yupik	\N	\N	252	1
6723218	113528	American	USA Arizona Gila River Amerindian	\N	\N	492	1
6723219	113528	American	USA Arizona Pima	\N	\N	100	1
6723220	113528	American	USA NMDP Alaska Native or Aleut	\N	\N	1376	1
6723221	113528	American	USA NMDP American Indian South or Central America	\N	\N	5926	1
6723222	113528	American	USA NMDP Caribbean Indian	\N	\N	14339	1
6723223	113528	American	USA NMDP North American Amerindian	\N	\N	35791	1
6723224	113528	American	USA North American Native	\N	\N	187	1
6723225	113528	American	USA South Dakota Lakota Sioux	\N	\N	302	1
6723226	113528	American	Guatemala Mayan	\N	\N	132	1
6723227	113556	American	Colombian Chimila	\N	\N	47	1
6723228	113539	American	Costa Rican Amerindians	\N	\N	123	1
6723229	113559	American	Colombian Wiwa	\N	\N	52	1
6723230	113561	Central/South Asian	Sri Lanka	\N	\N	93	1
6723231	113563	Central/South Asian	India	\N	5 patients with CBZ-SJS and 52 CBZ-tolerant controls	57	1
6723232	113528	Central/South Asian	India Andhra Pradesh Golla	\N	\N	111	1
6723233	113528	Central/South Asian	India Andhra Pradesh Telugu Speaking	\N	\N	186	1
6723234	113528	Central/South Asian	India Tamil Nadu	\N	\N	2492	1
6723235	113528	Central/South Asian	Pakistan Brahui	\N	\N	104	1
6723236	113528	Central/South Asian	Pakistan Mixed Pathan	\N	\N	100	1
6723237	113528	Central/South Asian	Pakistan Mixed Sindhi	\N	\N	101	1
6723238	113528	Central/South Asian	Sri Lanka Colombo	\N	\N	714	1
6723239	113528	Central/South Asian	Sri Lanka Colombo Sinhalese	\N	\N	101	1
6723240	113528	Central/South Asian	USA NMDP South Asian Indian	\N	\N	185391	1
6723241	113574	Central/South Asian	Indian	Tamil Nadu	Cord blood bank	2491	1
6723242	113576	East Asian	Koreans	\N	\N	1891	1
6723243	113578	East Asian	Thai	\N	\N	986	1
6723244	113580	East Asian	Koreans	\N	Bone marrow registry	10918	1
6723245	113582	East Asian	Chinese Han from Zhejiang province	\N	Bone marrow donors	8333	1
6723246	115400	East Asian	Japanese	\N	5824 families across Japan	18604	1
6723247	113584	East Asian	Han Chinese	\N	\N	98	1
6723248	113584	East Asian	Mongolian from Inner Mongolia	\N	\N	98	1
6723249	113584	East Asian	Mongolian from Yunnan Province	\N	\N	206	1
6723250	113584	East Asian	Hani	\N	\N	134	1
6723251	113584	East Asian	Dai	\N	\N	130	1
6723252	113584	East Asian	Yao	\N	\N	120	1
6723253	113584	East Asian	Wa	\N	\N	154	1
6723254	113528	East Asian	China Beijing Shijiazhuang Tianjian Han	\N	\N	618	1
6723255	113528	East Asian	China Canton Han	\N	\N	264	1
6723256	113528	East Asian	China Guangdong Province Meizhou Han	\N	\N	100	1
6723257	113528	East Asian	China Guangxi Region Maonan	\N	\N	108	1
6723258	113528	East Asian	China Guangzhou Han	\N	\N	106	1
6723259	113528	East Asian	China Guizhou Province Bouyei	\N	\N	109	1
6723260	113528	East Asian	China Guizhou Province Shui	\N	\N	153	1
6723261	113528	East Asian	China Jiangsu Han	\N	\N	3238	1
6723262	113528	East Asian	China Jiangsu Province Han	\N	\N	334	1
6723263	113528	East Asian	China North Han	\N	\N	105	1
6723264	113528	East Asian	China North Han pop 2	\N	\N	567	1
6723265	113528	East Asian	China Qinghai Province Hui	\N	\N	110	1
6723266	113528	East Asian	China South Han	\N	\N	284	1
6723267	113528	East Asian	China South Han pop 2	\N	\N	1098	1
6723268	113528	East Asian	China Southwest Dai	\N	\N	124	1
6723269	113528	East Asian	China Tibet Region Tibetan	\N	\N	158	1
6723270	113528	East Asian	China Yunnan Bulang	\N	\N	116	1
6723271	113528	East Asian	China Yunnan Hani	\N	\N	150	1
6723272	113528	East Asian	China Yunnan Province Han	\N	\N	101	1
6723273	113528	East Asian	China Yunnan Province Jinuo	\N	\N	109	1
6723274	113528	East Asian	China Yunnan Province Lisu	\N	\N	111	1
6723275	113528	East Asian	China Yunnan Province Nu	\N	\N	107	1
6723276	113528	East Asian	China Yunnan Province Wa	\N	\N	119	1
6724311	114925	East Asian	East Asian	\N	\N	8621	1
6723277	113528	East Asian	Germany DKMS - China minority	\N	\N	1282	1
6723278	113528	East Asian	Hong Kong Chinese	\N	\N	569	1
6723279	113528	East Asian	Hong Kong Chinese BMDR	\N	\N	7595	1
6723280	113528	East Asian	Hong Kong Chinese cord blood registry	\N	\N	3892	1
6723281	113528	East Asian	Indonesia Java Western	\N	\N	236	1
6723282	113528	East Asian	Indonesia Sundanese and Javanese	\N	\N	201	1
6723283	113528	East Asian	Japan Central	\N	\N	371	1
6723284	113528	East Asian	Japan Kyoto and Osaka	\N	\N	165	1
6723285	113528	East Asian	Japan pop 1	\N	\N	560	1
6723286	113528	East Asian	Japan pop 3	\N	\N	1018	1
6723287	113528	East Asian	Japan pop 5	\N	\N	117	1
6723288	113528	East Asian	Malaysia Peninsular Chinese	\N	\N	194	1
6723289	113528	East Asian	Russia Tuva pop 2	\N	\N	169	1
6723290	113528	East Asian	Singapore Chinese	\N	\N	149	1
6723291	113528	East Asian	Singapore Thai	\N	\N	100	1
6723292	113528	East Asian	South Korea pop 10	\N	\N	4128	1
6723293	113528	East Asian	South Korea pop 3	\N	\N	485	1
6723294	113528	East Asian	South Korea pop 8	\N	\N	7096	1
6723295	113528	East Asian	Taiwan Atayal	\N	\N	106	1
6723296	113528	East Asian	Taiwan Bunun	\N	\N	101	1
6723297	113528	East Asian	Taiwan Han Chinese	\N	\N	504	1
6723298	113528	East Asian	Taiwan Minnan pop 1	\N	\N	102	1
6723299	113528	East Asian	Taiwan pop 2	\N	\N	364	1
6723300	113528	East Asian	Taiwan pop 3	\N	\N	212	1
6723301	113528	East Asian	Taiwan Tzu Chi Cord Blood Bank	\N	\N	710	1
6723302	113528	East Asian	Thailand	\N	\N	142	1
6723303	113528	East Asian	Thailand Northeast pop 2	\N	\N	400	1
6723304	113528	East Asian	USA NMDP Chinese	\N	\N	99672	1
6723305	113528	East Asian	USA NMDP Filipino	\N	\N	50614	1
6723306	113528	East Asian	USA NMDP Japanese	\N	\N	24582	1
6723307	113528	East Asian	USA NMDP Korean	\N	\N	77584	1
6723308	113528	East Asian	USA NMDP Southeast Asian	\N	\N	27978	1
6723309	113528	East Asian	USA NMDP Vietnamese	\N	\N	43540	1
6723310	113528	East Asian	Vietnam Hanoi Kinh pop 2	\N	\N	170	1
6723311	113528	East Asian	Malaysia Peninsular Malay	\N	\N	951	1
6723312	113528	East Asian	Singapore Riau Malay	\N	\N	132	1
6723313	113537	East Asian	Han Chinese in Beijing, China	CHB	\N	108	1
6723314	113537	East Asian	Chinese Dai in Xishuangbanna, China	CHD	\N	109	1
6723315	113537	East Asian	Southern Han Chinese	CHS	\N	171	1
6723316	113537	East Asian	Japanese in Tokyo, Japan	JPT	\N	105	1
6723317	113656	East Asian	Han Chinese from Yunnan	\N	\N	239	1
6723318	113658	East Asian	Korean	\N	HSC donors	613	1
6723319	113660	East Asian	Burmese	\N	\N	170	1
6723320	113660	East Asian	Karen	\N	\N	200	1
6723321	113663	East Asian	Han Chinese from Liaoning	\N	Bone marrow donors	7823	1
6723322	113665	East Asian	Han Chinese from Nanning	\N	\N	562	1
6723323	113667	East Asian	Northeastern Thai	\N	\N	183	1
6723324	113669	East Asian	Thai	\N	\N	334	1
6723325	113528	European	Russians from Karelia	\N	\N	1075	1
6723326	113528	European	Russia North Ossetian	\N	\N	127	1
6723327	113671	European	Bulgarian	\N	\N	55	1
6723328	113673	European	Welsh	\N	Blood donors	254	1
6723329	113528	European	Australia New South Wales Caucasian	\N	\N	134	1
6723330	113528	European	Austria	\N	\N	200	1
6723331	113528	European	Croatia	\N	\N	150	1
6723332	113528	European	Croatia pop 4	\N	\N	4000	1
6723333	113528	European	Czech Republic	\N	\N	106	1
6723334	113528	European	Czech Republic NMDR	\N	\N	5099	1
6723335	113528	European	England North West	\N	\N	298	1
6723336	113528	European	France Corsica Island	\N	\N	100	1
6723337	113528	European	France Grenoble, Nantes and Rennes	\N	\N	6094	1
6723338	113528	European	France Southeast	\N	\N	130	1
6723339	113528	European	France West	\N	\N	100	1
6723340	113528	European	Germany DKMS - Austria minority	\N	\N	1698	1
6723341	113528	European	Germany DKMS - Bosnia and Herzegovina minority	\N	\N	1028	1
6723342	113528	European	Germany DKMS - Croatia minority	\N	\N	2057	1
6723343	113528	European	Germany DKMS - France minority	\N	\N	1406	1
6723344	113528	European	Germany DKMS - Greece minority	\N	\N	1894	1
6723345	113528	European	Germany DKMS - Italy minority	\N	\N	1159	1
6723346	113528	European	Germany DKMS - Netherlands minority	\N	\N	1374	1
6723347	113528	European	Germany DKMS - Portugal minority	\N	\N	1176	1
6723348	113528	European	Germany DKMS - Romania minority	\N	\N	1234	1
6723349	113528	European	Germany DKMS - Spain minority	\N	\N	1107	1
6723350	113528	European	Germany DKMS - United Kingdom minority	\N	\N	1043	1
6723351	113528	European	Germany Essen	\N	\N	174	1
6723352	113528	European	Germany pop 6	\N	\N	8862	1
6723353	113528	European	Germany pop 8	\N	\N	39689	1
6723354	113528	European	Greece pop 6	\N	\N	242	1
6723355	113528	European	Ireland Northern	\N	\N	1000	1
6723356	113528	European	Ireland South	\N	\N	250	1
6723357	113528	European	Italy Bergamo	\N	\N	101	1
6723358	113528	European	Italy North	\N	\N	277	1
6723359	113528	European	Italy pop 5	\N	\N	975	1
6723360	113528	European	Italy Sardinia pop3	\N	\N	100	1
6723361	113528	European	Italy South	\N	\N	141	1
6723362	113528	European	Italy South Campania Region	\N	\N	1089	1
6723363	113528	European	Madeira	\N	\N	185	1
6723364	113528	European	Macedonia pop 4	\N	\N	216	1
6723365	113528	European	Netherlands Leiden	\N	\N	1305	1
6723366	113528	European	Poland	\N	\N	200	1
6723367	113528	European	Poland DKMS	\N	\N	20653	1
6723368	113528	European	Portugal Azores Terceira Island	\N	\N	130	1
6723369	113528	European	Portugal Center pop 2	\N	\N	562	1
6723370	113528	European	Romania	\N	\N	348	1
6723371	113528	European	Serbia pop 2	\N	\N	102	1
6723372	113528	European	South Africa Caucasians	\N	\N	102	1
6723373	113528	European	Spain Gipzukoa Basque	\N	\N	100	1
6723374	113528	European	Spain Sevilla	\N	\N	278	1
6723375	113528	European	Sweden Northern Sami	\N	\N	154	1
6723376	113528	European	Sweden Southern Sami	\N	\N	130	1
6723377	113528	European	Switzerland Aargau-Solothurn	\N	\N	1838	1
6723378	113528	European	Switzerland Basel	\N	\N	1888	1
6723379	113528	European	Switzerland Bern	\N	\N	3545	1
6723380	113528	European	Switzerland Geneva pop 2	\N	\N	1267	1
6723381	113528	European	Switzerland Graubunden	\N	\N	759	1
6723382	113528	European	Switzerland Lausanne	\N	\N	993	1
6723383	113528	European	Switzerland Lugano	\N	\N	1169	1
6723384	113528	European	Switzerland Luzern	\N	\N	1553	1
6723385	113528	European	Switzerland Sion	\N	\N	832	1
6723386	113528	European	Switzerland St Gallen	\N	\N	2113	1
6723387	113528	European	Switzerland Zurich	\N	\N	4875	1
6723388	113528	European	United Kingdom pop 3	\N	\N	604	1
6723389	113528	European	USA Caucasian Bethesda	\N	\N	307	1
6723390	113528	European	USA Caucasian pop 2	\N	\N	265	1
6723391	113528	European	USA Caucasian pop 4	\N	\N	1070	1
6723392	113528	European	USA Eastern European	\N	\N	558	1
6723393	113528	European	USA European American pop 2	\N	\N	1245	1
6723394	113528	European	USA NMDP European Caucasian	\N	\N	1242890	1
6723395	113528	European	USA Philadelphia Caucasian	\N	\N	141	1
6723396	113528	European	USA San Antonio Caucasian	\N	\N	222	1
6723397	113528	European	USA San Francisco Caucasian	\N	\N	220	1
6723398	113528	European	USA Italy Ancestry	\N	\N	273	1
6723399	113528	European	USA Spain Ancestry	\N	\N	279	1
6723400	113528	European	Wales	\N	\N	1798	1
6723401	113537	European	Utah Residents (CEPH) with Northern and Western Europena Ancestry	CEU	\N	183	1
6723402	113537	European	Finnish in Finland	FIN	\N	105	1
6723403	113537	European	British in England and Scotland	GBR	\N	107	1
6723404	113537	European	Toscani in Italy	TSI	\N	112	1
6723405	113753	European	Serbian	\N	\N	1992	1
6723406	113755	European	Croatian	\N	\N	4000	1
6723407	113757	European	French	\N	Bone marrow donors	42636	1
6723408	113528	Latino	Mexico City Mestizo	\N	\N	121	1
6723409	113528	Latino	Mexico City Mestizo pop 2	\N	\N	234	1
6723410	113528	Latino	USA Hispanic	\N	\N	234	1
6723411	113528	Latino	USA Hispanic pop 2	\N	\N	1999	1
6723412	113528	Latino	USA Mexican American Mestizo	\N	\N	553	1
6723413	113528	Latino	USA NMDP Hispanic South or Central American	\N	\N	146714	1
6723414	113528	Latino	USA NMDP Mexican or Chicano	\N	\N	261235	1
6723415	113528	Latino	USA South Texas Hispanic	\N	\N	194	1
6723416	113528	Latino	Mexico Guadalajara Mestizo pop 2	\N	\N	103	1
6723417	113528	Latino	USA NMDP Caribbean Hispanic	\N	\N	115374	1
6723418	113537	Latino	Colombians from Medellin, Colombia	CLM	\N	148	1
6723419	113537	Latino	Mexican Ancestry from Los Angeles, USA	MXL	\N	107	1
6723420	113537	Latino	Puerto Ricans from Puerto Rico	PUR	\N	150	1
6723421	113774	Latino	Brazilians	Quilombos	\N	144	1
6723422	113539	Latino	Costa Rican Mestizos	Central Valley	\N	221	1
6723423	113539	Latino	Costa Rican Mestizos	Guanacaste	\N	110	1
6723424	113539	Latino	Nicaraguan Mestizos	\N	\N	155	1
6723425	113528	Near Eastern	England London Ashkenazi Jews	\N	\N	500	1
6723426	113528	Near Eastern	Israel Bukhara Jews	\N	\N	2317	1
6723427	113528	Near Eastern	Israel Kavkazi Jews	\N	\N	2840	1
6723428	113528	Near Eastern	Israel Poland Jews	\N	\N	13871	1
6723429	113528	Near Eastern	Israel USSR Jews	\N	\N	45681	1
6723430	113528	Near Eastern	Israel Argentina Jews	\N	\N	4307	1
6723431	113780	Near Eastern	Jordanians	\N	\N	146	1
6723432	113528	Near Eastern	Armenia combined Regions	\N	\N	100	1
6723433	113528	Near Eastern	Georgia Tibilisi	\N	\N	109	1
6723434	113528	Near Eastern	Germany DKMS - Turkey minority	\N	\N	4856	1
6723435	113528	Near Eastern	Iran Baloch	\N	\N	100	1
6723436	113528	Near Eastern	Iran Tehran	\N	\N	120	1
6723437	113528	Near Eastern	Israel Arab	\N	\N	12301	1
6723438	113528	Near Eastern	Israel Arab Druze	\N	\N	101	1
6723439	113528	Near Eastern	Israel Ashkenazi and Non Ashkenazi Jews	\N	\N	146	1
6723440	113528	Near Eastern	Israel Ashkenazi Jews	\N	\N	4625	1
6723441	113528	Near Eastern	Israel Druze	\N	\N	5914	1
6723442	113528	Near Eastern	Israel Georgia Jews	\N	\N	4471	1
6723443	113528	Near Eastern	Israel Iran Jews	\N	\N	8153	1
6723444	113528	Near Eastern	Israel Iraq Jews	\N	\N	13270	1
6723445	113528	Near Eastern	Israel Libya Jews	\N	\N	3739	1
6723446	113528	Near Eastern	Israel Morocco Jews	\N	\N	36718	1
6723447	113528	Near Eastern	Israel Tunisia Jews	\N	\N	9070	1
6723448	113528	Near Eastern	Israel USA Jews	\N	\N	6058	1
6723449	113528	Near Eastern	Israel YemenJews	\N	\N	15542	1
6723450	113528	Near Eastern	Libya Cyrenaica	\N	\N	118	1
6723451	113528	Near Eastern	Oman	\N	\N	118	1
6723452	113528	Near Eastern	Saudi Arabia Guraiat and Hail	\N	\N	213	1
6723453	113528	Near Eastern	Saudi Arabia pop 5	\N	\N	158	1
6723454	113528	Near Eastern	Tunisia	\N	\N	100	1
6723455	113528	Near Eastern	United Arab Emirates pop 2	\N	\N	373	1
6723456	113528	Near Eastern	USA NMDP Middle Eastern or North Coast of Africa	\N	\N	70890	1
6723457	113528	Near Eastern	Israel Ethiopia Jews	\N	\N	5928	1
6723458	113528	Near Eastern	Tunisia pop 3	\N	\N	104	1
6723459	115614	Near Eastern	Syrian	\N	\N	130	1
6723460	113814	Near Eastern	Iranian	Yazd Province	\N	90	1
6723461	113528	Oceanian	Australia Cape York Peninsula Aborigine	\N	\N	103	1
6723462	113528	Oceanian	Australia Yuendumu Aborigine	\N	\N	191	1
6723463	113528	Oceanian	New Zealand Maori with Admixed History	\N	\N	105	1
6723464	113528	Oceanian	Papua New Guinea Wosera Abelam	\N	\N	131	1
6723465	113528	Oceanian	USA Hawaii Okinawa	\N	\N	106	1
6723466	113528	Oceanian	USA NMDP Hawaiian or other Pacific Islander	\N	\N	11499	1
6723467	113528	Sub-Saharan African	Cameroon Beti	\N	\N	174	1
6723468	113528	Sub-Saharan African	Ghana Ga-Adangbe	\N	\N	131	1
6723469	113528	Sub-Saharan African	Kenya	\N	\N	144	1
6723470	113528	Sub-Saharan African	Kenya Luo	\N	\N	265	1
6723471	113528	Sub-Saharan African	Kenya Nandi	\N	\N	240	1
6723472	113528	Sub-Saharan African	Kenya, Nyanza Province, Luo tribe	\N	\N	100	1
6723473	113528	Sub-Saharan African	Mali Bandiagara	\N	\N	138	1
6723474	113528	Sub-Saharan African	Senegal Niokholo Mandenka	\N	\N	165	1
6723475	113528	Sub-Saharan African	South Africa Black	\N	\N	200	1
6723476	113528	Sub-Saharan African	South Africa Natal Zulu	\N	\N	100	1
6723477	113528	Sub-Saharan African	Uganda Kampala	\N	\N	161	1
6723478	113528	Sub-Saharan African	Uganda Kampala pop 2	\N	\N	175	1
6723479	113528	Sub-Saharan African	USA NMDP African	\N	\N	28557	1
6724312	114927	East Asian	East Asian	\N	\N	9431	1
6723480	113528	Sub-Saharan African	Zimbabwe Harare Shona	\N	\N	230	1
6723481	113537	Sub-Saharan African	Luhya in Webuye, Kenya	LWK	\N	116	1
6723482	113537	Sub-Saharan African	Yoruba in Ibadan, Nigeria	YRI	\N	186	1
6723483	113528	African American/Afro-Caribbean	USA African American	\N	\N	252	1
6723484	113528	African American/Afro-Caribbean	USA African American Bethesda	\N	\N	187	1
6723485	113528	African American/Afro-Caribbean	USA African American pop 2	\N	\N	149	1
6723486	113528	African American/Afro-Caribbean	USA African American pop 3	\N	\N	564	1
6723487	113528	African American/Afro-Caribbean	USA African American pop 4	\N	\N	2411	1
6723488	113528	African American/Afro-Caribbean	USA African American pop 8	\N	\N	605	1
6723489	113528	African American/Afro-Caribbean	USA NMDP African American	\N	\N	416581	1
6723490	113528	African American/Afro-Caribbean	USA NMDP Caribbean Black	\N	\N	33328	1
6723491	113537	African American/Afro-Caribbean	Americans of African Ancestry in SW USA	ASW	\N	112	1
6723492	113539	African American/Afro-Caribbean	Costa Ricans of Afro-Caribbean descent	\N	\N	102	1
6723493	113528	American	Argentina Gran Chaco Eastern Toba	\N	\N	135	1
6723494	113528	American	Chile Mapuches	\N	\N	104	1
6723495	113528	American	Ecuador Cayapa	\N	\N	183	1
6723496	113528	American	Mexico Oaxaca Mixtec	\N	\N	103	1
6723497	113528	American	Peru Titikaka Lake Uro	\N	\N	105	1
6723498	113528	American	USA Alaska Yupik	\N	\N	252	1
6723499	113528	American	USA Arizona Gila River Amerindian	\N	\N	492	1
6723500	113528	American	USA Arizona Pima	\N	\N	100	1
6723501	113528	American	USA NMDP Alaska Native or Aleut	\N	\N	1376	1
6723502	113528	American	USA NMDP American Indian South or Central America	\N	\N	5926	1
6723503	113528	American	USA NMDP Caribbean Indian	\N	\N	14339	1
6723504	113528	American	USA NMDP North American Amerindian	\N	\N	35791	1
6723505	113528	American	USA North American Native	\N	\N	187	1
6723506	113528	American	USA South Dakota Lakota Sioux	\N	\N	302	1
6723507	113528	American	Guatemala Mayan	\N	\N	132	1
6723508	113556	American	Colombian Chimila	\N	\N	47	1
6723509	113539	American	Costa Rican Amerindians	\N	\N	123	1
6723510	113559	American	Colombian Wiwa	\N	\N	52	1
6723511	113561	Central/South Asian	Sri Lanka	\N	\N	93	1
6723512	113563	Central/South Asian	India	\N	5 patients with CBZ-SJS and 52 CBZ-tolerant controls	57	1
6723513	113528	Central/South Asian	India Andhra Pradesh Golla	\N	\N	111	1
6723514	113528	Central/South Asian	India Andhra Pradesh Telugu Speaking	\N	\N	186	1
6723515	113528	Central/South Asian	India Tamil Nadu	\N	\N	2492	1
6723516	113528	Central/South Asian	Pakistan Brahui	\N	\N	104	1
6723517	113528	Central/South Asian	Pakistan Mixed Pathan	\N	\N	100	1
6723518	113528	Central/South Asian	Pakistan Mixed Sindhi	\N	\N	101	1
6723519	113528	Central/South Asian	Sri Lanka Colombo	\N	\N	714	1
6723520	113528	Central/South Asian	Sri Lanka Colombo Sinhalese	\N	\N	101	1
6723521	113528	Central/South Asian	USA NMDP South Asian Indian	\N	\N	185391	1
6723522	113574	Central/South Asian	Indian	Tamil Nadu	Cord blood bank	2491	1
6723523	113576	East Asian	Koreans	\N	\N	2009	1
6723524	113578	East Asian	Thai	\N	\N	986	1
6723525	113580	East Asian	Koreans	\N	bone marrow registry	10918	1
6723526	113582	East Asian	Chinese Han from Zhejiang province	\N	bone marrow donors	8333	1
6723527	113584	East Asian	Han Chinese	\N	\N	98	1
6723528	113584	East Asian	Mongolian from Inner Mongolia	\N	\N	98	1
6723529	113584	East Asian	Mongolian from Yunnan Province	\N	\N	206	1
6723530	113584	East Asian	Hani	\N	\N	134	1
6723531	113584	East Asian	Dai	\N	\N	130	1
6723532	113584	East Asian	Yao	\N	\N	120	1
6723533	113584	East Asian	Wa	\N	\N	154	1
6723534	113528	East Asian	China Beijing Shijiazhuang Tianjian Han	\N	\N	618	1
6723535	113528	East Asian	China Canton Han	\N	\N	264	1
6723536	113528	East Asian	China Guangdong Province Meizhou Han	\N	\N	100	1
6723537	113528	East Asian	China Guangxi Region Maonan	\N	\N	108	1
6723538	113528	East Asian	China Guangzhou Han	\N	\N	106	1
6723539	113528	East Asian	China Guizhou Province Bouyei	\N	\N	109	1
6723540	113528	East Asian	China Guizhou Province Shui	\N	\N	153	1
6723541	113528	East Asian	China Jiangsu Han	\N	\N	3238	1
6723542	113528	East Asian	China Jiangsu Province Han	\N	\N	334	1
6723543	113528	East Asian	China North Han	\N	\N	105	1
6723544	113528	East Asian	China North Han pop 2	\N	\N	567	1
6723545	113528	East Asian	China Qinghai Province Hui	\N	\N	110	1
6723546	113528	East Asian	China South Han	\N	\N	284	1
6723547	113528	East Asian	China South Han pop 2	\N	\N	1098	1
6723548	113528	East Asian	China Southwest Dai	\N	\N	124	1
6723549	113528	East Asian	China Tibet Region Tibetan	\N	\N	158	1
6723550	113528	East Asian	China Yunnan Bulang	\N	\N	116	1
6723551	113528	East Asian	China Yunnan Hani	\N	\N	150	1
6723552	113528	East Asian	China Yunnan Province Han	\N	\N	101	1
6723553	113528	East Asian	China Yunnan Province Jinuo	\N	\N	109	1
6723554	113528	East Asian	China Yunnan Province Lisu	\N	\N	111	1
6723555	113528	East Asian	China Yunnan Province Nu	\N	\N	107	1
6723556	113528	East Asian	China Yunnan Province Wa	\N	\N	119	1
6723557	113528	East Asian	Germany DKMS - China minority	\N	\N	1282	1
6723558	113528	East Asian	Hong Kong Chinese	\N	\N	569	1
6723559	113528	East Asian	Hong Kong Chinese BMDR	\N	\N	7595	1
6723560	113528	East Asian	Hong Kong Chinese cord blood registry	\N	\N	3892	1
6723561	113528	East Asian	Indonesia Java Western	\N	\N	236	1
6723562	113528	East Asian	Indonesia Sundanese and Javanese	\N	\N	201	1
6723563	113528	East Asian	Japan Central	\N	\N	371	1
6723564	113528	East Asian	Japan Kyoto and Osaka	\N	\N	165	1
6723565	113528	East Asian	Japan pop 1	\N	\N	560	1
6723566	113528	East Asian	Japan pop 16	\N	\N	18604	1
6723567	113528	East Asian	Japan pop 3	\N	\N	1018	1
6723568	113528	East Asian	Japan pop 5	\N	\N	117	1
6723569	113528	East Asian	Malaysia Peninsular Chinese	\N	\N	194	1
6723570	113528	East Asian	Russia Tuva pop 2	\N	\N	169	1
6723571	113528	East Asian	Singapore Chinese	\N	\N	149	1
6723572	113528	East Asian	Singapore Thai	\N	\N	100	1
6723573	113528	East Asian	South Korea pop 10	\N	\N	4128	1
6723574	113528	East Asian	South Korea pop 3	\N	\N	485	1
6723575	113528	East Asian	South Korea pop 8	\N	\N	7096	1
6723576	113528	East Asian	Taiwan Atayal	\N	\N	106	1
6723577	113528	East Asian	Taiwan Bunun	\N	\N	101	1
6723578	113528	East Asian	Taiwan Han Chinese	\N	\N	504	1
6723579	113528	East Asian	Taiwan Minnan pop 1	\N	\N	102	1
6723580	113528	East Asian	Taiwan pop 2	\N	\N	364	1
6723581	113528	East Asian	Taiwan pop 3	\N	\N	212	1
6723582	113528	East Asian	Taiwan Tzu Chi Cord Blood Bank	\N	\N	710	1
6723583	113528	East Asian	Thailand	\N	\N	142	1
6723584	113528	East Asian	Thailand Northeast pop 2	\N	\N	400	1
6723585	113528	East Asian	USA NMDP Chinese	\N	\N	99672	1
6723586	113528	East Asian	USA NMDP Filipino	\N	\N	50614	1
6723587	113528	East Asian	USA NMDP Japanese	\N	\N	24582	1
6723588	113528	East Asian	USA NMDP Korean	\N	\N	77584	1
6723589	113528	East Asian	USA NMDP Southeast Asian	\N	\N	27978	1
6723590	113528	East Asian	USA NMDP Vietnamese	\N	\N	43540	1
6723591	113528	East Asian	Vietnam Hanoi Kinh pop 2	\N	\N	170	1
6723592	113528	East Asian	Malaysia Peninsular Malay	\N	\N	951	1
6723593	113528	East Asian	Singapore Riau Malay	\N	\N	132	1
6723594	113537	East Asian	Han Chinese in Beijing, China	CHB	\N	108	1
6723595	113537	East Asian	Chinese Dai in Xishuangbanna, China	CHD	\N	109	1
6723596	113537	East Asian	Southern Han Chinese	CHS	\N	171	1
6723597	113537	East Asian	Japanese in Tokyo, Japan	JPT	\N	105	1
6723598	113656	East Asian	Han Chinese from Yunnan	\N	\N	239	1
6723599	113658	East Asian	Korean	\N	HSC donors	613	1
6723600	113660	East Asian	Burmese	\N	\N	170	1
6723601	113660	East Asian	Karen	\N	\N	200	1
6723602	113663	East Asian	Han Chinese from Liaoning	\N	Bone marrow donors	7823	1
6723603	113665	East Asian	Han Chinese from Nanning	\N	\N	562	1
6723604	113667	East Asian	Northeastern Thai	\N	\N	183	1
6723605	113669	East Asian	Thai	\N	\N	334	1
6723606	113671	European	Bulgarian	\N	\N	55	1
6723607	113673	European	Welsh	\N	Blood donors	254	1
6723608	113528	European	Australia New South Wales Caucasian	\N	\N	134	1
6723609	113528	European	Austria	\N	\N	200	1
6723610	113528	European	Croatia	\N	\N	150	1
6723611	113528	European	Croatia pop 4	\N	\N	4000	1
6723612	113528	European	Czech Republic	\N	\N	106	1
6723613	113528	European	Czech Republic NMDR	\N	\N	5099	1
6723614	113528	European	England North West	\N	\N	298	1
6723615	113528	European	France Corsica Island	\N	\N	100	1
6723616	113528	European	France Grenoble, Nantes and Rennes	\N	\N	6094	1
6723617	113528	European	France Southeast	\N	\N	130	1
6723618	113528	European	France West	\N	\N	100	1
6723619	113528	European	Germany DKMS - Austria minority	\N	\N	1698	1
6723620	113528	European	Germany DKMS - Bosnia and Herzegovina minority	\N	\N	1028	1
6723621	113528	European	Germany DKMS - Croatia minority	\N	\N	2057	1
6723622	113528	European	Germany DKMS - France minority	\N	\N	1406	1
6723623	113528	European	Germany DKMS - Greece minority	\N	\N	1894	1
6723624	113528	European	Germany DKMS - Italy minority	\N	\N	1159	1
6723625	113528	European	Germany DKMS - Netherlands minority	\N	\N	1374	1
6723626	113528	European	Germany DKMS - Portugal minority	\N	\N	1176	1
6723627	113528	European	Germany DKMS - Romania minority	\N	\N	1234	1
6723628	113528	European	Germany DKMS - Spain minority	\N	\N	1107	1
6723629	113528	European	Germany DKMS - United Kingdom minority	\N	\N	1043	1
6723630	113528	European	Germany Essen	\N	\N	174	1
6723631	113528	European	Germany pop 6	\N	\N	8862	1
6723632	113528	European	Germany pop 8	\N	\N	39689	1
6723633	113528	European	Greece pop 6	\N	\N	242	1
6723634	113528	European	Ireland Northern	\N	\N	1000	1
6723635	113528	European	Ireland South	\N	\N	250	1
6723636	113528	European	Italy Bergamo	\N	\N	101	1
6723637	113528	European	Italy North	\N	\N	277	1
6723638	113528	European	Italy pop 5	\N	\N	975	1
6723639	113528	European	Italy Sardinia pop3	\N	\N	100	1
6723640	113528	European	Italy South	\N	\N	141	1
6723641	113528	European	Italy South Campania Region	\N	\N	1089	1
6723642	113528	European	Madeira	\N	\N	185	1
6723643	113528	European	Macedonia pop 4	\N	\N	216	1
6723644	113528	European	Netherlands Leiden	\N	\N	1305	1
6723645	113528	European	Poland	\N	\N	200	1
6723646	113528	European	Poland DKMS	\N	\N	20653	1
6723647	113528	European	Portugal Azores Terceira Island	\N	\N	130	1
6723648	113528	European	Portugal Center pop 2	\N	\N	562	1
6723649	113528	European	Romania	\N	\N	348	1
6723650	113528	European	Russia North Ossetian	\N	\N	127	1
6723651	113528	European	Russians from Karelia	\N	\N	1075	1
6723652	113528	European	Serbia pop 2	\N	\N	102	1
6723653	113528	European	South Africa Caucasians	\N	\N	102	1
6723654	113528	European	Spain Gipzukoa Basque	\N	\N	100	1
6723655	113528	European	Spain Sevilla	\N	\N	278	1
6723656	113528	European	Sweden Northern Sami	\N	\N	154	1
6723657	113528	European	Sweden Southern Sami	\N	\N	130	1
6723658	113528	European	Switzerland Aargau-Solothurn	\N	\N	1838	1
6723659	113528	European	Switzerland Basel	\N	\N	1888	1
6723660	113528	European	Switzerland Bern	\N	\N	3545	1
6723661	113528	European	Switzerland Geneva pop 2	\N	\N	1267	1
6723662	113528	European	Switzerland Graubunden	\N	\N	759	1
6723663	113528	European	Switzerland Lausanne	\N	\N	993	1
6723664	113528	European	Switzerland Lugano	\N	\N	1169	1
6723665	113528	European	Switzerland Luzern	\N	\N	1553	1
6723666	113528	European	Switzerland Sion	\N	\N	832	1
6723667	113528	European	Switzerland St Gallen	\N	\N	2113	1
6723668	113528	European	Switzerland Zurich	\N	\N	4875	1
6723669	113528	European	United Kingdom pop 3	\N	\N	604	1
6723670	113528	European	USA Caucasian Bethesda	\N	\N	307	1
6723671	113528	European	USA Caucasian pop 2	\N	\N	265	1
6723672	113528	European	USA Caucasian pop 4	\N	\N	1070	1
6723673	113528	European	USA Eastern European	\N	\N	558	1
6723674	113528	European	USA European American pop 2	\N	\N	1245	1
6723675	113528	European	USA NMDP European Caucasian	\N	\N	1242890	1
6723676	113528	European	USA Philadelphia Caucasian	\N	\N	141	1
6723677	113528	European	USA San Antonio Caucasian	\N	\N	222	1
6723678	113528	European	USA San Francisco Caucasian	\N	\N	220	1
6723679	113528	European	USA Italy Ancestry	\N	\N	273	1
6723680	113528	European	USA Spain Ancestry	\N	\N	279	1
6723681	113528	European	Wales	\N	\N	1798	1
6723682	113537	European	Utah Residents (CEPH) with Northern and Western Europena Ancestry	CEU	\N	183	1
6723683	113537	European	Finnish in Finland	FIN	\N	105	1
6723684	113537	European	British in England and Scotland	GBR	\N	107	1
6723685	113537	European	Toscani in Italy	TSI	\N	112	1
6723686	113753	European	Serbian	\N	\N	1992	1
6723687	113755	European	Croatian	\N	\N	4000	1
6723688	113757	European	French	\N	Bone marrow donors	42636	1
6723689	113759	European	Albanian	\N	\N	432	1
6723690	113528	Latino	Mexico City Mestizo	\N	\N	121	1
6723691	113528	Latino	Mexico City Mestizo pop 2	\N	\N	234	1
6723692	113528	Latino	USA Hispanic	\N	\N	234	1
6723693	113528	Latino	USA Hispanic pop 2	\N	\N	1999	1
6723694	113528	Latino	USA Mexican American Mestizo	\N	\N	553	1
6723695	113528	Latino	USA NMDP Mexican or Chicano	\N	\N	261235	1
6723696	113528	Latino	USA NMDP Caribbean Hispanic	\N	\N	115374	1
6723697	113528	Latino	USA South Texas Hispanic	\N	\N	194	1
6723698	113528	Latino	Mexico Guadalajara Mestizo pop 2	\N	\N	103	1
6723699	113528	Latino	USA NMDP Hispanic South or Central American	\N	\N	146714	1
6723700	113537	Latino	Colombians from Medellin, Colombia	CLM	\N	148	1
6723701	113537	Latino	Mexican Ancestry from Los Angeles, USA	MXL	\N	107	1
6723702	113537	Latino	Puerto Ricans from Puerto Rico	PUR	\N	150	1
6723703	113774	Latino	Brazilians	Quilombos	\N	144	1
6723704	113539	Latino	Costa Rican Mestizos	Central Valley	\N	221	1
6723705	113539	Latino	Costa Rican Mestizos	Guanacaste	\N	110	1
6723706	113539	Latino	Nicaraguan Mestizos	\N	\N	155	1
6723707	113528	Near Eastern	England London Ashkenazi Jews	\N	\N	500	1
6723708	113780	Near Eastern	Jordanians	\N	\N	146	1
6723709	113528	Near Eastern	Armenia combined Regions	\N	\N	100	1
6723710	113528	Near Eastern	Georgia Tibilisi	\N	\N	109	1
6723711	113528	Near Eastern	Germany DKMS - Turkey minority	\N	\N	4856	1
6723712	113528	Near Eastern	Iran Baloch	\N	\N	100	1
6723713	113528	Near Eastern	Iran Tehran	\N	\N	120	1
6723714	113528	Near Eastern	Israel Arab	\N	\N	12301	1
6723715	113528	Near Eastern	Israel Arab Druze	\N	\N	101	1
6723716	113528	Near Eastern	Israel Ashkenazi and Non Ashkenazi Jews	\N	\N	146	1
6723717	113528	Near Eastern	Israel Ashkenazi Jews	\N	\N	4625	1
6723718	113528	Near Eastern	Israel Druze	\N	\N	5914	1
6723719	113528	Near Eastern	Israel Georgia Jews	\N	\N	4471	1
6723720	113528	Near Eastern	Israel Iran Jews	\N	\N	8153	1
6723721	113528	Near Eastern	Israel Iraq Jews	\N	\N	13270	1
6723722	113528	Near Eastern	Israel Libya Jews	\N	\N	3739	1
6723723	113528	Near Eastern	Israel Morocco Jews	\N	\N	36718	1
6723724	113528	Near Eastern	Israel Tunisia Jews	\N	\N	9070	1
6723725	113528	Near Eastern	Israel USA Jews	\N	\N	6058	1
6723726	113528	Near Eastern	Israel YemenJews	\N	\N	15542	1
6723727	113528	Near Eastern	Libya Cyrenaica	\N	\N	118	1
6723728	113528	Near Eastern	Oman	\N	\N	118	1
6723729	113528	Near Eastern	Saudi Arabia Guraiat and Hail	\N	\N	213	1
6723730	113528	Near Eastern	Saudi Arabia pop 5	\N	\N	158	1
6723731	113528	Near Eastern	Tunisia	\N	\N	100	1
6723732	113528	Near Eastern	United Arab Emirates pop 2	\N	\N	373	1
6723733	113528	Near Eastern	USA NMDP Middle Eastern or North Coast of Africa	\N	\N	70890	1
6723734	113528	Near Eastern	Tunisia pop 3	\N	\N	104	1
6723735	113528	Near Eastern	Israel Ethiopia Jews	\N	\N	5928	1
6723736	113528	Near Eastern	Israel Argentina Jews	\N	\N	4307	1
6723737	113528	Near Eastern	Israel Bukhara Jews	\N	\N	2317	1
6723738	113528	Near Eastern	Israel Kavkazi Jews	\N	\N	2840	1
6723739	113528	Near Eastern	Israel Poland Jews	\N	\N	13871	1
6723740	113528	Near Eastern	Israel USSR Jews	\N	\N	45681	1
6723741	113814	Near Eastern	Iranian	Yazd Province	\N	90	1
6723742	113528	Oceanian	Australia Cape York Peninsula Aborigine	\N	\N	103	1
6723743	113528	Oceanian	Australia Yuendumu Aborigine	\N	\N	191	1
6723744	113528	Oceanian	New Zealand Maori with Admixed History	\N	\N	105	1
6723745	113528	Oceanian	Papua New Guinea Wosera Abelam	\N	\N	131	1
6723746	113528	Oceanian	USA Hawaii Okinawa	\N	\N	106	1
6723747	113528	Oceanian	USA NMDP Hawaiian or other Pacific Islander	\N	\N	11499	1
6723748	113528	Sub-Saharan African	Cameroon Beti	\N	\N	174	1
6723749	113528	Sub-Saharan African	Ghana Ga-Adangbe	\N	\N	131	1
6723750	113528	Sub-Saharan African	Kenya	\N	\N	144	1
6723751	113528	Sub-Saharan African	Kenya Luo	\N	\N	265	1
6723752	113528	Sub-Saharan African	Kenya Nandi	\N	\N	240	1
6723753	113528	Sub-Saharan African	Kenya, Nyanza Province, Luo tribe	\N	\N	100	1
6723754	113528	Sub-Saharan African	Mali Bandiagara	\N	\N	138	1
6723755	113528	Sub-Saharan African	Senegal Niokholo Mandenka	\N	\N	165	1
6723756	113528	Sub-Saharan African	South Africa Black	\N	\N	200	1
6723757	113528	Sub-Saharan African	South Africa Natal Zulu	\N	\N	100	1
6723758	113528	Sub-Saharan African	Uganda Kampala	\N	\N	161	1
6723759	113528	Sub-Saharan African	Uganda Kampala pop 2	\N	\N	175	1
6723760	113528	Sub-Saharan African	USA NMDP African	\N	\N	28557	1
6723761	113528	Sub-Saharan African	Zimbabwe Harare Shona	\N	\N	230	1
6723762	113537	Sub-Saharan African	Luhya in Webuye, Kenya	LWK	\N	116	1
6723763	113537	Sub-Saharan African	Yoruba in Ibadan, Nigeria	YRI	\N	186	1
6723764	871408	Central/South Asian	South Asian	gnomAD v3.1	\N	1492	1
6723765	871408	Central/South Asian	South Asian	gnomAD v3.1	\N	1493	1
6723766	871411	Central/South Asian	North Indian	\N	Non-syndromic hearing loss patients	210	1
6723767	871411	Central/South Asian	North Indian	\N	Healthy controls	101	1
6723768	871408	East Asian	East Asian	gnomAD v3.1	\N	1476	1
6723769	871408	East Asian	East Asian	gnomAD v3.1	\N	1480	1
6723770	871408	East Asian	East Asian	gnomAD v3.1	\N	1481	1
6723771	871408	East Asian	East Asian	gnomAD v3.1	\N	1482	1
6723772	871418	East Asian	Northern Chinese	\N	Non-syndromic hearing loss patients	514	1
6723773	871418	East Asian	Northern Chinese	\N	Healthy controls	117	1
6723774	871421	East Asian	Chinese	\N	Sporadic hearing loss patients	434	1
6723775	871423	East Asian	Chinese	\N	Newborns	14913	1
6724313	114929	East Asian	East Asian	\N	\N	8619	1
6723776	871425	East Asian	Chinese	\N	Hearing loss patients	155	1
6723777	871427	East Asian	Chinese	\N	Mitochondrial disease patients	139	1
6723778	871429	East Asian	Korean	\N	Non-syndromic hearing loss patients	227	1
6723779	871429	East Asian	Korean	\N	Healthy controls	75	1
6723780	871429	East Asian	Korean	\N	Healthy controls	142	1
6723781	871433	East Asian	Indonesian	\N	Sensorineural hearing loss patients	75	1
6723782	871433	East Asian	Indonesian	\N	Sensorineural hearing loss patients	50	1
6723783	871433	East Asian	Indonesian	\N	Healthy controls	100	1
6723784	871437	East Asian	Han Chinese	\N	Sensorineural hearing loss patients	1835	1
6723785	871437	East Asian	Hui	\N	Sensorineural hearing loss patients	306	1
6723786	871437	East Asian	Uyghur	\N	Sensorineural hearing loss patients	208	1
6723787	871441	East Asian	Tibetan	\N	Non-syndromic hearing loss patients	121	1
6723788	871408	European	Amish	gnomAD v3.1	\N	379	1
6723789	871408	European	Amish	gnomAD v3.1	\N	391	1
6723790	871408	European	Amish	gnomAD v3.1	\N	392	1
6723791	871408	European	European (Finnish)	gnomAD v3.1	\N	4878	1
6723792	871408	European	European (Finnish)	gnomAD v3.1	\N	4884	1
6723793	871408	European	European (Finnish)	gnomAD v3.1	\N	4889	1
6723794	871408	European	European (Finnish)	gnomAD v3.1	\N	4890	1
6723795	871408	European	European (Finnish)	gnomAD v3.1	\N	4891	1
6723796	871408	European	European (Finnish)	gnomAD v3.1	\N	4892	1
6723797	871408	European	European (non-Finnish)	gnomAD v3.1	\N	25803	1
6723798	871408	European	European (non-Finnish)	gnomAD v3.1	\N	25830	1
6723799	871408	European	European (non-Finnish)	gnomAD v3.1	\N	25836	1
6723800	871408	European	European (non-Finnish)	gnomAD v3.1	\N	25837	1
6723801	871408	European	European (non-Finnish)	gnomAD v3.1	\N	25840	1
6723802	871408	European	European (non-Finnish)	gnomAD v3.1	\N	25841	1
6723803	871408	European	European (non-Finnish)	gnomAD v3.1	\N	25842	1
6723804	871408	European	European (non-Finnish)	gnomAD v3.1	\N	25844	1
6723805	871408	European	European (non-Finnish)	gnomAD v3.1	\N	25845	1
6723806	871408	European	European (non-Finnish)	gnomAD v3.1	\N	25846	1
6723807	871408	European	European (non-Finnish)	gnomAD v3.1	\N	25847	1
6723808	871408	European	European (non-Finnish)	gnomAD v3.1	\N	25848	1
6723809	871408	European	European (non-Finnish)	gnomAD v3.1	\N	25849	1
6723810	871465	European	European Brazilians	\N	Healthy controls	110	1
6723811	871467	European	Greek	\N	Non-syndromic hearing loss patients	478	1
6723812	871469	European	Latvian	\N	Population controls	191	1
6723813	871471	European	Polish	\N	Population controls	500	1
6723814	871473	European	Belarusian	\N	Population controls	300	1
6723815	871473	European	Belarusian	\N	Sensorineural hearing loss patients	391	1
6723816	871476	European	South African Caucasian	\N	Population controls	104	1
6723817	871476	European	South African Afrikaner	\N	Population controls	93	1
6723818	871479	European	Austrian	\N	Hearing impaired cases	122	1
6723819	871481	European	European American	\N	Controls	100	1
6723820	871408	Near Eastern	Ashkenazi Jewish	gnomAD v3.1	\N	1414	1
6723821	871408	Near Eastern	Ashkenazi Jewish	gnomAD v3.1	\N	1415	1
6723822	871485	Near Eastern	Turkish	\N	Profound hearing loss patients	95	1
6723823	871485	Near Eastern	Turkish	\N	Healthy controls	67	1
6723824	871488	Near Eastern	Moroccan	\N	Sporadic hearing loss cases	80	1
6723825	871488	Near Eastern	Moroccan	\N	Healthy controls	100	1
6723826	871491	Near Eastern	Egyptian	\N	Sensorineural hearing loss patients	97	1
6723827	871491	Near Eastern	Egyptian	\N	Healthy controls	300	1
6723828	871494	Near Eastern	Turkish	\N	Non-syndromic sensorineural hearing loss patients	168	1
6723829	871496	Near Eastern	Tunisian	\N	Non-syndromic hearing loss patients	100	1
6723830	871496	Near Eastern	Tunisian	\N	Healthy controls	100	1
6723831	871499	Near Eastern	Iranian	\N	Non-syndromic hearing loss patients	1000	1
6723832	871465	Sub-Saharan African	African-Brazilians	\N	Healthy controls	190	1
6723833	871502	Sub-Saharan African	South African Black	\N	Healthy controls	106	1
6723834	871504	Sub-Saharan African	Indigenous South Africans	\N	Hearing impaired cases	182	1
6723835	871504	Sub-Saharan African	Indigenous South Africans	\N	Healthy controls	63	1
6723836	871476	Sub-Saharan African	South African Black	\N	Population controls	112	1
6723837	115325	Central/South Asian	South Asian	\N	\N	477	1
6723838	115327	Central/South Asian	South Asian	\N	\N	15297	1
6723839	115329	Central/South Asian	South Asian	\N	\N	13388	1
6723840	115331	Central/South Asian	South Asian	\N	\N	14052	1
6723841	115333	Central/South Asian	South Asian	\N	\N	26224	1
6723842	115335	East Asian	Korean	leukemia patients and controls	\N	84	1
6723843	115325	East Asian	East Asian	\N	\N	504	1
6723844	115327	East Asian	East Asian	\N	\N	9358	1
6723845	115329	East Asian	East Asian	\N	\N	8168	1
6723846	115331	East Asian	East Asian	\N	\N	7959	1
6723847	115333	East Asian	East Asian	\N	\N	6654	1
6723848	115325	European	European	\N	\N	495	1
6723849	115327	European	Finnish	\N	\N	12885	1
6723850	115327	European	non-Finnish	\N	\N	63216	1
6723851	115329	European	Finnish	\N	\N	11094	1
6723852	115329	European	non-Finnish	\N	\N	53051	1
6723853	115331	European	Finnish	\N	\N	10218	1
6723854	115331	European	non-Finnish	\N	\N	50488	1
6723855	115333	European	Finnish	\N	\N	8851	1
6723856	115333	European	non-Finnish	\N	\N	42921	1
6723857	115325	Latino	Latino	\N	\N	341	1
6723858	115327	Latino	Latino	\N	\N	17019	1
6723859	115329	Latino	Latino	\N	\N	14548	1
6723860	115331	Latino	Latino	\N	\N	15597	1
6723861	115333	Latino	Latino	\N	\N	12819	1
6723862	\N	American	Amish	gnomAD v3.1.2 AMI	\N	912	1
6723863	\N	American	Amish	gnomAD v3.1.2 AMI	\N	912	1
6723864	\N	American	Amish	gnomAD v3.1.2 AMI	\N	912	1
6723865	\N	European	Finnish	gnomAD v3.1.2 FIN	\N	10620	1
6723866	\N	European	Finnish	gnomAD v3.1.2 FIN	\N	10580	1
6723867	\N	European	Finnish	gnomAD v3.1.2 FIN	\N	10608	1
6723868	\N	European	Finnish	gnomAD v3.1.2 FIN	\N	10626	1
6723869	\N	European	Finnish	gnomAD v3.1.2 FIN	\N	10620	1
6723870	\N	European	Finnish	gnomAD v3.1.2 FIN	\N	10618	1
6723871	\N	European	Finnish	gnomAD v3.1.2 FIN	\N	10628	1
6723872	\N	European	Finnish	gnomAD v3.1.2 FIN	\N	10610	1
6723873	\N	European	Finnish	gnomAD v3.1.2 FIN	\N	10610	1
6723874	\N	European	Finnish	gnomAD v3.1.2 FIN	\N	10622	1
6723875	\N	European	Finnish	gnomAD v3.1.2 FIN	\N	10628	1
6723876	\N	European	Finnish	gnomAD v3.1.2 FIN	\N	10614	1
6723877	\N	European	Finnish	gnomAD v3.1.2 FIN	\N	10618	1
6723878	\N	European	Finnish	gnomAD v3.1.2 FIN	\N	10622	1
6723879	\N	European	Finnish	gnomAD v3.1.2 FIN	\N	10608	1
6723880	\N	European	Finnish	gnomAD v3.1.2 FIN	\N	10626	1
6723881	\N	European	Finnish	gnomAD v3.1.2 FIN	\N	10616	1
6723882	\N	European	Finnish	gnomAD v3.1.2 FIN	\N	10598	1
6723883	\N	European	Finnish	gnomAD v3.1.2 FIN	\N	8398	1
6723884	\N	European	Finnish	gnomAD v3.1.2 FIN	\N	10612	1
6723885	\N	European	Finnish	gnomAD v3.1.2 FIN	\N	10622	1
6723886	\N	European	Non-Finnish European	gnomAD v3.1.2 NFE	\N	68028	1
6723887	\N	European	Non-Finnish European	gnomAD v3.1.2 NFE	\N	68030	1
6723888	\N	European	Non-Finnish European	gnomAD v3.1.2 NFE	\N	68034	1
6723889	\N	European	Non-Finnish European	gnomAD v3.1.2 NFE	\N	67780	1
6723890	\N	European	Non-Finnish European	gnomAD v3.1.2 NFE	\N	67912	1
6723891	\N	European	Non-Finnish European	gnomAD v3.1.2 NFE	\N	68030	1
6723892	\N	European	Non-Finnish European	gnomAD v3.1.2 NFE	\N	68020	1
6723893	\N	European	Non-Finnish European	gnomAD v3.1.2 NFE	\N	68042	1
6723894	\N	European	Non-Finnish European	gnomAD v3.1.2 NFE	\N	68040	1
6723895	\N	European	Non-Finnish European	gnomAD v3.1.2 NFE	\N	68008	1
6723896	\N	European	Non-Finnish European	gnomAD v3.1.2 NFE	\N	68042	1
6723897	\N	European	Non-Finnish European	gnomAD v3.1.2 NFE	\N	68018	1
6723898	\N	European	Non-Finnish European	gnomAD v3.1.2 NFE	\N	68000	1
6723899	\N	European	Non-Finnish European	gnomAD v3.1.2 NFE	\N	68002	1
6723900	\N	European	Non-Finnish European	gnomAD v3.1.2 NFE	\N	67998	1
6723901	\N	European	Non-Finnish European	gnomAD v3.1.2 NFE	\N	68022	1
6723902	\N	European	Non-Finnish European	gnomAD v3.1.2 NFE	\N	68032	1
6723903	\N	European	Non-Finnish European	gnomAD v3.1.2 NFE	\N	68028	1
6723904	\N	European	Non-Finnish European	gnomAD v3.1.2 NFE	\N	68020	1
6723905	\N	European	Non-Finnish European	gnomAD v3.1.2 NFE	\N	68042	1
6723906	\N	European	Non-Finnish European	gnomAD v3.1.2 NFE	\N	68028	1
6723907	\N	European	Non-Finnish European	gnomAD v3.1.2 NFE	\N	68032	1
6723908	\N	European	Non-Finnish European	gnomAD v3.1.2 NFE	\N	68046	1
6723909	\N	European	Non-Finnish European	gnomAD v3.1.2 NFE	\N	68022	1
6723910	\N	European	Non-Finnish European	gnomAD v3.1.2 NFE	\N	68032	1
6723911	\N	European	Non-Finnish European	gnomAD v3.1.2 NFE	\N	67988	1
6723912	\N	European	Non-Finnish European	gnomAD v3.1.2 NFE	\N	68016	1
6723913	\N	European	Non-Finnish European	gnomAD v3.1.2 NFE	\N	67124	1
6723914	\N	European	Non-Finnish European	gnomAD v3.1.2 NFE	\N	68000	1
6723915	\N	European	Non-Finnish European	gnomAD v3.1.2 NFE	\N	68032	1
6723916	\N	European	Non-Finnish European	gnomAD v3.1.2 NFE	\N	68022	1
6723917	\N	European	Non-Finnish European	gnomAD v3.1.2 NFE	\N	68016	1
6723918	\N	European	Non-Finnish European	gnomAD v3.1.2 NFE	\N	68022	1
6723919	\N	European	Non-Finnish European	gnomAD v3.1.2 NFE	\N	68038	1
6723920	\N	European	Non-Finnish European	gnomAD v3.1.2 NFE	\N	67996	1
6723921	\N	European	Non-Finnish European	gnomAD v3.1.2 NFE	\N	68036	1
6723922	\N	European	Non-Finnish European	gnomAD v3.1.2 NFE	\N	68000	1
6723923	\N	European	Non-Finnish European	gnomAD v3.1.2 NFE	\N	68010	1
6723924	\N	European	Non-Finnish European	gnomAD v3.1.2 NFE	\N	68024	1
6723925	\N	European	Non-Finnish European	gnomAD v3.1.2 NFE	\N	68028	1
6723926	\N	European	Non-Finnish European	gnomAD v3.1.2 NFE	\N	68036	1
6723927	\N	European	Non-Finnish European	gnomAD v3.1.2 NFE	\N	68036	1
6723928	\N	European	Non-Finnish European	gnomAD v3.1.2 NFE	\N	68046	1
6723929	\N	European	Non-Finnish European	gnomAD v3.1.2 NFE	\N	68028	1
6723930	\N	European	Non-Finnish European	gnomAD v3.1.2 NFE	\N	68024	1
6723931	\N	European	Non-Finnish European	gnomAD v3.1.2 NFE	\N	68040	1
6723932	\N	European	Non-Finnish European	gnomAD v3.1.2 NFE	\N	68036	1
6723933	\N	European	Non-Finnish European	gnomAD v3.1.2 NFE	\N	68012	1
6723934	\N	European	Non-Finnish European	gnomAD v3.1.2 NFE	\N	68000	1
6723935	\N	European	Non-Finnish European	gnomAD v3.1.2 NFE	\N	67992	1
6723936	\N	European	Non-Finnish European	gnomAD v3.1.2 NFE	\N	68006	1
6723937	\N	European	Non-Finnish European	gnomAD v3.1.2 NFE	\N	67996	1
6723938	\N	European	Non-Finnish European	gnomAD v3.1.2 NFE	\N	68018	1
6723939	\N	European	Non-Finnish European	gnomAD v3.1.2 NFE	\N	68032	1
6723940	\N	European	Non-Finnish European	gnomAD v3.1.2 NFE	\N	68032	1
6723941	\N	European	Non-Finnish European	gnomAD v3.1.2 NFE	\N	68028	1
6723942	\N	European	Non-Finnish European	gnomAD v3.1.2 NFE	\N	68024	1
6723943	\N	European	Non-Finnish European	gnomAD v3.1.2 NFE	\N	68030	1
6723944	\N	European	Non-Finnish European	gnomAD v3.1.2 NFE	\N	67784	1
6723945	\N	European	Non-Finnish European	gnomAD v3.1.2 NFE	\N	67846	1
6723946	\N	European	Non-Finnish European	gnomAD v3.1.2 NFE	\N	67782	1
6723947	\N	European	Non-Finnish European	gnomAD v3.1.2 NFE	\N	68004	1
6723948	\N	European	Non-Finnish European	gnomAD v3.1.2 NFE	\N	68038	1
6723949	\N	European	Non-Finnish European	gnomAD v3.1.2 NFE	\N	68034	1
6723950	\N	European	Non-Finnish European	gnomAD v3.1.2 NFE	\N	68044	1
6723951	\N	European	Non-Finnish European	gnomAD v3.1.2 NFE	\N	67958	1
6723952	\N	European	Non-Finnish European	gnomAD v3.1.2 NFE	\N	68020	1
6723953	\N	European	Non-Finnish European	gnomAD v3.1.2 NFE	\N	67996	1
6723954	\N	European	Non-Finnish European	gnomAD v3.1.2 NFE	\N	68036	1
6723955	\N	European	Non-Finnish European	gnomAD v3.1.2 NFE	\N	68038	1
6723956	\N	European	Non-Finnish European	gnomAD v3.1.2 NFE	\N	68030	1
6723957	\N	European	Non-Finnish European	gnomAD v3.1.2 NFE	\N	68042	1
6723958	\N	European	Non-Finnish European	gnomAD v3.1.2 NFE	\N	68036	1
6723959	\N	European	Non-Finnish European	gnomAD v3.1.2 NFE	\N	67984	1
6723960	\N	European	Non-Finnish European	gnomAD v3.1.2 NFE	\N	68030	1
6723961	\N	European	Non-Finnish European	gnomAD v3.1.2 NFE	\N	68028	1
6723962	\N	European	Non-Finnish European	gnomAD v3.1.2 NFE	\N	68026	1
6723963	\N	European	Non-Finnish European	gnomAD v3.1.2 NFE	\N	68004	1
6723964	\N	European	Non-Finnish European	gnomAD v3.1.2 NFE	\N	68016	1
6723965	\N	European	Non-Finnish European	gnomAD v3.1.2 NFE	\N	68036	1
6723966	\N	European	Non-Finnish European	gnomAD v3.1.2 NFE	\N	68012	1
6723967	\N	European	Non-Finnish European	gnomAD v3.1.2 NFE	\N	68034	1
6723968	\N	European	Non-Finnish European	gnomAD v3.1.2 NFE	\N	68024	1
6723969	\N	European	Non-Finnish European	gnomAD v3.1.2 NFE	\N	68020	1
6723970	\N	European	Non-Finnish European	gnomAD v3.1.2 NFE	\N	68010	1
6723971	\N	European	Non-Finnish European	gnomAD v3.1.2 NFE	\N	68034	1
6723972	\N	European	Non-Finnish European	gnomAD v3.1.2 NFE	\N	68036	1
6723973	\N	European	Non-Finnish European	gnomAD v3.1.2 NFE	\N	68032	1
6723974	\N	European	Non-Finnish European	gnomAD v3.1.2 NFE	\N	65812	1
6723975	\N	European	Non-Finnish European	gnomAD v3.1.2 NFE	\N	65810	1
6723976	\N	European	Non-Finnish European	gnomAD v3.1.2 NFE	\N	68030	1
6723977	\N	European	Non-Finnish European	gnomAD v3.1.2 NFE	\N	68026	1
6723978	\N	European	Non-Finnish European	gnomAD v3.1.2 NFE	\N	68028	1
6723979	\N	European	Non-Finnish European	gnomAD v3.1.2 NFE	\N	68014	1
6723980	\N	European	Non-Finnish European	gnomAD v3.1.2 NFE	\N	68040	1
6723981	\N	European	Non-Finnish European	gnomAD v3.1.2 NFE	\N	68000	1
6723982	\N	European	Non-Finnish European	gnomAD v3.1.2 NFE	\N	67532	1
6723983	\N	European	Non-Finnish European	gnomAD v3.1.2 NFE	\N	68036	1
6723984	\N	European	Non-Finnish European	gnomAD v3.1.2 NFE	\N	68000	1
6723985	\N	European	Non-Finnish European	gnomAD v3.1.2 NFE	\N	68014	1
6723986	\N	European	Non-Finnish European	gnomAD v3.1.2 NFE	\N	68026	1
6723987	\N	European	Non-Finnish European	gnomAD v3.1.2 NFE	\N	68016	1
6723988	\N	European	Non-Finnish European	gnomAD v3.1.2 NFE	\N	67992	1
6723989	\N	European	Non-Finnish European	gnomAD v3.1.2 NFE	\N	68026	1
6723990	\N	Latino	Latino/Admixed American	gnomAD v3.1.2 AMR	\N	15264	1
6723991	\N	Latino	Latino/Admixed American	gnomAD v3.1.2 AMR	\N	15280	1
6723992	\N	Latino	Latino/Admixed American	gnomAD v3.1.2 AMR	\N	15280	1
6723993	\N	Latino	Latino/Admixed American	gnomAD v3.1.2 AMR	\N	15274	1
6723994	\N	Latino	Latino/Admixed American	gnomAD v3.1.2 AMR	\N	15288	1
6723995	\N	Latino	Latino/Admixed American	gnomAD v3.1.2 AMR	\N	15266	1
6723996	\N	Latino	Latino/Admixed American	gnomAD v3.1.2 AMR	\N	15276	1
6723997	\N	Latino	Latino/Admixed American	gnomAD v3.1.2 AMR	\N	15290	1
6723998	\N	Latino	Latino/Admixed American	gnomAD v3.1.2 AMR	\N	15290	1
6723999	\N	Latino	Latino/Admixed American	gnomAD v3.1.2 AMR	\N	15290	1
6724000	\N	Latino	Latino/Admixed American	gnomAD v3.1.2 AMR	\N	15260	1
6724001	\N	Latino	Latino/Admixed American	gnomAD v3.1.2 AMR	\N	15274	1
6724002	\N	Latino	Latino/Admixed American	gnomAD v3.1.2 AMR	\N	15278	1
6724003	\N	Latino	Latino/Admixed American	gnomAD v3.1.2 AMR	\N	15278	1
6724004	\N	Latino	Latino/Admixed American	gnomAD v3.1.2 AMR	\N	15282	1
6724005	\N	Latino	Latino/Admixed American	gnomAD v3.1.2 AMR	\N	15284	1
6724006	\N	Latino	Latino/Admixed American	gnomAD v3.1.2 AMR	\N	15284	1
6724007	\N	Latino	Latino/Admixed American	gnomAD v3.1.2 AMR	\N	15282	1
6724008	\N	Latino	Latino/Admixed American	gnomAD v3.1.2 AMR	\N	15284	1
6724009	\N	Latino	Latino/Admixed American	gnomAD v3.1.2 AMR	\N	15136	1
6724010	\N	Latino	Latino/Admixed American	gnomAD v3.1.2 AMR	\N	15282	1
6724011	\N	Latino	Latino/Admixed American	gnomAD v3.1.2 AMR	\N	15282	1
6724012	\N	Latino	Latino/Admixed American	gnomAD v3.1.2 AMR	\N	15278	1
6724013	\N	Latino	Latino/Admixed American	gnomAD v3.1.2 AMR	\N	15274	1
6724014	\N	Latino	Latino/Admixed American	gnomAD v3.1.2 AMR	\N	15240	1
6724015	\N	Latino	Latino/Admixed American	gnomAD v3.1.2 AMR	\N	15282	1
6724016	\N	Latino	Latino/Admixed American	gnomAD v3.1.2 AMR	\N	15278	1
6724017	\N	Latino	Latino/Admixed American	gnomAD v3.1.2 AMR	\N	15274	1
6724018	\N	Latino	Latino/Admixed American	gnomAD v3.1.2 AMR	\N	15286	1
6724019	\N	Latino	Latino/Admixed American	gnomAD v3.1.2 AMR	\N	15266	1
6724020	\N	Latino	Latino/Admixed American	gnomAD v3.1.2 AMR	\N	15270	1
6724021	\N	Latino	Latino/Admixed American	gnomAD v3.1.2 AMR	\N	15278	1
6724022	\N	Latino	Latino/Admixed American	gnomAD v3.1.2 AMR	\N	14712	1
6724023	\N	Latino	Latino/Admixed American	gnomAD v3.1.2 AMR	\N	14702	1
6724024	\N	Latino	Latino/Admixed American	gnomAD v3.1.2 AMR	\N	15264	1
6724025	\N	Latino	Latino/Admixed American	gnomAD v3.1.2 AMR	\N	15226	1
6724026	\N	Latino	Latino/Admixed American	gnomAD v3.1.2 AMR	\N	15264	1
6724027	\N	Central/South Asian	South Asian	gnomAD v3.1.2 SAS	\N	4824	1
6724028	\N	Central/South Asian	South Asian	gnomAD v3.1.2 SAS	\N	4824	1
6724029	\N	Central/South Asian	South Asian	gnomAD v3.1.2 SAS	\N	4824	1
6724030	\N	Central/South Asian	South Asian	gnomAD v3.1.2 SAS	\N	4832	1
6724031	\N	Central/South Asian	South Asian	gnomAD v3.1.2 SAS	\N	4828	1
6724032	\N	Central/South Asian	South Asian	gnomAD v3.1.2 SAS	\N	4834	1
6724033	\N	Central/South Asian	South Asian	gnomAD v3.1.2 SAS	\N	4830	1
6724034	\N	Central/South Asian	South Asian	gnomAD v3.1.2 SAS	\N	4828	1
6724035	\N	Central/South Asian	South Asian	gnomAD v3.1.2 SAS	\N	4830	1
6724036	\N	Central/South Asian	South Asian	gnomAD v3.1.2 SAS	\N	4830	1
6724037	\N	Central/South Asian	South Asian	gnomAD v3.1.2 SAS	\N	4828	1
6724038	\N	Central/South Asian	South Asian	gnomAD v3.1.2 SAS	\N	4820	1
6724039	\N	Central/South Asian	South Asian	gnomAD v3.1.2 SAS	\N	4836	1
6724040	\N	Central/South Asian	South Asian	gnomAD v3.1.2 SAS	\N	4832	1
6724041	\N	Central/South Asian	South Asian	gnomAD v3.1.2 SAS	\N	4826	1
6724042	\N	Central/South Asian	South Asian	gnomAD v3.1.2 SAS	\N	4802	1
6724043	\N	Central/South Asian	South Asian	gnomAD v3.1.2 SAS	\N	4830	1
6724044	\N	Central/South Asian	South Asian	gnomAD v3.1.2 SAS	\N	4808	1
6724045	\N	Central/South Asian	South Asian	gnomAD v3.1.2 SAS	\N	4824	1
6724046	\N	Central/South Asian	South Asian	gnomAD v3.1.2 SAS	\N	4830	1
6724047	\N	Central/South Asian	South Asian	gnomAD v3.1.2 SAS	\N	4826	1
6724048	\N	Central/South Asian	South Asian	gnomAD v3.1.2 SAS	\N	4826	1
6724049	\N	Central/South Asian	South Asian	gnomAD v3.1.2 SAS	\N	4820	1
6724314	114931	East Asian	East Asian	\N	\N	8624	1
6724050	\N	Central/South Asian	South Asian	gnomAD v3.1.2 SAS	\N	4832	1
6724051	\N	Central/South Asian	South Asian	gnomAD v3.1.2 SAS	\N	4832	1
6724052	\N	East Asian	Eastern Asian	gnomAD v3.1.2 EAS	\N	5138	1
6724053	\N	East Asian	Eastern Asian	gnomAD v3.1.2 EAS	\N	5204	1
6724054	\N	East Asian	Eastern Asian	gnomAD v3.1.2 EAS	\N	5180	1
6724055	\N	East Asian	Eastern Asian	gnomAD v3.1.2 EAS	\N	5194	1
6724056	\N	East Asian	Eastern Asian	gnomAD v3.1.2 EAS	\N	5186	1
6724057	\N	East Asian	Eastern Asian	gnomAD v3.1.2 EAS	\N	5192	1
6724058	\N	East Asian	Eastern Asian	gnomAD v3.1.2 EAS	\N	5200	1
6724059	\N	East Asian	Eastern Asian	gnomAD v3.1.2 EAS	\N	5192	1
6724060	\N	East Asian	Eastern Asian	gnomAD v3.1.2 EAS	\N	5194	1
6724061	\N	East Asian	Eastern Asian	gnomAD v3.1.2 EAS	\N	5204	1
6724062	\N	East Asian	Eastern Asian	gnomAD v3.1.2 EAS	\N	5178	1
6724063	\N	East Asian	Eastern Asian	gnomAD v3.1.2 EAS	\N	5186	1
6724064	\N	East Asian	Eastern Asian	gnomAD v3.1.2 EAS	\N	5164	1
6724065	\N	East Asian	Eastern Asian	gnomAD v3.1.2 EAS	\N	5194	1
6724066	\N	East Asian	Eastern Asian	gnomAD v3.1.2 EAS	\N	5194	1
6724067	\N	East Asian	Eastern Asian	gnomAD v3.1.2 EAS	\N	5184	1
6724068	\N	East Asian	Eastern Asian	gnomAD v3.1.2 EAS	\N	5182	1
6724069	\N	East Asian	Eastern Asian	gnomAD v3.1.2 EAS	\N	5200	1
6724070	\N	East Asian	Eastern Asian	gnomAD v3.1.2 EAS	\N	5024	1
6724071	\N	East Asian	Eastern Asian	gnomAD v3.1.2 EAS	\N	5096	1
6724072	\N	East Asian	Eastern Asian	gnomAD v3.1.2 EAS	\N	5194	1
6724073	\N	East Asian	Eastern Asian	gnomAD v3.1.2 EAS	\N	5188	1
6724074	\N	Near Eastern	Ashkenazi Jewish	gnomAD v3.1.2 ASJ	\N	3468	1
6724075	\N	Near Eastern	Ashkenazi Jewish	gnomAD v3.1.2 ASJ	\N	3470	1
6724076	\N	Near Eastern	Ashkenazi Jewish	gnomAD v3.1.2 ASJ	\N	3468	1
6724077	\N	Near Eastern	Ashkenazi Jewish	gnomAD v3.1.2 ASJ	\N	3470	1
6724078	\N	Near Eastern	Ashkenazi Jewish	gnomAD v3.1.2 ASJ	\N	3470	1
6724079	\N	Near Eastern	Ashkenazi Jewish	gnomAD v3.1.2 ASJ	\N	3470	1
6724080	\N	Near Eastern	Ashkenazi Jewish	gnomAD v3.1.2 ASJ	\N	3468	1
6724081	\N	Near Eastern	Ashkenazi Jewish	gnomAD v3.1.2 ASJ	\N	3468	1
6724082	\N	Near Eastern	Ashkenazi Jewish	gnomAD v3.1.2 ASJ	\N	3468	1
6724083	\N	Near Eastern	Ashkenazi Jewish	gnomAD v3.1.2 ASJ	\N	3472	1
6724084	\N	Near Eastern	Ashkenazi Jewish	gnomAD v3.1.2 ASJ	\N	3472	1
6724085	\N	Near Eastern	Ashkenazi Jewish	gnomAD v3.1.2 ASJ	\N	3470	1
6724086	\N	Near Eastern	Ashkenazi Jewish	gnomAD v3.1.2 ASJ	\N	3468	1
6724087	\N	Near Eastern	Ashkenazi Jewish	gnomAD v3.1.2 ASJ	\N	3470	1
6724088	\N	Near Eastern	Ashkenazi Jewish	gnomAD v3.1.2 ASJ	\N	3472	1
6724089	\N	Near Eastern	Ashkenazi Jewish	gnomAD v3.1.2 ASJ	\N	3470	1
6724090	\N	Near Eastern	Ashkenazi Jewish	gnomAD v3.1.2 ASJ	\N	3470	1
6724091	\N	Near Eastern	Ashkenazi Jewish	gnomAD v3.1.2 ASJ	\N	3386	1
6724092	\N	Near Eastern	Ashkenazi Jewish	gnomAD v3.1.2 ASJ	\N	3470	1
6724093	\N	Near Eastern	Ashkenazi Jewish	gnomAD v3.1.2 ASJ	\N	3468	1
6724094	\N	Near Eastern	Ashkenazi Jewish	gnomAD v3.1.2 ASJ	\N	3458	1
6724095	\N	Near Eastern	Ashkenazi Jewish	gnomAD v3.1.2 ASJ	\N	3468	1
6724096	\N	Near Eastern	Ashkenazi Jewish	gnomAD v3.1.2 ASJ	\N	3472	1
6724097	\N	Near Eastern	Middle Eastern	gnomAD v3.1.2 MID	\N	316	1
6724098	\N	Near Eastern	Middle Eastern	gnomAD v3.1.2 MID	\N	316	1
6724099	\N	Near Eastern	Middle Eastern	gnomAD v3.1.2 MID	\N	316	1
6724100	\N	Near Eastern	Middle Eastern	gnomAD v3.1.2 MID	\N	316	1
6724101	\N	Near Eastern	Middle Eastern	gnomAD v3.1.2 MID	\N	316	1
6724102	\N	Near Eastern	Middle Eastern	gnomAD v3.1.2 MID	\N	316	1
6724103	\N	Near Eastern	Middle Eastern	gnomAD v3.1.2 MID	\N	316	1
6724104	\N	Near Eastern	Middle Eastern	gnomAD v3.1.2 MID	\N	310	1
6724105	\N	Sub-Saharan African	African/African American	gnomAD v3.1.2 AFR	\N	41446	1
6724106	\N	Sub-Saharan African	African/African American	gnomAD v3.1.2 AFR	\N	41418	1
6724107	\N	Sub-Saharan African	African/African American	gnomAD v3.1.2 AFR	\N	41438	1
6724108	\N	Sub-Saharan African	African/African American	gnomAD v3.1.2 AFR	\N	41404	1
6724109	\N	Sub-Saharan African	African/African American	gnomAD v3.1.2 AFR	\N	41446	1
6724110	\N	Sub-Saharan African	African/African American	gnomAD v3.1.2 AFR	\N	41420	1
6724111	\N	Sub-Saharan African	African/African American	gnomAD v3.1.2 AFR	\N	41396	1
6724112	\N	Sub-Saharan African	African/African American	gnomAD v3.1.2 AFR	\N	41388	1
6724113	\N	Sub-Saharan African	African/African American	gnomAD v3.1.2 AFR	\N	41428	1
6724114	\N	Sub-Saharan African	African/African American	gnomAD v3.1.2 AFR	\N	41398	1
6724115	\N	Sub-Saharan African	African/African American	gnomAD v3.1.2 AFR	\N	41390	1
6724116	\N	Sub-Saharan African	African/African American	gnomAD v3.1.2 AFR	\N	41442	1
6724117	\N	Sub-Saharan African	African/African American	gnomAD v3.1.2 AFR	\N	41472	1
6724118	\N	Sub-Saharan African	African/African American	gnomAD v3.1.2 AFR	\N	41456	1
6724119	\N	Sub-Saharan African	African/African American	gnomAD v3.1.2 AFR	\N	41442	1
6724120	\N	Sub-Saharan African	African/African American	gnomAD v3.1.2 AFR	\N	41420	1
6724121	\N	Sub-Saharan African	African/African American	gnomAD v3.1.2 AFR	\N	41442	1
6724122	\N	Sub-Saharan African	African/African American	gnomAD v3.1.2 AFR	\N	41440	1
6724123	\N	Sub-Saharan African	African/African American	gnomAD v3.1.2 AFR	\N	41432	1
6724124	\N	Sub-Saharan African	African/African American	gnomAD v3.1.2 AFR	\N	41388	1
6724125	\N	Sub-Saharan African	African/African American	gnomAD v3.1.2 AFR	\N	41426	1
6724126	\N	Sub-Saharan African	African/African American	gnomAD v3.1.2 AFR	\N	41426	1
6724127	\N	Sub-Saharan African	African/African American	gnomAD v3.1.2 AFR	\N	41422	1
6724128	\N	Sub-Saharan African	African/African American	gnomAD v3.1.2 AFR	\N	41430	1
6724129	\N	Sub-Saharan African	African/African American	gnomAD v3.1.2 AFR	\N	41422	1
6724130	\N	Sub-Saharan African	African/African American	gnomAD v3.1.2 AFR	\N	41454	1
6724131	\N	Sub-Saharan African	African/African American	gnomAD v3.1.2 AFR	\N	41430	1
6724132	\N	Sub-Saharan African	African/African American	gnomAD v3.1.2 AFR	\N	41458	1
6724133	\N	Sub-Saharan African	African/African American	gnomAD v3.1.2 AFR	\N	41428	1
6724134	\N	Sub-Saharan African	African/African American	gnomAD v3.1.2 AFR	\N	41434	1
6724135	\N	Sub-Saharan African	African/African American	gnomAD v3.1.2 AFR	\N	41450	1
6724136	\N	Sub-Saharan African	African/African American	gnomAD v3.1.2 AFR	\N	41448	1
6724137	\N	Sub-Saharan African	African/African American	gnomAD v3.1.2 AFR	\N	41446	1
6724138	\N	Sub-Saharan African	African/African American	gnomAD v3.1.2 AFR	\N	41452	1
6724139	\N	Sub-Saharan African	African/African American	gnomAD v3.1.2 AFR	\N	41446	1
6724140	\N	Sub-Saharan African	African/African American	gnomAD v3.1.2 AFR	\N	41466	1
6724141	\N	Sub-Saharan African	African/African American	gnomAD v3.1.2 AFR	\N	41446	1
6724142	\N	Sub-Saharan African	African/African American	gnomAD v3.1.2 AFR	\N	41426	1
6724143	\N	Sub-Saharan African	African/African American	gnomAD v3.1.2 AFR	\N	41418	1
6724144	\N	Sub-Saharan African	African/African American	gnomAD v3.1.2 AFR	\N	41418	1
6724145	\N	Sub-Saharan African	African/African American	gnomAD v3.1.2 AFR	\N	41402	1
6724146	\N	Sub-Saharan African	African/African American	gnomAD v3.1.2 AFR	\N	41404	1
6724147	\N	Sub-Saharan African	African/African American	gnomAD v3.1.2 AFR	\N	41436	1
6724148	\N	Sub-Saharan African	African/African American	gnomAD v3.1.2 AFR	\N	41430	1
6724149	\N	Sub-Saharan African	African/African American	gnomAD v3.1.2 AFR	\N	41448	1
6724150	\N	Sub-Saharan African	African/African American	gnomAD v3.1.2 AFR	\N	41436	1
6724151	\N	Sub-Saharan African	African/African American	gnomAD v3.1.2 AFR	\N	41446	1
6724152	\N	Sub-Saharan African	African/African American	gnomAD v3.1.2 AFR	\N	41450	1
6724153	\N	Sub-Saharan African	African/African American	gnomAD v3.1.2 AFR	\N	41310	1
6724154	\N	Sub-Saharan African	African/African American	gnomAD v3.1.2 AFR	\N	41430	1
6724155	\N	Sub-Saharan African	African/African American	gnomAD v3.1.2 AFR	\N	41416	1
6724156	\N	Sub-Saharan African	African/African American	gnomAD v3.1.2 AFR	\N	41390	1
6724157	\N	Sub-Saharan African	African/African American	gnomAD v3.1.2 AFR	\N	41458	1
6724158	\N	Sub-Saharan African	African/African American	gnomAD v3.1.2 AFR	\N	41446	1
6724159	\N	Sub-Saharan African	African/African American	gnomAD v3.1.2 AFR	\N	41346	1
6724160	\N	Sub-Saharan African	African/African American	gnomAD v3.1.2 AFR	\N	41408	1
6724161	\N	Sub-Saharan African	African/African American	gnomAD v3.1.2 AFR	\N	41454	1
6724162	\N	Sub-Saharan African	African/African American	gnomAD v3.1.2 AFR	\N	41446	1
6724163	\N	Sub-Saharan African	African/African American	gnomAD v3.1.2 AFR	\N	41346	1
6724164	\N	Sub-Saharan African	African/African American	gnomAD v3.1.2 AFR	\N	41440	1
6724165	\N	Sub-Saharan African	African/African American	gnomAD v3.1.2 AFR	\N	41440	1
6724166	\N	Sub-Saharan African	African/African American	gnomAD v3.1.2 AFR	\N	41420	1
6724167	\N	Sub-Saharan African	African/African American	gnomAD v3.1.2 AFR	\N	41378	1
6724168	\N	Sub-Saharan African	African/African American	gnomAD v3.1.2 AFR	\N	41410	1
6724169	\N	Sub-Saharan African	African/African American	gnomAD v3.1.2 AFR	\N	41376	1
6724170	\N	Sub-Saharan African	African/African American	gnomAD v3.1.2 AFR	\N	41450	1
6724171	\N	Sub-Saharan African	African/African American	gnomAD v3.1.2 AFR	\N	41452	1
6724172	\N	Sub-Saharan African	African/African American	gnomAD v3.1.2 AFR	\N	41434	1
6724173	\N	Sub-Saharan African	African/African American	gnomAD v3.1.2 AFR	\N	40722	1
6724174	\N	Sub-Saharan African	African/African American	gnomAD v3.1.2 AFR	\N	40428	1
6724175	\N	Sub-Saharan African	African/African American	gnomAD v3.1.2 AFR	\N	41442	1
6724176	\N	Sub-Saharan African	African/African American	gnomAD v3.1.2 AFR	\N	41420	1
6724177	\N	Sub-Saharan African	African/African American	gnomAD v3.1.2 AFR	\N	41356	1
6724178	\N	Sub-Saharan African	African/African American	gnomAD v3.1.2 AFR	\N	41432	1
6724179	\N	Sub-Saharan African	African/African American	gnomAD v3.1.2 AFR	\N	41428	1
6724180	\N	Sub-Saharan African	African/African American	gnomAD v3.1.2 AFR	\N	41430	1
6724181	\N	Sub-Saharan African	African/African American	gnomAD v3.1.2 AFR	\N	41424	1
6724182	\N	Sub-Saharan African	African/African American	gnomAD v3.1.2 AFR	\N	41420	1
6724183	117537	African American/Afro-Caribbean	African American	\N	African Americans	38	1
6724184	117539	American	South/Central American	\N	\N	64	1
6724185	117541	Central/South Asian	Indian	\N	\N	35	1
6724186	117543	Central/South Asian	Indian	\N	\N	93	1
6724187	117546	Central/South Asian	Indian	\N	\N	96	1
6724188	117539	Central/South Asian	South/Central Asian	\N	\N	192	1
6724189	\N	Central/South Asian	South Asian	from http://gnomad.broadinstitute.org, accessed 09/22/2021	\N	15291	1
6724190	\N	Central/South Asian	South Asian	from http://gnomad.broadinstitute.org, accessed 09/22/2022	\N	15299	1
6724191	\N	Central/South Asian	South Asian	from http://gnomad.broadinstitute.org, accessed 09/22/2023	\N	15285	1
6724192	\N	Central/South Asian	South Asian	from http://gnomad.broadinstitute.org, accessed 09/22/2024	\N	15297	1
6724193	\N	Central/South Asian	South Asian	from http://gnomad.broadinstitute.org, accessed 09/22/2025	\N	15265	1
6724194	117548	East Asian	Japanese	\N	\N	267	1
6724195	117550	East Asian	Japanese	\N	\N	120	1
6724196	117552	East Asian	Korean	\N	\N	24	1
6724197	117541	East Asian	Chinese	\N	\N	35	1
6724198	117541	East Asian	Malays	\N	\N	35	1
6724199	117543	East Asian	Chinese	\N	\N	94	1
6724200	117543	East Asian	Malays	\N	\N	97	1
6724201	117566	East Asian	Japanese	\N	\N	177	1
6724202	117559	East Asian	Chinese	\N	\N	111	1
6724203	117555	East Asian	Korean	\N	\N	200	1
6724204	117557	East Asian	Korean	\N	\N	81	1
6724205	117546	East Asian	Chinese	\N	\N	96	1
6724206	117546	East Asian	Malays	\N	\N	96	1
6724207	117561	East Asian	Chinese	\N	\N	106	1
6724208	117561	East Asian	Korean	\N	\N	469	1
6724209	117561	East Asian	Vietanamese	\N	\N	104	1
6724210	117568	East Asian	Japanese	\N	\N	80	1
6724211	117539	East Asian	East asian	\N	\N	239	1
6724212	117571	East Asian	Chinese	\N	\N	32	1
6724213	1045981	East Asian	Thai	\N	\N	1205	1
6724214	\N	East Asian	East Asian	from http://gnomad.broadinstitute.org, accessed 09/21/2021	\N	9185	1
6724215	\N	East Asian	East Asian	from http://gnomad.broadinstitute.org, accessed 09/21/2021	\N	9196	1
6724216	\N	East Asian	East Asian	from http://gnomad.broadinstitute.org, accessed 09/21/2021	\N	9969	1
6724315	114935	East Asian	East Asian	\N	\N	8623	1
6724217	\N	East Asian	East Asian	from http://gnomad.broadinstitute.org, accessed 09/21/2021	\N	9161	1
6724218	\N	East Asian	East Asian	from http://gnomad.broadinstitute.org, accessed 09/21/2021	\N	9976	1
6724219	\N	East Asian	East Asian	from http://gnomad.broadinstitute.org, accessed 09/21/2021	\N	9187	1
6724220	\N	East Asian	East Asian	from http://gnomad.broadinstitute.org, accessed 09/21/2021	\N	9971	1
6724221	117541	European	Caucasian	\N	\N	36	1
6724222	117580	European	Finnish	\N	\N	468	1
6724223	117578	European	German	\N	\N	250	1
6724224	117537	European	American	\N	\N	69	1
6724225	117586	European	German	\N	\N	276	1
6724226	117586	European	Turkish	\N	\N	78	1
6724227	117539	European	European	\N	\N	151	1
6724228	117583	European	German	\N	\N	99	1
6724229	117593	European	Canadian	\N	\N	41	1
6724230	117591	European	Dutch	\N	\N	1885	1
6724231	117589	European	French	\N	\N	185	1
6724232	117595	European	German	\N	\N	236	1
6724233	\N	European	Non-Finnish	from http://gnomad.broadinstitute.org, accessed 09/22/2021	\N	56674	1
6724234	\N	European	Non-Finnish	from http://gnomad.broadinstitute.org, accessed 09/22/2022	\N	56746	1
6724235	\N	European	Non-Finnish	from http://gnomad.broadinstitute.org, accessed 09/22/2023	\N	64188	1
6724236	\N	European	Non-Finnish	from http://gnomad.broadinstitute.org, accessed 09/22/2024	\N	56607	1
6724237	\N	European	Non-Finnish	from http://gnomad.broadinstitute.org, accessed 09/22/2025	\N	64290	1
6724238	\N	European	Non-Finnish	from http://gnomad.broadinstitute.org, accessed 09/22/2026	\N	64274	1
6724239	\N	European	Non-Finnish	from http://gnomad.broadinstitute.org, accessed 09/22/2026	\N	56565	1
6724240	\N	European	Non-Finnish	from http://gnomad.broadinstitute.org, accessed 09/22/2026	\N	64165	1
6724241	117539	Near Eastern	Middle East & North Africa	\N	\N	162	1
6724242	117539	Oceanian	Oceanian	\N	\N	28	1
6724243	117586	Sub-Saharan African	Ugandan	\N	\N	109	1
6724244	117539	Sub-Saharan African	Sub-Saharan Africa	\N	\N	105	1
6724245	117595	Sub-Saharan African	Tanzanian	\N	\N	366	1
6724246	114883	African American/Afro-Caribbean	African American	African Ancestry in Southwest US	Healthy individuals	112	1
6724247	114885	African American/Afro-Caribbean	ESP6500:African_American	\N	\N	2203	1
6724248	114887	African American/Afro-Caribbean	African American	\N	Healthy individuals and pediatric ALL patients	248	1
6724249	114889	Central/South Asian	South Asian	\N	\N	15389	1
6724250	114891	Central/South Asian	South Asian	\N	\N	15390	1
6724251	114893	Central/South Asian	South Asian	\N	\N	15380	1
6724252	114895	Central/South Asian	South Asian	\N	\N	15391	1
6724253	114897	Central/South Asian	South Asian	\N	\N	15391	1
6724254	114899	Central/South Asian	South Asian	\N	\N	15386	1
6724255	114901	Central/South Asian	South Asian	\N	\N	15271	1
6724256	114903	Central/South Asian	South Asian	\N	\N	15381	1
6724257	114905	Central/South Asian	South Asian	\N	\N	15391	1
6724258	114907	Central/South Asian	South Asian	\N	\N	15391	1
6724259	114909	Central/South Asian	South Asian	\N	\N	15390	1
6724260	114911	Central/South Asian	South Asian	\N	\N	15349	1
6724261	114913	Central/South Asian	South Asian	\N	\N	15384	1
6724262	114915	Central/South Asian	South Asian	\N	\N	15381	1
6724263	114917	Central/South Asian	South Asian	\N	\N	15391	1
6724264	114919	Central/South Asian	South Asian	\N	\N	15391	1
6724265	114921	Central/South Asian	South Asian	\N	\N	15391	1
6724266	114923	Central/South Asian	South Asian	\N	\N	15391	1
6724267	114925	Central/South Asian	South Asian	\N	\N	15387	1
6724268	114927	Central/South Asian	South Asian	\N	\N	15355	1
6724269	114929	Central/South Asian	South Asian	\N	\N	15389	1
6724270	114931	Central/South Asian	South Asian	\N	\N	15391	1
6724271	114933	Central/South Asian	South Asian	\N	\N	15386	1
6724272	114935	Central/South Asian	South Asian	\N	\N	15390	1
6724273	114937	Central/South Asian	South Asian	\N	\N	15391	1
6724274	114939	Central/South Asian	Indian, Pakistani, Sri Lankan and Nepali	\N	Healthy individuals	99	1
6724275	114941	Central/South Asian	Indian	\N	Gastrointestinal disease patients	126	1
6724276	114943	Central/South Asian	Indian	\N	ALL patients	98	1
6724277	114945	Central/South Asian	Indian	\N	Healthy individuals	225	1
6724278	114947	Central/South Asian	Indian	\N	Healthy individuals	120	1
6724279	114949	Central/South Asian	Indian	\N	Pediatric ALL patients	71	1
6724280	114951	Central/South Asian	Indian	Singaporean	Healthy individuals and pediatric ALL patients	200	1
6724281	114953	Central/South Asian	Indian	Singaporean	Healthy individuals	163	1
6724282	114955	Central/South Asian	"Asian"	from Britain	Pediatric ALL patients	164	1
6724283	114957	Central/South Asian	Indian	\N	Pediatric ALL patients	72	1
6724284	114959	Central/South Asian	Indian	Singaporean	Healthy individuals	94	1
6724285	114961	Central/South Asian	Indian and Pakistani	British	Gastroenterology patients	85	1
6724286	114963	Central/South Asian	Indian	Southern Indian	Healthy individuals	326	1
6724287	114965	Central/South Asian	Indian	Tamilian	Healthy individuals	112	1
6724288	114965	Central/South Asian	Indian	Kannadiga	Healthy individuals	161	1
6724289	114965	Central/South Asian	Indian	Andhrite	Healthy individuals	158	1
6724290	114965	Central/South Asian	Indian	Keralite	Healthy individuals	177	1
6724291	114889	East Asian	East Asian	\N	\N	9429	1
6724292	114891	East Asian	East Asian	\N	\N	9433	1
6724293	114893	East Asian	East Asian	\N	\N	9434	1
6724294	114895	East Asian	East Asian	\N	\N	8624	1
6724295	114897	East Asian	East Asian	\N	\N	9435	1
6724296	114899	East Asian	East Asian	\N	\N	9427	1
6724297	114901	East Asian	East Asian	\N	\N	9417	1
6724298	114977	East Asian	Japanese (JPT)	\N	\N	44	1
6724299	114977	East Asian	Han Chinese (HCB)	\N	\N	42	1
6724300	114903	East Asian	East Asian	\N	\N	9432	1
6724301	114905	East Asian	East Asian	\N	\N	8624	1
6724302	114907	East Asian	East Asian	\N	\N	8624	1
6724303	114909	East Asian	East Asian	\N	\N	9433	1
6724304	114911	East Asian	East Asian	\N	\N	9431	1
6724305	114913	East Asian	East Asian	\N	\N	9435	1
6724306	114915	East Asian	East Asian	\N	\N	9434	1
6724307	114917	East Asian	East Asian	\N	\N	8624	1
6724308	114919	East Asian	East Asian	\N	\N	8624	1
6724309	114921	East Asian	East Asian	\N	\N	8624	1
6724310	114923	East Asian	East Asian	\N	\N	8624	1
6724316	114935	East Asian	East Asian	\N	\N	9433	1
6724317	114937	East Asian	East Asian	\N	\N	9434	1
6724318	114998	East Asian	Japanese	\N	Pediatric ALL patients	71	1
6724319	115000	East Asian	Japanese	\N	Healthy individuals and inflammatory bowel disease patients	111	1
6724320	115002	East Asian	Japanese	\N	Healthy individuals and inflammatory bowel disease patients	279	1
6724321	115004	East Asian	Chinese	Han Chinese	Healthy individuals and inflammatory bowel disease patients	462	1
6724322	115006	East Asian	Taiwanese	\N	Healthy individuals	249	1
6724323	115006	East Asian	Thai	\N	Healthy individuals	100	1
6724324	115009	East Asian	Chinese	Han Chinese	Lupus patients	126	1
6724325	114939	East Asian	Chinese	Han Chinese	Healthy individuals	192	1
6724326	115012	East Asian	Japanese	\N	Healthy individuals	192	1
6724327	115014	East Asian	Japanese	\N	Healthy individuals	192	1
6724328	115016	East Asian	Thai	\N	Pediatric ALL patients	75	1
6724329	115018	East Asian	Korean	\N	Lupus patients	342	1
6724330	115020	East Asian	Korean	\N	Inflammatory bowel disease patients	204	1
6724331	114951	East Asian	Chinese	Singaporean	Healthy individuals and pediatric ALL patients	271	1
6724332	114953	East Asian	Chinese	Singaporean	Healthy individuals	153	1
6724333	115024	East Asian	Korean	\N	Inflammatory bowel disease patients	286	1
6724334	115026	East Asian	Korean	\N	Pediatric ALL patients	100	1
6724335	115028	East Asian	Korean	\N	Hospital patients	900	1
6724336	115030	East Asian	Japanese	\N	Healthy individuals	151	1
6724337	115032	East Asian	Japanese	\N	Healthy individuals	157	1
6724338	115034	East Asian	Japanese	\N	Rheumatic disease patients and healthy individuals	507	1
6724339	115036	East Asian	Korean	\N	Healthy individuals	400	1
6724340	115036	East Asian	Vietnamese	Viet Kinh	Healthy individuals	159	1
6724341	115039	East Asian	Korean	\N	Pediatric inflammatory bowel disease patients	137	1
6724342	115041	East Asian	Korean	\N	Dermatology patients	123	1
6724343	114955	East Asian	Asian	in Britain	Pediatric ALL patients	8	1
6724344	115044	East Asian	Tibetan	\N	Healthy individuals	50	1
6724345	115046	East Asian	Taiwanese	Han Taiwanese	Healthy individuals	117	1
6724346	115046	East Asian	Taiwanese	Taiwan aborigines	Healthy individuals	409	1
6724347	114959	East Asian	Chinese	Singaporean	Healthy individuals	166	1
6724348	115050	East Asian	Japanese	\N	Healthy individuals and lupus patients	242	1
6724349	115052	East Asian	Japanese	\N	Healthy individuals and inflammatory bowel disease patients	279	1
6724350	115054	East Asian	Chinese	Han Chinese	Healthy individuals and renal transplant recipients	332	1
6724351	115056	East Asian	Thai	Northeastern Thai	Healthy individuals	200	1
6724352	115058	East Asian	Japanese	\N	Inflammatory bowel disease patients	147	1
6724353	115060	East Asian	Japanese	\N	Liver disease patients	236	1
6724354	115062	East Asian	Japanese	\N	Inflammatory bowel disease patients	16	1
6724355	115064	East Asian	Thai	\N	Renal transplant recipients	139	1
6724356	115066	East Asian	Chinese	\N	Renal transplant recipients	150	1
6724357	115068	East Asian	Chinese	\N	Renal transplant recipients	155	1
6724358	115070	East Asian	Chinese	Uygur Chinese	Healthy individuals	160	1
6724359	115072	East Asian	Chinese	Han Chinese	Healthy individuals	87	1
6724360	115072	East Asian	Chinese	Yao Chinese	Healthy individuals	126	1
6724361	115075	East Asian	Chinese	Han Chinese	Healthy individuals	312	1
6724362	115075	East Asian	Chinese	Jing Chinese	Healthy individuals	103	1
6724363	115075	East Asian	Chinese	Yao Chinese	Healthy individuals	126	1
6724364	115075	East Asian	Chinese	Uygur Chinese	Healthy individuals	160	1
6724365	115080	East Asian	Chinese	Han Chinese	Renal failure patients and healthy individuals	278	1
6724366	115006	East Asian	Filipino	\N	Healthy individuals	100	1
6724367	115006	East Asian	Indonesian	\N	Healthy individuals	100	1
6724368	114951	East Asian	Malay	Singaporean	Healthy individuals and pediatric ALL patients	217	1
6724369	114953	East Asian	Malay	Singaporean	Healthy individuals	163	1
6724370	114959	East Asian	Malay	Singaporean	Healthy individuals	104	1
6724371	114889	European	Finnish	\N	\N	12687	1
6724372	114889	European	non-Finnish	\N	\N	63320	1
6724373	114891	European	Finnish	\N	\N	12897	1
6724374	114891	European	non-Finnish	\N	\N	63331	1
6724375	114893	European	Finnish	\N	\N	12582	1
6724376	114893	European	non-Finnish	\N	\N	63275	1
6724377	114895	European	Finnish	\N	\N	11150	1
6724378	114895	European	non-Finnish	\N	\N	55828	1
6724379	114897	European	Finnish	\N	\N	12897	1
6724380	114897	European	non-Finnish	\N	\N	63342	1
6724381	114899	European	Finnish	\N	\N	12883	1
6724382	114899	European	non-Finnish	\N	\N	63270	1
6724383	114901	European	Finnish	\N	\N	12867	1
6724384	114901	European	non-Finnish	\N	\N	63178	1
6724385	114977	European	Utah European descent (CEU)	\N	\N	57	1
6724386	114903	European	Finnish	\N	\N	12888	1
6724387	114903	European	non-Finnish	\N	\N	63327	1
6724388	114905	European	Finnish	\N	\N	11148	1
6724389	114905	European	non-Finnish	\N	\N	55828	1
6724390	114907	European	Finnish	\N	\N	11150	1
6724391	114907	European	non-Finnish	\N	\N	55815	1
6724392	114909	European	Finnish	\N	\N	12845	1
6724393	114909	European	non-Finnish	\N	\N	63228	1
6724394	114911	European	Finnish	\N	\N	12894	1
6724395	114911	European	non-Finnish	\N	\N	63271	1
6724396	114913	European	Finnish	\N	\N	12889	1
6724397	114913	European	non-Finnish	\N	\N	63325	1
6724398	114915	European	Finnish	\N	\N	12619	1
6724399	114915	European	non-Finnish	\N	\N	63281	1
6724400	115116	European	European American	\N	\N	4253	1
6724401	114917	European	Finnish	\N	\N	11147	1
6724402	114917	European	non-Finnish	\N	\N	55849	1
6724403	114919	European	Finnish	\N	\N	11139	1
6724404	114919	European	non-Finnish	\N	\N	55834	1
6724405	114921	European	Finnish	\N	\N	11149	1
6724406	114921	European	non-Finnish	\N	\N	55842	1
6724407	114923	European	Finnish	\N	\N	11149	1
6724408	114923	European	non-Finnish	\N	\N	55850	1
6724409	114925	European	Finnish	\N	\N	11138	1
6724410	114925	European	non-Finnish	\N	\N	55771	1
6724411	114927	European	Finnish	\N	\N	12895	1
6724412	114927	European	non-Finnish	\N	\N	63282	1
6724413	114929	European	Finnish	\N	\N	11127	1
6724414	114929	European	non-Finnish	\N	\N	55799	1
6724415	114931	European	Finnish	\N	\N	11150	1
6724416	114931	European	non-Finnish	\N	\N	55839	1
6724417	114933	European	Finnish	\N	\N	11149	1
6724418	114933	European	non-Finnish	\N	\N	55846	1
6724419	114935	European	Finnish	\N	\N	12879	1
6724420	114935	European	non-Finnish	\N	\N	63312	1
6724421	114937	European	Finnish	\N	\N	12895	1
6724422	114937	European	non-Finnish	\N	\N	63335	1
6724423	115140	European	Portuguese	Northern Portuguese	Healthy individuals	310	1
6724424	115142	European	Portuguese	\N	Healthy individuals	143	1
6724425	115144	European	British	\N	Healthy individuals	199	1
6724426	115146	European	Spanish	\N	Solid organ transplant donors and recipients	569	1
6724427	115148	European	Slovakian	\N	Healthy individuals and pediatric inflammatory bowel disease patients	395	1
6724428	115150	European	Polish	\N	Hemodialysis patients	87	1
6724429	115152	European	Polish	\N	Pediatric ALL patients and healthy individuals	98	1
6724430	114939	European	British	\N	Healthy individuals	199	1
6724431	115155	European	Spanish	\N	Healthy individuals and ulcerative colitis patients	169	1
6724432	115155	European	Dutch	\N	Healthy individuals and ulcerative colitis patients	190	1
6724433	115158	European	Spanish	\N	Rheumatoid arthritis patients	111	1
6724434	115160	European	Greek	Cretan	Healthy individuals and inflammatory bowel disease patients	342	1
6724435	115162	European	Slovakian	\N	Inflammatory bowel disease patients	330	1
6724436	115164	European	Italian	Sicilian	Patients with inflammatory bowel disease, autoimmune or hematologic diseases	184	1
6724437	115166	European	Serbian and Montenegrin	\N	Healthy individuals and pediatric ALL patients	200	1
6724438	115168	European	French	\N	Healthy individuals	468	1
6724439	115170	European	Greek	\N	Pediatric inflammatory bowel disease patients	97	1
6724440	115172	European	Swedish	\N	Healthy individuals	800	1
6724441	115174	European	South African	White	Healthy individuals and neurology patients	85	1
6724442	115176	European	Swedish	Blekinge County	Inflammatory bowel disease patients	55	1
6724443	114887	European	American	\N	Healthy individuals	282	1
6724444	115179	European	Polish	\N	Healthy individuals	358	1
6724445	115181	European	Polish	\N	Renal transplant recipients	180	1
6724446	115183	European	Polish	\N	Renal transplant recipients	157	1
6724447	115185	European	Italian	\N	Inflammatory bowel disease patients	51	1
6724448	114955	European	British	White	Pediatric ALL patients	1965	1
6724449	114955	European	British	Mediterranean	Pediatric ALL patients	16	1
6724450	115189	European	Norwegian	Saami	Cardiology patients	194	1
6724451	115189	European	Norwegian	White	Cardiology patients	66	1
6724452	115192	European	British	\N	Pediatric ALL patients	147	1
6724453	115194	European	British	\N	Healthy individuals	199	1
6724454	115196	European	Slovenian	\N	Healthy individuals	194	1
6724455	115198	European	Russian	\N	Healthy individuals and pediatric hematology patients	700	1
6724456	115200	European	Danish	\N	Crohn's disease patients	120	1
6724457	115202	European	Italian	\N	Healthy individuals	103	1
6724458	115204	European	Italian	Sardinian	Healthy individuals	259	1
6724459	115206	European	Russian	\N	Pediatric hematology patients, other pediatric patients and healthy adults	995	1
6724460	115208	European	German	\N	Healthy individuals	1214	1
6724461	115210	European	German	\N	Healthy individuals	1214	1
6724462	115212	European	Italian	\N	Healthy individuals	943	1
6724463	115214	European	Polish	\N	Healthy individuals and inflammatory bowel disease patients	274	1
6724464	115216	European	Czech	\N	Healthy individuals and inflammatory bowel disease patients	696	1
6724465	115218	European	European	\N	Healthy individuals and patients receiving thipurine therapy	191	1
6724466	115220	European	Lithuanian	\N	Inflammatory bowel disease patients	551	1
6724467	115222	European	Italian	\N	Autoimmune disease patients	78	1
6724468	115224	European	Greenlandic	\N	Outpatient patients	142	1
6724469	115224	European	Danish	\N	Healthy individuals	200	1
6724470	114889	Latino	Latino	\N	\N	17198	1
6724471	114891	Latino	Latino	\N	\N	17203	1
6724472	114893	Latino	Latino	\N	\N	17144	1
6724473	114895	Latino	Latino	\N	\N	16787	1
6724474	114897	Latino	Latino	\N	\N	17206	1
6724475	114899	Latino	Latino	\N	\N	17201	1
6724476	114901	Latino	Latino	\N	\N	17176	1
6724477	114903	Latino	Latino	\N	\N	17206	1
6724478	114905	Latino	Latino	\N	\N	16786	1
6724479	114907	Latino	Latino	\N	\N	16785	1
6724480	114909	Latino	Latino	\N	\N	17206	1
6724481	114911	Latino	Latino	\N	\N	17184	1
6724482	114913	Latino	Latino	\N	\N	17203	1
6724483	114915	Latino	Latino	\N	\N	17148	1
6724484	114917	Latino	Latino	\N	\N	16788	1
6724485	114919	Latino	Latino	\N	\N	16791	1
6724486	114921	Latino	Latino	\N	\N	16791	1
6724487	114923	Latino	Latino	\N	\N	16787	1
6724488	114925	Latino	Latino	\N	\N	16783	1
6724489	114927	Latino	Latino	\N	\N	17184	1
6724490	114929	Latino	Latino	\N	\N	16780	1
6724491	114931	Latino	Latino	\N	\N	16789	1
6724492	114933	Latino	Latino	\N	\N	16790	1
6724493	114935	Latino	Latino	\N	\N	17200	1
6724494	114937	Latino	Latino	\N	\N	17206	1
6724495	115252	Latino	Chilean	\N	Pediatric ALL patients	103	1
6724496	115254	Latino	Colombian	Mestizo	Healthy individuals	140	1
6724497	115256	Latino	Mexican	\N	Healthy individuals and pediatric ALL patients	849	1
6724498	115044	Latino	Bolivian	\N	Healthy individuals	115	1
6724499	115259	Latino	Mexican	\N	Lupus patients and rheumatoid arthritis patients	553	1
6724500	115261	Latino	Mexican	Baja California	Healthy individuals	150	1
6724501	115263	Latino	Brazilian	\N	Pediatric ALL patients	116	1
6724502	115265	Latino	Mexican	\N	Healthy individuals and ALL patients	147	1
6724503	115267	Near Eastern	Turkish	\N	Pediatric ALL patients	58	1
6724504	115269	Near Eastern	Palestinian	\N	Pediatric ALL patients	56	1
6724505	115271	Near Eastern	Iranian	Southeastern Iranian	Healthy individuals	832	1
6724506	115273	Near Eastern	Israeli	Moslem	Healthy individuals	194	1
6724507	115273	Near Eastern	Israeli	Druze	Healthy individuals	156	1
6724508	115276	Near Eastern	Jordanian	\N	Healthy individuals and rheumatoid arthritis patients	360	1
6724509	115278	Near Eastern	Jordanian	\N	Healthy individuals	169	1
6724510	114955	Near Eastern	Middle Eastern	from Britain	Pediatric ALL patients	15	1
6724511	115281	Near Eastern	Iranian	Southern Iran	Healthy individuals	500	1
6724512	115283	Near Eastern	Arabs	Israeli	Healthy individuals	118	1
6724513	115283	Near Eastern	Druze	Israeli	Healthy individuals	46	1
6724514	115283	Near Eastern	Kurdish	Israeli	Healthy individuals	73	1
6724515	115287	Near Eastern	Turkish	\N	Pediatric ALL patients	106	1
6724516	115289	Near Eastern	Tunisian	\N	Healthy individuals and ALL patients	206	1
6724517	115291	Near Eastern	Moroccan	\N	Healthy individuals	103	1
6724518	115293	Near Eastern	Tunisian	\N	Crohn's disease patients	208	1
6724519	115295	Near Eastern	Egyptian	\N	Pediatric ALL patients	25	1
6724520	115297	Near Eastern	Egyptian	\N	Healthy individuals	200	1
6724521	115299	Near Eastern	Libyan	\N	Pediatric ALL patients	50	1
6724522	115299	Near Eastern	Libyan	Tawargha	Healthy individuals	38	1
6724523	115299	Near Eastern	Libyan	Yefren	Healthy individuals	54	1
6724524	115299	Near Eastern	Libyan	Tripoli	Healthy individuals	154	1
6724525	115304	Near Eastern	Lebanese, Palestinian, Syrian, Iraqi	\N	Pediatric ALL patients	143	1
6724526	115306	Near Eastern	Tunisian	\N	Crohn's disease patients	88	1
6724527	115273	Near Eastern	Israeli	Jewish	Healthy individuals	531	1
6724528	115283	Near Eastern	Israeli	Jewish	Healthy individuals	164	1
6724529	115283	Near Eastern	Ethiopian	Jewish/Israeli	Healthy individuals	169	1
6724530	114977	Sub-Saharan African	Yoruban (YRI)	\N	\N	58	1
6724531	115144	Sub-Saharan African	Ghanaian	\N	Healthy individuals	217	1
6724532	115174	Sub-Saharan African	South African	Black	Healthy individuals and neurology patients	227	1
6724533	115174	Sub-Saharan African	South African	Mixed ancestry	Healthy individuals and neurology patients	272	1
6724534	114955	Sub-Saharan African	Black	from Britain	Pediatric ALL patients	55	1
6724535	115194	Sub-Saharan African	Kenyan	\N	Healthy individuals	101	1
6724536	115317	Sub-Saharan African	Angolan	Cabinda	Healthy individuals	103	1
6724537	115319	Sub-Saharan African	Ghanaian	Akwapim	Healthy individuals	90	1
6724538	115319	Sub-Saharan African	Ghanaian	Ashanti	Healthy individuals	103	1
6724539	115319	Sub-Saharan African	Ghanaian	Ewe	Healthy individuals	183	1
6724540	115319	Sub-Saharan African	Ghanaian	Fanti	Healthy individuals	160	1
6724541	115319	Sub-Saharan African	Ghanaian	Ga	Healthy individuals	183	1
6724542	116461	African American/Afro-Caribbean	African-American (United States)	\N	\N	202	1
6724543	116463	African American/Afro-Caribbean	African-American (United States)	\N	\N	443	1
6724544	116465	African American/Afro-Caribbean	African-American (United States)	\N	\N	211	1
6724545	116467	African American/Afro-Caribbean	Jamaican	\N	\N	72	1
6724546	113931	African American/Afro-Caribbean	African Caribbean (Barbados)	\N	\N	92	1
6724547	113931	African American/Afro-Caribbean	African-Ancestry (Southwest U.S)	\N	\N	61	1
6724548	116467	Central/South Asian	Sri Lankan	\N	\N	229	1
6724549	116472	Central/South Asian	Indian (Malaysia)	\N	\N	102	1
6724550	116474	Central/South Asian	Indian	\N	\N	84	1
6724551	116467	Central/South Asian	Indian	\N	\N	119	1
6724552	116467	Central/South Asian	Bangladeshi	\N	\N	26	1
6724553	116472	Central/South Asian	Indian ( Malaysia)	\N	\N	102	1
6724554	113931	Central/South Asian	Gujarati Indian (Houston, U.S.)	\N	\N	103	1
6724555	113931	Central/South Asian	Telugu Indian (U.K.)	\N	\N	92	1
6724556	113931	Central/South Asian	Punjabi (Lahore, Pakistan)	\N	\N	96	1
6724557	113931	Central/South Asian	Sri Lankan Tamil (U.K.)	\N	\N	102	1
6724558	116483	East Asian	Japanese	\N	\N	150	1
6724559	116485	East Asian	Japanese	\N	\N	48	1
6724560	116487	East Asian	Japanese	\N	\N	78	1
6724561	116467	East Asian	Chinese (Hong Kong)	\N	\N	50	1
6724562	116467	East Asian	Thai	\N	\N	76	1
6724563	116467	East Asian	Indonesian	\N	\N	60	1
6724564	116474	East Asian	Malaysian	\N	\N	93	1
6724565	116472	East Asian	Malaysian	\N	\N	100	1
6724566	116467	East Asian	Vietnamese	\N	\N	83	1
6724567	116474	East Asian	Chinese	\N	\N	89	1
6724568	116472	East Asian	Chinese (Malaysia)	\N	\N	104	1
6724569	116467	East Asian	Burmese (Burma/Myanmar)	\N	\N	32	1
6724570	113931	East Asian	Japanese (Tokyo, Japan)	\N	\N	104	1
6724571	113931	East Asian	Kinh (Ho Chi Minh City, Vietnam)	\N	\N	99	1
6724572	113931	East Asian	Han Chinese (Beijing, China)	\N	\N	103	1
6724573	113931	East Asian	Southern Han Chinese (China)	\N	\N	105	1
6724574	113931	East Asian	Chinese Dai (Xishuangbanna, China)	\N	\N	93	1
6724575	116467	European	Icelandic	\N	\N	69	1
6724576	116467	European	British	\N	\N	59	1
6724577	116467	European	Greek cypriots	\N	\N	47	1
6724578	116467	European	Basque	\N	\N	27	1
6724579	116467	European	Catalan	\N	\N	46	1
6724580	116508	European	German	\N	\N	100	1
6724581	116510	European	British	\N	\N	90	1
6724582	116461	European	American (U.S)	\N	\N	291	1
6724583	113931	European	Northern and Western European Ancestry (Utah, U.S.)	\N	\N	99	1
6724584	113931	European	Finnish (Finland)	\N	\N	99	1
6724585	113931	European	British (England and Scotland)	\N	\N	91	1
6724586	113931	European	Iberian Spanish (Spain)	\N	\N	107	1
6724587	113931	European	Toscani (Italy)	\N	\N	107	1
6724588	116465	European	Caucasian (United States)	\N	\N	183	1
6724589	116463	European	Caucasian (United States)	\N	\N	135	1
6724590	116461	Latino	Hispanic (U.S and Puerto Rico)	\N	\N	153	1
6724591	113931	Latino	Colombian (Medellin, Colombia)	\N	\N	94	1
6724592	113931	Latino	Mexian Ancestry (Los Angeles, US)	\N	\N	64	1
6724593	113931	Latino	Peruvian (Lima, Peru)	\N	\N	85	1
6724594	113931	Latino	Puerto Rican (Puerto Rico)	\N	\N	104	1
6724595	116463	Latino	Hispanic (United States and Puerto Rico)	\N	\N	118	1
6724596	116465	Latino	Hispanic (United States and Puerto Rico)	\N	\N	87	1
6724597	116510	Near Eastern	Anatolian (Turkey)	\N	\N	96	1
6724598	116467	Near Eastern	Yemenese	\N	\N	61	1
6724599	116510	Near Eastern	Yemenese	\N	\N	120	1
6724600	116467	Near Eastern	Lebanese	\N	\N	42	1
6724601	116531	Near Eastern	Saudi Arabian	\N	\N	192	1
6724602	116508	Near Eastern	Egyptian	\N	\N	100	1
6724603	116510	Near Eastern	Ifrane Berber (Morocco)	\N	\N	72	1
6724604	116510	Near Eastern	Algerian	\N	\N	183	1
6724605	116467	Oceanian	Papua New Guinean	\N	\N	105	1
6724606	116467	Oceanian	Tongan	\N	\N	41	1
6724607	116467	Oceanian	Fijian	\N	\N	16	1
6724608	116467	Sub-Saharan African	Malawian	\N	\N	76	1
6724609	116510	Sub-Saharan African	Chewa(Malawi)	\N	\N	91	1
6724610	116510	Sub-Saharan African	Tumbuka (Malawi)	\N	\N	61	1
6724611	116510	Sub-Saharan African	Yao (Malawi)	\N	\N	56	1
6724612	116467	Sub-Saharan African	Ivory Coast	\N	\N	74	1
6724613	116467	Sub-Saharan African	Luo (Kenya)	\N	\N	81	1
6724614	116467	Sub-Saharan African	Madagascar	\N	\N	67	1
6724615	116510	Sub-Saharan African	Manjak (Senegal)	\N	\N	96	1
6724616	116510	Sub-Saharan African	Wolof (Senegal)	\N	\N	95	1
6724617	116510	Sub-Saharan African	Bulsa (Ghana)	\N	\N	90	1
6724618	116510	Sub-Saharan African	Kasena (Ghana)	\N	\N	45	1
6724619	116510	Sub-Saharan African	Igbo (Nigeria)	\N	\N	99	1
6724620	116510	Sub-Saharan African	Arabe (Cameroon)	\N	\N	90	1
6724621	116510	Sub-Saharan African	Kotoko (Cameroon)	\N	\N	42	1
6724622	116510	Sub-Saharan African	Cameroon-Mambila	\N	\N	76	1
6724623	116510	Sub-Saharan African	Ethiopia-Amhara	\N	\N	149	1
6724624	116510	Sub-Saharan African	Anauk (Ethiopia)	\N	\N	106	1
6724625	116510	Sub-Saharan African	Oromo (Ethiopia)	\N	\N	102	1
6724626	116510	Sub-Saharan African	North Sudan	\N	\N	156	1
6724627	116510	Sub-Saharan African	Dinka (South Sudan)	\N	\N	41	1
6724628	116510	Sub-Saharan African	Uganda	\N	\N	39	1
6724629	116510	Sub-Saharan African	Chagga (Tanzania)	\N	\N	50	1
6724630	116510	Sub-Saharan African	Bantu speakers (Mozambique)	\N	\N	84	1
6724631	116510	Sub-Saharan African	Zimbabwe	\N	\N	56	1
6724632	116510	Sub-Saharan African	Bantu speakers (South Africa)	\N	\N	101	1
6724633	116510	Sub-Saharan African	Lemba (South Africa)	\N	\N	96	1
6724634	113931	Sub-Saharan African	Esan (Nigeria)	\N	\N	99	1
6724635	113931	Sub-Saharan African	Western Division Gambian (The Gambia)	\N	\N	113	1
6724636	113931	Sub-Saharan African	Luhya-Webuye (Kenya)	\N	\N	99	1
6724637	113931	Sub-Saharan African	Mende (Sierra Leone)	\N	\N	85	1
6724638	113931	Sub-Saharan African	Yoruba-Ibadan (Nigeria)	\N	\N	108	1
6724639	116581	African American/Afro-Caribbean	African American	\N	\N	225	1
6724640	113845	African American/Afro-Caribbean	African American	\N	warfarin treated cohort	220	1
6724641	116572	African American/Afro-Caribbean	African American	\N	\N	368	1
6724642	116579	African American/Afro-Caribbean	African American	\N	\N	300	1
6724643	116585	African American/Afro-Caribbean	African American	\N	warfarin-treated African Americans	338	1
6724644	116574	African American/Afro-Caribbean	African American	\N	IWPC; warfarin-treated African Americans	327	1
6724645	116574	African American/Afro-Caribbean	African American	\N	UAB warfarin treated cohort	206	1
6724646	116574	African American/Afro-Caribbean	African American	\N	replication cohort, warfarin patients from IWPC sites	432	1
6724647	116570	African American/Afro-Caribbean	African American	\N	warfarin-treated African Americans	274	1
6724648	116583	African American/Afro-Caribbean	African American	\N	\N	60	1
6724649	\N	African American/Afro-Caribbean	African American	Americans of African Ancestry in SW USA	1000 Genomes ASW population	61	1
6724650	116590	American	Amerindian	Guarani	Brazillian	75	1
6724651	116590	American	Amerindian	Tupinikin	Brazillian	147	1
6724652	113847	American	American Indian and Alaska Native	Center of Alaska Native Health Research cohort (CANHR)	\N	350	1
6724653	113847	American	American Indian and Alaska Native	Southcentral Foundation cohort (SCF)	\N	359	1
6724654	116605	Central/South Asian	Indians	\N	\N	46	1
6724655	116603	Central/South Asian	Indians	\N	\N	46	1
6724656	113864	Central/South Asian	North Indians	\N	\N	225	1
6724657	113850	Central/South Asian	Indian	Bihar	\N	267	1
6724658	113850	Central/South Asian	Indian	Delhi	\N	213	1
6724659	113850	Central/South Asian	Indian	Haryana	\N	108	1
6724660	113850	Central/South Asian	Indian	Punjab	\N	225	1
6724661	113850	Central/South Asian	Indian	Uttar Pradesh	\N	1101	1
6724662	113862	Central/South Asian	South Indians	\N	\N	240	1
6724663	\N	Central/South Asian	Bengali from Bangladesh	BEB	1000 Genomes	86	1
6724664	\N	Central/South Asian	Gujarati Indian from Houston, Texas	GIH	1000 Genomes	103	1
6724665	\N	Central/South Asian	Indian Telugu from the UK	ITU	1000 Genomes	102	1
6724666	\N	Central/South Asian	Punjabi from Lahore, Pakistan	PJL	1000 Genomes	96	1
6724667	\N	Central/South Asian	Sri Lankan Tamil from the UK	STU	1000 Genomes	102	1
6724668	116605	East Asian	Han Chinese in Taiwan	\N	\N	307	1
6724669	116605	East Asian	Indonesian	\N	\N	51	1
6724670	113878	East Asian	Chinese	\N	\N	222	1
6724671	116603	East Asian	Chinese	\N	\N	96	1
6724672	116603	East Asian	Malays	\N	warfarin treated patients	91	1
6724673	113884	East Asian	Indonesian	\N	\N	135	1
6724674	116616	East Asian	chinese	\N	warfarin treated cohort	809	1
6724675	113880	East Asian	Indonesian	\N	healthy control	103	1
6724676	113880	East Asian	Indonesian	\N	warfarin treated patients	103	1
6724677	113876	East Asian	Chinese	\N	\N	220	1
6724678	116583	East Asian	Chinese	\N	\N	196	1
6724679	\N	East Asian	Chinese Dai in Xishuangbanna, China	CDX	1000 Genomes	93	1
6724680	\N	East Asian	Han Chinese in Bejing, China	CHB	1000 Genomes	103	1
6724681	\N	East Asian	Japanese in Tokyo, Japan	JPT	1000 Genomes	104	1
6724682	\N	East Asian	Kinh in Ho Chi Minh City, Vietnam	KHV	1000 Genomes	99	1
6724683	\N	East Asian	Southern Han Chinese	CHS	1000 Genomes	105	1
6724684	116581	European	European-American	\N	\N	216	1
6724685	116635	European	Swedish patients	\N	warfarin-treated cohort	1496	1
6724686	116572	European	European-American	\N	warfarin-treated cohort	681	1
6724687	113892	European	Caucasian	\N	warfarin-treated cohort	283	1
6724688	116590	European	white from brazil	\N	\N	608	1
6724689	113897	European	Italy	\N	warfarin-treated cohort	266	1
6724690	116583	European	white	\N	\N	122	1
6724691	\N	European	British in England and Scotland	GBR	1000 Genomes	91	1
6724692	\N	European	Finnish in Finland	FIN	1000 Genomes	99	1
6724693	\N	European	Iberian Population in Spain	IBS	1000 Genomes	107	1
6724694	\N	European	Toscani in Italia	TSI	1000 Genomes	107	1
6724695	\N	European	Utah Residents (CEPH) with Northern and Western Ancestry	CEU	1000 Genomes	99	1
6724696	113905	Latino	Caribbean Hispanics	\N	warfarin treated patients	255	1
6724697	\N	Latino	Colombians from Medellin, Colombia	CLM	1000 Genomes	94	1
6724698	\N	Latino	Mexican Ancestry from Los Angeles USA	MXL	1000 Genomes	64	1
6724699	\N	Latino	Peruvians from Lima, Peru	PEL	1000 Genomes	85	1
6724700	\N	Latino	Puerto Ricans from Puerto Rico	PUR	1000 Genomes	104	1
6724701	116657	Near Eastern	Ashkenazi Jews in NY	\N	\N	260	1
6724702	116657	Near Eastern	Sephardi Jews in NY	\N	\N	80	1
6724703	116660	Near Eastern	Israeli population	Arab Moslem	\N	96	1
6724704	116660	Near Eastern	Israeli population	Druze	\N	180	1
6724705	116660	Near Eastern	Israeli population	Jewish	\N	162	1
6724706	116242	Near Eastern	Iranaians	\N	warfarin treated patients	81	1
6724707	116645	Near Eastern	Lebanese	\N	\N	161	1
6724708	116647	Near Eastern	Lebanese	\N	\N	231	1
6724709	113912	Near Eastern	Israeli patients	\N	warfarin-treated cohort	210	1
6724710	113908	Near Eastern	Omani	\N	\N	157	1
6724711	113910	Near Eastern	Moroccan patients	\N	acenocoumarol treated patients	96	1
6724712	116651	Near Eastern	Arabic population in Saudi Arabia	\N	healthy adults	131	1
6724713	116655	Near Eastern	Ashkenazi Jews	\N	\N	184	1
6724714	116655	Near Eastern	Ethiopian Jews	\N	\N	188	1
6724715	116649	Near Eastern	Iranian	\N	\N	115	1
6724716	116590	Sub-Saharan African	Black from Brazil	\N	\N	117	1
6724717	\N	Sub-Saharan African	Esan in Nigeria	ESN	1000 Genomes	99	1
6724718	\N	Sub-Saharan African	Luhya in Webuye, Kenya	LWK	1000 Genomes	99	1
6724719	\N	Sub-Saharan African	Mandinka in the Gambia	MAG	1000 Genomes	113	1
6724720	\N	Sub-Saharan African	Mende in Sierra Leone	MSL	1000 Genomes	85	1
6724721	\N	Sub-Saharan African	Yoruba in Ibadan, Nigeria	YRI	1000 Genomes	108	1
\.




--
-- Data for Name: publication_supplement; Type: TABLE DATA; Schema: cpic; Owner: -
--

COPY cpic.publication_supplement (id, publicationid, description, url, version) FROM stdin;
726028	110016	\N	https://files.cpicpgx.org/data/guideline/publication/warfarin/2011/IWPC_dose_calculator.xls	1
725969	571448	Supplement to publication	https://files.cpicpgx.org/data/guideline/publication/NSAID/2020/32189324-supplement.pdf	2
725970	571447	Supplement to publication	https://files.cpicpgx.org/data/guideline/publication/PPI/2020/32770672-supplement.pdf	2
725971	110006	Supplement to publication	https://files.cpicpgx.org/data/guideline/publication/SSRI/2015/25974703-supplement.pdf	2
725980	110011	Supplement to publication	https://files.cpicpgx.org/data/guideline/publication/TCA/2013/23486447-supplement.pdf	2
725981	110004	Supplement to publication	https://files.cpicpgx.org/data/guideline/publication/TCA/2016/27997040-supplement.pdf	2
725984	110014	Supplement to publication	https://files.cpicpgx.org/data/guideline/publication/abacavir/2012/22378157-supplement.pdf	2
725985	110015	Supplement to publication	https://files.cpicpgx.org/data/guideline/publication/abacavir/2014/24561393-supplement.pdf	2
725986	110027	Supplement to publication	https://files.cpicpgx.org/data/guideline/publication/allopurinol/2013/23232549-supplement.pdf	2
725987	110018	Supplement to publication	https://files.cpicpgx.org/data/guideline/publication/allopurinol/2015/26094938-supplement.pdf	2
725989	110008	Supplement to publication	https://files.cpicpgx.org/data/guideline/publication/atazanavir/2015/26417955-supplement.pdf	2
725990	110035	Supplement to publication	https://files.cpicpgx.org/data/guideline/publication/atomoxetine/2019/30801677-supplement.pdf	2
725991	110009	Supplement to publication	https://files.cpicpgx.org/data/guideline/publication/carbamazepine/2013/23695185-supplement.pdf	2
725992	110034	Supplement to publication	https://files.cpicpgx.org/data/guideline/publication/carbamazepine/2017/29392710-supplement.pdf	2
725993	110005	Supplement to publication	https://files.cpicpgx.org/data/guideline/publication/clopidogrel/2011/21716271-supplement.pdf	2
725994	110028	Supplement to publication	https://files.cpicpgx.org/data/guideline/publication/clopidogrel/2013/23698643-supplement.pdf	2
725997	110031	Supplement to publication	https://files.cpicpgx.org/data/guideline/publication/codeine/2012/22205192-supplement.pdf	2
726000	110033	Supplement to publication	https://files.cpicpgx.org/data/guideline/publication/codeine/2014/24458010-supplement.pdf	2
726001	110036	Supplement to publication	https://files.cpicpgx.org/data/guideline/publication/efavirenz/2019/31006110-supplement.pdf	2
726002	110019	Supplement to publication	https://files.cpicpgx.org/data/guideline/publication/fluoropyrimidines/2013/23988873-supplement.pdf	2
726003	110029	Supplement to publication	https://files.cpicpgx.org/data/guideline/publication/fluoropyrimidines/2017/29152729-supplement.pdf	2
726004	110023	Supplement to publication	https://files.cpicpgx.org/data/guideline/publication/ivacaftor/2014/24598717-supplement.pdf	2
726005	110013	Supplement to publication	https://files.cpicpgx.org/data/guideline/publication/ondansetron/2016/28002639-supplement.pdf	2
726007	417705	Supplement to publication	https://files.cpicpgx.org/data/guideline/publication/opioids/2020/33387367-supplement.pdf	2
726008	110007	Supplement to publication	https://files.cpicpgx.org/data/guideline/publication/pegintron/2013/24096968-supplement.pdf	2
726011	110003	Supplement to publication	https://files.cpicpgx.org/data/guideline/publication/phenytoin/2014/25099164-supplement.pdf	2
726012	110077	Supplement to publication	https://files.cpicpgx.org/data/guideline/publication/phenytoin/2020/32779747-supplement.pdf	2
726013	110000	Supplement to publication	https://files.cpicpgx.org/data/guideline/publication/rasburicase/2014/24787449-supplement.pdf	2
726014	110021	Supplement to publication	https://files.cpicpgx.org/data/guideline/publication/simvastatin/2012/22617227-supplement.pdf	2
726015	110022	Supplement to publication	https://files.cpicpgx.org/data/guideline/publication/simvastatin/2014/24918167-supplement.pdf	2
726019	110002	Supplement to publication	https://files.cpicpgx.org/data/guideline/publication/tacrolimus/2015/25801146-supplement.pdf	2
726020	110010	Supplement to publication	https://files.cpicpgx.org/data/guideline/publication/tamoxifen/2017/29385237-supplement.pdf	2
726021	110017	Supplement to publication	https://files.cpicpgx.org/data/guideline/publication/thiopurines/2011/21270794-supplement.pdf	2
726022	110024	Supplement to publication	https://files.cpicpgx.org/data/guideline/publication/thiopurines/2013/23422873-supplement.pdf	2
726023	110026	Supplement to publication	https://files.cpicpgx.org/data/guideline/publication/thiopurines/2018/30447069-supplement.pdf	2
726024	110032	Supplement to publication	https://files.cpicpgx.org/data/guideline/publication/volatile_anesthetic_succinylcholine/2018/30499100-supplement.pdf	2
726025	110001	Supplement to publication	https://files.cpicpgx.org/data/guideline/publication/voriconazole/2016/27981572-supplement.pdf	2
726027	110016	Supplement to publication	https://files.cpicpgx.org/data/guideline/publication/warfarin/2011/21900891-supplement.pdf	2
726029	110030	Supplement to publication	https://files.cpicpgx.org/data/guideline/publication/warfarin/2017/28198005-supplement.pdf	2
876862	876861	Supplement to publication	https://files.cpicpgx.org/data/guideline/publication/aminoglycosides/2021/34032273-supplement.pdf	1
1608552	1608551	Supplement to publication	https://files.cpicpgx.org/data/guideline/publication/clopidogrel/2022/35034351-supplement.pdf	1
1608553	1508721	Supplement to publication	https://files.cpicpgx.org/data/guideline/publication/statins/2022/supplement.pdf	1
2510457	2510456	Supplement to publication	https://files.cpicpgx.org/data/guideline/publication/G6PD/2022/36049896-supplement.pdf	1
3070388	3070387	Supplement to publication	https://files.cpicpgx.org/data/guideline/publication/serotonin_reuptake_inhibitor_antidepressants/2023/37032427-supplement.pdf	1
5407446	5407445	\N	https://files.cpicpgx.org/data/guideline/publication/methadone/2024/38863207-supplement.pdf	1
5407448	5407447	\N	https://files.cpicpgx.org/data/guideline/publication/beta_blockers/2024/38951961-supplement.pdf	1
6605827	6605826	Supplement to publication	https://files.cpicpgx.org/data/guideline/publication/hydralazine/2025/40974042-supplement.pdf	1
\.


--
-- Data for Name: recommendation; Type: TABLE DATA; Schema: cpic; Owner: -
--

COPY cpic.recommendation (id, guidelineid, drugid, implications, drugrecommendation, classification, phenotypes, activityscore, allelestatus, lookupkey, population, comments, version, dosinginformation, alternatedrugavailable, otherprescribingguidance) FROM stdin;
6725359	100421	RxNorm:190521	{"HLA-B": "Low or reduced risk of abacavir hypersensitivity"}	Use abacavir per standard dosing guidelines	Strong	{}	{}	{"HLA-B": "HLA-B*57:01 negative"}	{"HLA-B": "*57:01 negative"}	general	n/a	1	f	f	f
6725360	100421	RxNorm:190521	{"HLA-B": "Significantly increased risk of abacavir hypersensitivity"}	Abacavir is not recommended	Strong	{}	{}	{"HLA-B": "HLA-B*57:01 positive"}	{"HLA-B": "*57:01 positive"}	general	n/a	1	f	f	f
6725361	100422	RxNorm:519	{"HLA-B": "Low or reduced risk of allopurinol-induced SCAR"}	Use allopurinol per standard dosing guidelines	Strong	{}	{}	{"HLA-B": "HLA-B*58:01 negative"}	{"HLA-B": "*58:01 negative"}	general	n/a	1	f	f	f
6725362	100422	RxNorm:519	{"HLA-B": "Significantly increased risk of allopurinol-induced SCAR"}	Allopurinol is contraindicated	Strong	{}	{}	{"HLA-B": "HLA-B*58:01 positive"}	{"HLA-B": "*58:01 positive"}	general	n/a	1	f	f	f
6725363	826283	RxNorm:641	{"MT-RNR1": "Very high risk of developing hearing loss if administered an aminoglycoside antibiotic."}	Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.	Strong	{"MT-RNR1": "increased risk of aminoglycoside-induced hearing loss"}	{}	{}	{"MT-RNR1": "increased risk of aminoglycoside-induced hearing loss"}	general	If no effective alternative to an aminoglycoside antibiotic is available, evaluate for hearing loss frequently during therapy and ensure that all appropriate precautions are utilized (e.g., lowest possible dose and duration, utilization of therapeutic drug monitoring, hydration, renal function monitoring).	1	f	f	f
6725364	826283	RxNorm:641	{"MT-RNR1": "Normal risk of developing hearing loss if administered an aminoglycoside antibiotic."}	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	Strong	{"MT-RNR1": "normal risk of aminoglycoside-induced hearing loss"}	{}	{}	{"MT-RNR1": "normal risk of aminoglycoside-induced hearing loss"}	general	Individuals without MT-RNR1 aminoglycoside-induced hearing loss increased risk variants are still at risk of aminoglycoside-associated hearing loss, especially with high drug levels or prolonged courses.	1	f	f	f
6725365	826283	RxNorm:641	{"MT-RNR1": "Weak or no evidence for an increased risk of MT-RNR1 associated hearing loss if administered an aminoglycoside antibiotic."}	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	Optional	{"MT-RNR1": "uncertain risk of aminoglycoside-induced hearing loss"}	{}	{}	{"MT-RNR1": "uncertain risk of aminoglycoside-induced hearing loss"}	general	Individuals without MT-RNR1 aminoglycoside-induced hearing loss increased risk variants are still at risk of aminoglycoside-associated hearing loss, especially with high drug levels or prolonged courses.	1	f	f	f
6725366	826283	ATC:D06AX07	{"MT-RNR1": "Very high risk of developing hearing loss if administered an aminoglycoside antibiotic."}	Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.	Strong	{"MT-RNR1": "increased risk of aminoglycoside-induced hearing loss"}	{}	{}	{"MT-RNR1": "increased risk of aminoglycoside-induced hearing loss"}	general	If no effective alternative to an aminoglycoside antibiotic is available, evaluate for hearing loss frequently during therapy and ensure that all appropriate precautions are utilized (e.g., lowest possible dose and duration, utilization of therapeutic drug monitoring, hydration, renal function monitoring).	1	f	f	f
6725367	826283	ATC:D06AX07	{"MT-RNR1": "Normal risk of developing hearing loss if administered an aminoglycoside antibiotic."}	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	Strong	{"MT-RNR1": "normal risk of aminoglycoside-induced hearing loss"}	{}	{}	{"MT-RNR1": "normal risk of aminoglycoside-induced hearing loss"}	general	Individuals without MT-RNR1 aminoglycoside-induced hearing loss increased risk variants are still at risk of aminoglycoside-associated hearing loss, especially with high drug levels or prolonged courses.	1	f	f	f
6725368	826283	ATC:D06AX07	{"MT-RNR1": "Weak or no evidence for an increased risk of MT-RNR1 associated hearing loss if administered an aminoglycoside antibiotic."}	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	Optional	{"MT-RNR1": "uncertain risk of aminoglycoside-induced hearing loss"}	{}	{}	{"MT-RNR1": "uncertain risk of aminoglycoside-induced hearing loss"}	general	Individuals without MT-RNR1 aminoglycoside-induced hearing loss increased risk variants are still at risk of aminoglycoside-associated hearing loss, especially with high drug levels or prolonged courses.	1	f	f	f
6725369	826283	RxNorm:6099	{"MT-RNR1": "Very high risk of developing hearing loss if administered an aminoglycoside antibiotic."}	Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.	Strong	{"MT-RNR1": "increased risk of aminoglycoside-induced hearing loss"}	{}	{}	{"MT-RNR1": "increased risk of aminoglycoside-induced hearing loss"}	general	If no effective alternative to an aminoglycoside antibiotic is available, evaluate for hearing loss frequently during therapy and ensure that all appropriate precautions are utilized (e.g., lowest possible dose and duration, utilization of therapeutic drug monitoring, hydration, renal function monitoring).	1	f	f	f
6725370	826283	RxNorm:6099	{"MT-RNR1": "Normal risk of developing hearing loss if administered an aminoglycoside antibiotic."}	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	Strong	{"MT-RNR1": "normal risk of aminoglycoside-induced hearing loss"}	{}	{}	{"MT-RNR1": "normal risk of aminoglycoside-induced hearing loss"}	general	Individuals without MT-RNR1 aminoglycoside-induced hearing loss increased risk variants are still at risk of aminoglycoside-associated hearing loss, especially with high drug levels or prolonged courses.	1	f	f	f
6725371	826283	RxNorm:6099	{"MT-RNR1": "Weak or no evidence for an increased risk of MT-RNR1 associated hearing loss if administered an aminoglycoside antibiotic."}	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	Optional	{"MT-RNR1": "uncertain risk of aminoglycoside-induced hearing loss"}	{}	{}	{"MT-RNR1": "uncertain risk of aminoglycoside-induced hearing loss"}	general	Individuals without MT-RNR1 aminoglycoside-induced hearing loss increased risk variants are still at risk of aminoglycoside-associated hearing loss, especially with high drug levels or prolonged courses.	1	f	f	f
6725372	826283	RxNorm:7934	{"MT-RNR1": "Very high risk of developing hearing loss if administered an aminoglycoside antibiotic."}	Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.	Strong	{"MT-RNR1": "increased risk of aminoglycoside-induced hearing loss"}	{}	{}	{"MT-RNR1": "increased risk of aminoglycoside-induced hearing loss"}	general	If no effective alternative to an aminoglycoside antibiotic is available, evaluate for hearing loss frequently during therapy and ensure that all appropriate precautions are utilized (e.g., lowest possible dose and duration, utilization of therapeutic drug monitoring, hydration, renal function monitoring).	1	f	f	f
6725373	826283	RxNorm:7934	{"MT-RNR1": "Normal risk of developing hearing loss if administered an aminoglycoside antibiotic."}	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	Strong	{"MT-RNR1": "normal risk of aminoglycoside-induced hearing loss"}	{}	{}	{"MT-RNR1": "normal risk of aminoglycoside-induced hearing loss"}	general	Individuals without MT-RNR1 aminoglycoside-induced hearing loss increased risk variants are still at risk of aminoglycoside-associated hearing loss, especially with high drug levels or prolonged courses.	1	f	f	f
6725374	826283	RxNorm:7934	{"MT-RNR1": "Weak or no evidence for an increased risk of MT-RNR1 associated hearing loss if administered an aminoglycoside antibiotic."}	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	Optional	{"MT-RNR1": "uncertain risk of aminoglycoside-induced hearing loss"}	{}	{}	{"MT-RNR1": "uncertain risk of aminoglycoside-induced hearing loss"}	general	Individuals without MT-RNR1 aminoglycoside-induced hearing loss increased risk variants are still at risk of aminoglycoside-associated hearing loss, especially with high drug levels or prolonged courses.	1	f	f	f
6725375	826283	RxNorm:2049549	{"MT-RNR1": "Very high risk of developing hearing loss if administered an aminoglycoside antibiotic."}	Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.	Strong	{"MT-RNR1": "increased risk of aminoglycoside-induced hearing loss"}	{}	{}	{"MT-RNR1": "increased risk of aminoglycoside-induced hearing loss"}	general	If no effective alternative to an aminoglycoside antibiotic is available, evaluate for hearing loss frequently during therapy and ensure that all appropriate precautions are utilized (e.g., lowest possible dose and duration, utilization of therapeutic drug monitoring, hydration, renal function monitoring).	1	f	f	f
6725376	826283	RxNorm:2049549	{"MT-RNR1": "Normal risk of developing hearing loss if administered an aminoglycoside antibiotic."}	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	Strong	{"MT-RNR1": "normal risk of aminoglycoside-induced hearing loss"}	{}	{}	{"MT-RNR1": "normal risk of aminoglycoside-induced hearing loss"}	general	Individuals without MT-RNR1 aminoglycoside-induced hearing loss increased risk variants are still at risk of aminoglycoside-associated hearing loss, especially with high drug levels or prolonged courses.	1	f	f	f
6725377	826283	RxNorm:2049549	{"MT-RNR1": "Weak or no evidence for an increased risk of MT-RNR1 associated hearing loss if administered an aminoglycoside antibiotic."}	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	Optional	{"MT-RNR1": "uncertain risk of aminoglycoside-induced hearing loss"}	{}	{}	{"MT-RNR1": "uncertain risk of aminoglycoside-induced hearing loss"}	general	Individuals without MT-RNR1 aminoglycoside-induced hearing loss increased risk variants are still at risk of aminoglycoside-associated hearing loss, especially with high drug levels or prolonged courses.	1	f	f	f
6725378	826283	RxNorm:10109	{"MT-RNR1": "Very high risk of developing hearing loss if administered an aminoglycoside antibiotic."}	Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.	Strong	{"MT-RNR1": "increased risk of aminoglycoside-induced hearing loss"}	{}	{}	{"MT-RNR1": "increased risk of aminoglycoside-induced hearing loss"}	general	If no effective alternative to an aminoglycoside antibiotic is available, evaluate for hearing loss frequently during therapy and ensure that all appropriate precautions are utilized (e.g., lowest possible dose and duration, utilization of therapeutic drug monitoring, hydration, renal function monitoring).	1	f	f	f
6725379	826283	RxNorm:10109	{"MT-RNR1": "Normal risk of developing hearing loss if administered an aminoglycoside antibiotic."}	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	Strong	{"MT-RNR1": "normal risk of aminoglycoside-induced hearing loss"}	{}	{}	{"MT-RNR1": "normal risk of aminoglycoside-induced hearing loss"}	general	Individuals without MT-RNR1 aminoglycoside-induced hearing loss increased risk variants are still at risk of aminoglycoside-associated hearing loss, especially with high drug levels or prolonged courses.	1	f	f	f
6725380	826283	RxNorm:10109	{"MT-RNR1": "Weak or no evidence for an increased risk of MT-RNR1 associated hearing loss if administered an aminoglycoside antibiotic."}	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	Optional	{"MT-RNR1": "uncertain risk of aminoglycoside-induced hearing loss"}	{}	{}	{"MT-RNR1": "uncertain risk of aminoglycoside-induced hearing loss"}	general	Individuals without MT-RNR1 aminoglycoside-induced hearing loss increased risk variants are still at risk of aminoglycoside-associated hearing loss, especially with high drug levels or prolonged courses.	1	f	f	f
6725381	826283	RxNorm:10627	{"MT-RNR1": "Very high risk of developing hearing loss if administered an aminoglycoside antibiotic."}	Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.	Strong	{"MT-RNR1": "increased risk of aminoglycoside-induced hearing loss"}	{}	{}	{"MT-RNR1": "increased risk of aminoglycoside-induced hearing loss"}	general	If no effective alternative to an aminoglycoside antibiotic is available, evaluate for hearing loss frequently during therapy and ensure that all appropriate precautions are utilized (e.g., lowest possible dose and duration, utilization of therapeutic drug monitoring, hydration, renal function monitoring).	1	f	f	f
6725382	826283	RxNorm:10627	{"MT-RNR1": "Normal risk of developing hearing loss if administered an aminoglycoside antibiotic."}	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	Strong	{"MT-RNR1": "normal risk of aminoglycoside-induced hearing loss"}	{}	{}	{"MT-RNR1": "normal risk of aminoglycoside-induced hearing loss"}	general	Individuals without MT-RNR1 aminoglycoside-induced hearing loss increased risk variants are still at risk of aminoglycoside-associated hearing loss, especially with high drug levels or prolonged courses.	1	f	f	f
6725383	826283	RxNorm:10627	{"MT-RNR1": "Weak or no evidence for an increased risk of MT-RNR1 associated hearing loss if administered an aminoglycoside antibiotic."}	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	Optional	{"MT-RNR1": "uncertain risk of aminoglycoside-induced hearing loss"}	{}	{}	{"MT-RNR1": "uncertain risk of aminoglycoside-induced hearing loss"}	general	Individuals without MT-RNR1 aminoglycoside-induced hearing loss increased risk variants are still at risk of aminoglycoside-associated hearing loss, especially with high drug levels or prolonged courses.	1	f	f	f
6725384	826283	RxNorm:3328	{"MT-RNR1": "Very high risk of developing hearing loss if administered an aminoglycoside antibiotic."}	Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.	Strong	{"MT-RNR1": "increased risk of aminoglycoside-induced hearing loss"}	{}	{}	{"MT-RNR1": "increased risk of aminoglycoside-induced hearing loss"}	general	If no effective alternative to an aminoglycoside antibiotic is available, evaluate for hearing loss frequently during therapy and ensure that all appropriate precautions are utilized (e.g., lowest possible dose and duration, utilization of therapeutic drug monitoring, hydration, renal function monitoring).	1	f	f	f
6725385	826283	RxNorm:3328	{"MT-RNR1": "Normal risk of developing hearing loss if administered an aminoglycoside antibiotic."}	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	Strong	{"MT-RNR1": "normal risk of aminoglycoside-induced hearing loss"}	{}	{}	{"MT-RNR1": "normal risk of aminoglycoside-induced hearing loss"}	general	Individuals without MT-RNR1 aminoglycoside-induced hearing loss increased risk variants are still at risk of aminoglycoside-associated hearing loss, especially with high drug levels or prolonged courses.	1	f	f	f
6725386	826283	RxNorm:3328	{"MT-RNR1": "Weak or no evidence for an increased risk of MT-RNR1 associated hearing loss if administered an aminoglycoside antibiotic."}	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	Optional	{"MT-RNR1": "uncertain risk of aminoglycoside-induced hearing loss"}	{}	{}	{"MT-RNR1": "uncertain risk of aminoglycoside-induced hearing loss"}	general	Individuals without MT-RNR1 aminoglycoside-induced hearing loss increased risk variants are still at risk of aminoglycoside-associated hearing loss, especially with high drug levels or prolonged courses.	1	f	f	f
6725387	826283	RxNorm:7299	{"MT-RNR1": "Very high risk of developing hearing loss if administered an aminoglycoside antibiotic."}	Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.	Strong	{"MT-RNR1": "increased risk of aminoglycoside-induced hearing loss"}	{}	{}	{"MT-RNR1": "increased risk of aminoglycoside-induced hearing loss"}	general	If no effective alternative to an aminoglycoside antibiotic is available, evaluate for hearing loss frequently during therapy and ensure that all appropriate precautions are utilized (e.g., lowest possible dose and duration, utilization of therapeutic drug monitoring, hydration, renal function monitoring).	1	f	f	f
6725388	826283	RxNorm:7299	{"MT-RNR1": "Normal risk of developing hearing loss if administered an aminoglycoside antibiotic."}	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	Strong	{"MT-RNR1": "normal risk of aminoglycoside-induced hearing loss"}	{}	{}	{"MT-RNR1": "normal risk of aminoglycoside-induced hearing loss"}	general	Individuals without MT-RNR1 aminoglycoside-induced hearing loss increased risk variants are still at risk of aminoglycoside-associated hearing loss, especially with high drug levels or prolonged courses.	1	f	f	f
6725389	826283	RxNorm:7299	{"MT-RNR1": "Weak or no evidence for an increased risk of MT-RNR1 associated hearing loss if administered an aminoglycoside antibiotic."}	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	Optional	{"MT-RNR1": "uncertain risk of aminoglycoside-induced hearing loss"}	{}	{}	{"MT-RNR1": "uncertain risk of aminoglycoside-induced hearing loss"}	general	Individuals without MT-RNR1 aminoglycoside-induced hearing loss increased risk variants are still at risk of aminoglycoside-associated hearing loss, especially with high drug levels or prolonged courses.	1	f	f	f
6725390	826283	RxNorm:7337	{"MT-RNR1": "Very high risk of developing hearing loss if administered an aminoglycoside antibiotic."}	Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.	Strong	{"MT-RNR1": "increased risk of aminoglycoside-induced hearing loss"}	{}	{}	{"MT-RNR1": "increased risk of aminoglycoside-induced hearing loss"}	general	If no effective alternative to an aminoglycoside antibiotic is available, evaluate for hearing loss frequently during therapy and ensure that all appropriate precautions are utilized (e.g., lowest possible dose and duration, utilization of therapeutic drug monitoring, hydration, renal function monitoring).	1	f	f	f
6725391	826283	RxNorm:7337	{"MT-RNR1": "Normal risk of developing hearing loss if administered an aminoglycoside antibiotic."}	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	Strong	{"MT-RNR1": "normal risk of aminoglycoside-induced hearing loss"}	{}	{}	{"MT-RNR1": "normal risk of aminoglycoside-induced hearing loss"}	general	Individuals without MT-RNR1 aminoglycoside-induced hearing loss increased risk variants are still at risk of aminoglycoside-associated hearing loss, especially with high drug levels or prolonged courses.	1	f	f	f
6725407	2405438	RxNorm:3445	{"G6PD": "Low-to-no risk of acute hemolytic anemia"}	No reason to avoid based on G6PD status at standard doses	Optional	{"G6PD": "Deficient"}	{}	{}	{"G6PD": "Deficient"}	general	Closer monitoring may be indicated higher-than-normal dosages, and in the setting of infection or other oxidative stress including concomitant use of multiple medium and low-to-no risk drugs.	1	f	f	f
6725392	826283	RxNorm:7337	{"MT-RNR1": "Weak or no evidence for an increased risk of MT-RNR1 associated hearing loss if administered an aminoglycoside antibiotic."}	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	Optional	{"MT-RNR1": "uncertain risk of aminoglycoside-induced hearing loss"}	{}	{}	{"MT-RNR1": "uncertain risk of aminoglycoside-induced hearing loss"}	general	Individuals without MT-RNR1 aminoglycoside-induced hearing loss increased risk variants are still at risk of aminoglycoside-associated hearing loss, especially with high drug levels or prolonged courses.	1	f	f	f
6725393	826283	RxNorm:NA	{"MT-RNR1": "Very high risk of developing hearing loss if administered an aminoglycoside antibiotic."}	Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.	Strong	{"MT-RNR1": "increased risk of aminoglycoside-induced hearing loss"}	{}	{}	{"MT-RNR1": "increased risk of aminoglycoside-induced hearing loss"}	general	If no effective alternative to an aminoglycoside antibiotic is available, evaluate for hearing loss frequently during therapy and ensure that all appropriate precautions are utilized (e.g., lowest possible dose and duration, utilization of therapeutic drug monitoring, hydration, renal function monitoring).	1	f	f	f
6725394	826283	RxNorm:NA	{"MT-RNR1": "Normal risk of developing hearing loss if administered an aminoglycoside antibiotic."}	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	Strong	{"MT-RNR1": "normal risk of aminoglycoside-induced hearing loss"}	{}	{}	{"MT-RNR1": "normal risk of aminoglycoside-induced hearing loss"}	general	Individuals without MT-RNR1 aminoglycoside-induced hearing loss increased risk variants are still at risk of aminoglycoside-associated hearing loss, especially with high drug levels or prolonged courses.	1	f	f	f
6725395	826283	RxNorm:NA	{"MT-RNR1": "Weak or no evidence for an increased risk of MT-RNR1 associated hearing loss if administered an aminoglycoside antibiotic."}	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	Optional	{"MT-RNR1": "uncertain risk of aminoglycoside-induced hearing loss"}	{}	{}	{"MT-RNR1": "uncertain risk of aminoglycoside-induced hearing loss"}	general	Individuals without MT-RNR1 aminoglycoside-induced hearing loss increased risk variants are still at risk of aminoglycoside-associated hearing loss, especially with high drug levels or prolonged courses.	1	f	f	f
6725396	2405438	RxNorm:7833	{"G6PD": "Low-to-no risk of acute hemolytic anemia"}	No reason to avoid based on G6PD status	Strong	{"G6PD": "Normal"}	{}	{}	{"G6PD": "Normal"}	general	\N	1	f	f	f
6725397	2405438	RxNorm:7833	{"G6PD": "Low-to-no risk of acute hemolytic anemia"}	No reason to avoid based on G6PD status at standard doses	Optional	{"G6PD": "Deficient"}	{}	{}	{"G6PD": "Deficient"}	general	Closer monitoring may be indicated higher-than-normal dosages, and in the setting of infection or other oxidative stress including concomitant use of multiple medium and low-to-no risk drugs.	1	f	f	f
6725398	2405438	RxNorm:7833	{"G6PD": "High risk of acute exacerbation of chronic hemolysis"}	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	Optional	{"G6PD": "Deficient with CNSHA"}	{}	{}	{"G6PD": "Deficient with CNSHA"}	general	There are insufficient data in patients with the G6PD Deficient with CNSHA phenotype, but the risk of using any drug should be weighed carefully against the benefits in these rare patients due to the underlying pathophysiology that confers high risk for acute exacerbation of chronic hemolysis.	1	f	f	f
6725399	2405438	RxNorm:7833	{"G6PD": "Low-to-no risk of acute hemolytic anemia"}	No reason to avoid based on G6PD status at standard doses	Moderate	{"G6PD": "Variable"}	{}	{}	{"G6PD": "Variable"}	general	Due to X-linked mosaicism, individuals with more than one X chromosome (e.g., females, individuals with Klinefelter syndrome) and heterozygous for one non-deficient (class IV) and one deficient (class I–III) allele may display a normal or a deficient phenotype.	1	f	f	f
6725400	2405438	RxNorm:7833	{"G6PD": "Unknown risk of acute hemolytic anemia"}	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	Moderate	{"G6PD": "Indeterminate"}	{}	{}	{"G6PD": "Indeterminate"}	general	\N	1	f	f	f
6725401	2405438	RxNorm:2551	{"G6PD": "Low-to-no risk of acute hemolytic anemia"}	No reason to avoid based on G6PD status	Strong	{"G6PD": "Normal"}	{}	{}	{"G6PD": "Normal"}	general	\N	1	f	f	f
6725402	2405438	RxNorm:2551	{"G6PD": "Low-to-no risk of acute hemolytic anemia"}	No reason to avoid based on G6PD status at standard doses	Optional	{"G6PD": "Deficient"}	{}	{}	{"G6PD": "Deficient"}	general	Closer monitoring may be indicated higher-than-normal dosages, and in the setting of infection or other oxidative stress including concomitant use of multiple medium and low-to-no risk drugs.	1	f	f	f
6725403	2405438	RxNorm:2551	{"G6PD": "High risk of acute exacerbation of chronic hemolysis"}	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	Optional	{"G6PD": "Deficient with CNSHA"}	{}	{}	{"G6PD": "Deficient with CNSHA"}	general	There are insufficient data in patients with the G6PD Deficient with CNSHA phenotype, but the risk of using any drug should be weighed carefully against the benefits in these rare patients due to the underlying pathophysiology that confers high risk for acute exacerbation of chronic hemolysis.	1	f	f	f
6725404	2405438	RxNorm:2551	{"G6PD": "Low-to-no risk of acute hemolytic anemia"}	No reason to avoid based on G6PD status at standard doses	Moderate	{"G6PD": "Variable"}	{}	{}	{"G6PD": "Variable"}	general	Due to X-linked mosaicism, individuals with more than one X chromosome (e.g., females, individuals with Klinefelter syndrome) and heterozygous for one non-deficient (class IV) and one deficient (class I–III) allele may display a normal or a deficient phenotype.	1	f	f	f
6725405	2405438	RxNorm:2551	{"G6PD": "Unknown risk of acute hemolytic anemia"}	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	Moderate	{"G6PD": "Indeterminate"}	{}	{}	{"G6PD": "Indeterminate"}	general	\N	1	f	f	f
6725406	2405438	RxNorm:3445	{"G6PD": "Low-to-no risk of acute hemolytic anemia"}	No reason to avoid based on G6PD status	Strong	{"G6PD": "Normal"}	{}	{}	{"G6PD": "Normal"}	general	\N	1	f	f	f
6725426	2405438	RxNorm:6572	{"G6PD": "Low-to-no risk of acute hemolytic anemia"}	No reason to avoid based on G6PD status	Strong	{"G6PD": "Normal"}	{}	{}	{"G6PD": "Normal"}	general	\N	1	f	f	f
6725408	2405438	RxNorm:3445	{"G6PD": "High risk of acute exacerbation of chronic hemolysis"}	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	Optional	{"G6PD": "Deficient with CNSHA"}	{}	{}	{"G6PD": "Deficient with CNSHA"}	general	There are insufficient data in patients with the G6PD Deficient with CNSHA phenotype, but the risk of using any drug should be weighed carefully against the benefits in these rare patients due to the underlying pathophysiology that confers high risk for acute exacerbation of chronic hemolysis.	1	f	f	f
6725409	2405438	RxNorm:3445	{"G6PD": "Low-to-no risk of acute hemolytic anemia"}	No reason to avoid based on G6PD status at standard doses	Moderate	{"G6PD": "Variable"}	{}	{}	{"G6PD": "Variable"}	general	Due to X-linked mosaicism, individuals with more than one X chromosome (e.g., females, individuals with Klinefelter syndrome) and heterozygous for one non-deficient (class IV) and one deficient (class I–III) allele may display a normal or a deficient phenotype.	1	f	f	f
6725410	2405438	RxNorm:3445	{"G6PD": "Unknown risk of acute hemolytic anemia"}	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	Moderate	{"G6PD": "Indeterminate"}	{}	{}	{"G6PD": "Indeterminate"}	general	\N	1	f	f	f
6725411	2405438	RxNorm:3639	{"G6PD": "Low-to-no risk of acute hemolytic anemia"}	No reason to avoid based on G6PD status	Strong	{"G6PD": "Normal"}	{}	{}	{"G6PD": "Normal"}	general	\N	1	f	f	f
6725412	2405438	RxNorm:3639	{"G6PD": "Low-to-no risk of acute hemolytic anemia"}	No reason to avoid based on G6PD status at standard doses	Optional	{"G6PD": "Deficient"}	{}	{}	{"G6PD": "Deficient"}	general	Closer monitoring may be indicated higher-than-normal dosages, and in the setting of infection or other oxidative stress including concomitant use of multiple medium and low-to-no risk drugs.	1	f	f	f
6725413	2405438	RxNorm:3639	{"G6PD": "High risk of acute exacerbation of chronic hemolysis"}	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	Optional	{"G6PD": "Deficient with CNSHA"}	{}	{}	{"G6PD": "Deficient with CNSHA"}	general	There are insufficient data in patients with the G6PD Deficient with CNSHA phenotype, but the risk of using any drug should be weighed carefully against the benefits in these rare patients due to the underlying pathophysiology that confers high risk for acute exacerbation of chronic hemolysis.	1	f	f	f
6725414	2405438	RxNorm:3639	{"G6PD": "Low-to-no risk of acute hemolytic anemia"}	No reason to avoid based on G6PD status at standard doses	Moderate	{"G6PD": "Variable"}	{}	{}	{"G6PD": "Variable"}	general	Due to X-linked mosaicism, individuals with more than one X chromosome (e.g., females, individuals with Klinefelter syndrome) and heterozygous for one non-deficient (class IV) and one deficient (class I–III) allele may display a normal or a deficient phenotype.	1	f	f	f
6725415	2405438	RxNorm:3639	{"G6PD": "Unknown risk of acute hemolytic anemia"}	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	Moderate	{"G6PD": "Indeterminate"}	{}	{}	{"G6PD": "Indeterminate"}	general	\N	1	f	f	f
6725416	2405438	RxNorm:4601	{"G6PD": "Low-to-no risk of acute hemolytic anemia"}	No reason to avoid based on G6PD status	Strong	{"G6PD": "Normal"}	{}	{}	{"G6PD": "Normal"}	general	\N	1	f	f	f
6725417	2405438	RxNorm:4601	{"G6PD": "Low-to-no risk of acute hemolytic anemia"}	No reason to avoid based on G6PD status at standard doses	Optional	{"G6PD": "Deficient"}	{}	{}	{"G6PD": "Deficient"}	general	Closer monitoring may be indicated higher-than-normal dosages, and in the setting of infection or other oxidative stress including concomitant use of multiple medium and low-to-no risk drugs.	1	f	f	f
6725418	2405438	RxNorm:4601	{"G6PD": "High risk of acute exacerbation of chronic hemolysis"}	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	Optional	{"G6PD": "Deficient with CNSHA"}	{}	{}	{"G6PD": "Deficient with CNSHA"}	general	There are insufficient data in patients with the G6PD Deficient with CNSHA phenotype, but the risk of using any drug should be weighed carefully against the benefits in these rare patients due to the underlying pathophysiology that confers high risk for acute exacerbation of chronic hemolysis.	1	f	f	f
6725419	2405438	RxNorm:4601	{"G6PD": "Low-to-no risk of acute hemolytic anemia"}	No reason to avoid based on G6PD status at standard doses	Moderate	{"G6PD": "Variable"}	{}	{}	{"G6PD": "Variable"}	general	Due to X-linked mosaicism, individuals with more than one X chromosome (e.g., females, individuals with Klinefelter syndrome) and heterozygous for one non-deficient (class IV) and one deficient (class I–III) allele may display a normal or a deficient phenotype.	1	f	f	f
6725420	2405438	RxNorm:4601	{"G6PD": "Unknown risk of acute hemolytic anemia"}	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	Moderate	{"G6PD": "Indeterminate"}	{}	{}	{"G6PD": "Indeterminate"}	general	\N	1	f	f	f
6725421	2405438	RxNorm:4815	{"G6PD": "Low-to-no risk of acute hemolytic anemia"}	No reason to avoid based on G6PD status	Strong	{"G6PD": "Normal"}	{}	{}	{"G6PD": "Normal"}	general	\N	1	f	f	f
6725422	2405438	RxNorm:4815	{"G6PD": "Low-to-no risk of acute hemolytic anemia"}	No reason to avoid based on G6PD status at standard doses	Optional	{"G6PD": "Deficient"}	{}	{}	{"G6PD": "Deficient"}	general	Closer monitoring may be indicated higher-than-normal dosages, and in the setting of infection or other oxidative stress including concomitant use of multiple medium and low-to-no risk drugs.	1	f	f	f
6725423	2405438	RxNorm:4815	{"G6PD": "High risk of acute exacerbation of chronic hemolysis"}	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	Optional	{"G6PD": "Deficient with CNSHA"}	{}	{}	{"G6PD": "Deficient with CNSHA"}	general	There are insufficient data in patients with the G6PD Deficient with CNSHA phenotype, but the risk of using any drug should be weighed carefully against the benefits in these rare patients due to the underlying pathophysiology that confers high risk for acute exacerbation of chronic hemolysis.	1	f	f	f
6725424	2405438	RxNorm:4815	{"G6PD": "Low-to-no risk of acute hemolytic anemia"}	No reason to avoid based on G6PD status at standard doses	Moderate	{"G6PD": "Variable"}	{}	{}	{"G6PD": "Variable"}	general	Due to X-linked mosaicism, individuals with more than one X chromosome (e.g., females, individuals with Klinefelter syndrome) and heterozygous for one non-deficient (class IV) and one deficient (class I–III) allele may display a normal or a deficient phenotype.	1	f	f	f
6725425	2405438	RxNorm:4815	{"G6PD": "Unknown risk of acute hemolytic anemia"}	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	Moderate	{"G6PD": "Indeterminate"}	{}	{}	{"G6PD": "Indeterminate"}	general	\N	1	f	f	f
6725427	2405438	RxNorm:6572	{"G6PD": "Low-to-no risk of acute hemolytic anemia"}	No reason to avoid based on G6PD status at standard doses	Optional	{"G6PD": "Deficient"}	{}	{}	{"G6PD": "Deficient"}	general	Closer monitoring may be indicated higher-than-normal dosages, and in the setting of infection or other oxidative stress including concomitant use of multiple medium and low-to-no risk drugs.	1	f	f	f
6725428	2405438	RxNorm:6572	{"G6PD": "High risk of acute exacerbation of chronic hemolysis"}	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	Optional	{"G6PD": "Deficient with CNSHA"}	{}	{}	{"G6PD": "Deficient with CNSHA"}	general	There are insufficient data in patients with the G6PD Deficient with CNSHA phenotype, but the risk of using any drug should be weighed carefully against the benefits in these rare patients due to the underlying pathophysiology that confers high risk for acute exacerbation of chronic hemolysis.	1	f	f	f
6725429	2405438	RxNorm:6572	{"G6PD": "Low-to-no risk of acute hemolytic anemia"}	No reason to avoid based on G6PD status at standard doses	Moderate	{"G6PD": "Variable"}	{}	{}	{"G6PD": "Variable"}	general	Due to X-linked mosaicism, individuals with more than one X chromosome (e.g., females, individuals with Klinefelter syndrome) and heterozygous for one non-deficient (class IV) and one deficient (class I–III) allele may display a normal or a deficient phenotype.	1	f	f	f
6725430	2405438	RxNorm:6572	{"G6PD": "Unknown risk of acute hemolytic anemia"}	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	Moderate	{"G6PD": "Indeterminate"}	{}	{}	{"G6PD": "Indeterminate"}	general	\N	1	f	f	f
6725431	2405438	RxNorm:7240	{"G6PD": "Low-to-no risk of acute hemolytic anemia"}	No reason to avoid based on G6PD status	Strong	{"G6PD": "Normal"}	{}	{}	{"G6PD": "Normal"}	general	\N	1	f	f	f
6725432	2405438	RxNorm:7240	{"G6PD": "Low-to-no risk of acute hemolytic anemia"}	No reason to avoid based on G6PD status at standard doses	Optional	{"G6PD": "Deficient"}	{}	{}	{"G6PD": "Deficient"}	general	Closer monitoring may be indicated higher-than-normal dosages, and in the setting of infection or other oxidative stress including concomitant use of multiple medium and low-to-no risk drugs.	1	f	f	f
6725433	2405438	RxNorm:7240	{"G6PD": "High risk of acute exacerbation of chronic hemolysis"}	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	Optional	{"G6PD": "Deficient with CNSHA"}	{}	{}	{"G6PD": "Deficient with CNSHA"}	general	There are insufficient data in patients with the G6PD Deficient with CNSHA phenotype, but the risk of using any drug should be weighed carefully against the benefits in these rare patients due to the underlying pathophysiology that confers high risk for acute exacerbation of chronic hemolysis.	1	f	f	f
6725434	2405438	RxNorm:7240	{"G6PD": "Low-to-no risk of acute hemolytic anemia"}	No reason to avoid based on G6PD status at standard doses	Moderate	{"G6PD": "Variable"}	{}	{}	{"G6PD": "Variable"}	general	Due to X-linked mosaicism, individuals with more than one X chromosome (e.g., females, individuals with Klinefelter syndrome) and heterozygous for one non-deficient (class IV) and one deficient (class I–III) allele may display a normal or a deficient phenotype.	1	f	f	f
6725435	2405438	RxNorm:7240	{"G6PD": "Unknown risk of acute hemolytic anemia"}	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	Moderate	{"G6PD": "Indeterminate"}	{}	{}	{"G6PD": "Indeterminate"}	general	\N	1	f	f	f
6725436	2405438	RxNorm:7517	{"G6PD": "Low-to-no risk of acute hemolytic anemia"}	No reason to avoid based on G6PD status	Strong	{"G6PD": "Normal"}	{}	{}	{"G6PD": "Normal"}	general	\N	1	f	f	f
6725437	2405438	RxNorm:7517	{"G6PD": "Low-to-no risk of acute hemolytic anemia"}	No reason to avoid based on G6PD status at standard doses	Optional	{"G6PD": "Deficient"}	{}	{}	{"G6PD": "Deficient"}	general	Closer monitoring may be indicated higher-than-normal dosages, and in the setting of infection or other oxidative stress including concomitant use of multiple medium and low-to-no risk drugs.	1	f	f	f
6725438	2405438	RxNorm:7517	{"G6PD": "High risk of acute exacerbation of chronic hemolysis"}	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	Optional	{"G6PD": "Deficient with CNSHA"}	{}	{}	{"G6PD": "Deficient with CNSHA"}	general	There are insufficient data in patients with the G6PD Deficient with CNSHA phenotype, but the risk of using any drug should be weighed carefully against the benefits in these rare patients due to the underlying pathophysiology that confers high risk for acute exacerbation of chronic hemolysis.	1	f	f	f
6725439	2405438	RxNorm:7517	{"G6PD": "Low-to-no risk of acute hemolytic anemia"}	No reason to avoid based on G6PD status at standard doses	Moderate	{"G6PD": "Variable"}	{}	{}	{"G6PD": "Variable"}	general	Due to X-linked mosaicism, individuals with more than one X chromosome (e.g., females, individuals with Klinefelter syndrome) and heterozygous for one non-deficient (class IV) and one deficient (class I–III) allele may display a normal or a deficient phenotype.	1	f	f	f
6725440	2405438	RxNorm:7517	{"G6PD": "Unknown risk of acute hemolytic anemia"}	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	Moderate	{"G6PD": "Indeterminate"}	{}	{}	{"G6PD": "Indeterminate"}	general	\N	1	f	f	f
6725441	2405438	RxNorm:7623	{"G6PD": "Low-to-no risk of acute hemolytic anemia"}	No reason to avoid based on G6PD status	Strong	{"G6PD": "Normal"}	{}	{}	{"G6PD": "Normal"}	general	\N	1	f	f	f
6725442	2405438	RxNorm:7623	{"G6PD": "Low-to-no risk of acute hemolytic anemia"}	No reason to avoid based on G6PD status at standard doses	Optional	{"G6PD": "Deficient"}	{}	{}	{"G6PD": "Deficient"}	general	Closer monitoring may be indicated higher-than-normal dosages, and in the setting of infection or other oxidative stress including concomitant use of multiple medium and low-to-no risk drugs.	1	f	f	f
6725443	2405438	RxNorm:7623	{"G6PD": "High risk of acute exacerbation of chronic hemolysis"}	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	Optional	{"G6PD": "Deficient with CNSHA"}	{}	{}	{"G6PD": "Deficient with CNSHA"}	general	There are insufficient data in patients with the G6PD Deficient with CNSHA phenotype, but the risk of using any drug should be weighed carefully against the benefits in these rare patients due to the underlying pathophysiology that confers high risk for acute exacerbation of chronic hemolysis.	1	f	f	f
6726466	100413	RxNorm:42355	{"CYP2D6": "Reduced metabolism of fluvoxamine to less active compounds when compared to CYP2D6 normal metabolizers. Higher plasma concentrations may increase the probability of side effects."}	Initiate therapy with recommended starting dose.	Moderate	{"CYP2D6": "Intermediate Metabolizer"}	{"CYP2D6": "0.5"}	{}	{"CYP2D6": "0.5"}	general	n/a	1	f	f	f
6725444	2405438	RxNorm:7623	{"G6PD": "Low-to-no risk of acute hemolytic anemia"}	No reason to avoid based on G6PD status at standard doses	Moderate	{"G6PD": "Variable"}	{}	{}	{"G6PD": "Variable"}	general	Due to X-linked mosaicism, individuals with more than one X chromosome (e.g., females, individuals with Klinefelter syndrome) and heterozygous for one non-deficient (class IV) and one deficient (class I–III) allele may display a normal or a deficient phenotype.	1	f	f	f
6725445	2405438	RxNorm:7623	{"G6PD": "Unknown risk of acute hemolytic anemia"}	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	Moderate	{"G6PD": "Indeterminate"}	{}	{}	{"G6PD": "Indeterminate"}	general	\N	1	f	f	f
6725446	100414	RxNorm:704	{"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}	Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "0.25", "CYP2C19": "n/a"}	{}	{"CYP2D6": "0.25", "CYP2C19": "Intermediate Metabolizer"}	general	Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.	1	f	f	f
6725447	100414	RxNorm:704	{"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}	Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "0.5", "CYP2C19": "n/a"}	{}	{"CYP2D6": "0.5", "CYP2C19": "Intermediate Metabolizer"}	general	Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.	1	f	f	f
6725448	100414	RxNorm:704	{"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}	Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "0.75", "CYP2C19": "n/a"}	{}	{"CYP2D6": "0.75", "CYP2C19": "Intermediate Metabolizer"}	general	Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.	1	f	f	f
6725449	100414	RxNorm:704	{"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}	Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "1.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "1.0", "CYP2C19": "Intermediate Metabolizer"}	general	Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.	1	f	f	f
6725450	100414	RxNorm:704	{"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}	Initiate therapy with recommended starting dose.	Strong	{"CYP2D6": "Normal Metabolizer", "CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "1.25", "CYP2C19": "n/a"}	{}	{"CYP2D6": "1.25", "CYP2C19": "Intermediate Metabolizer"}	general	Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.	1	f	f	f
6725451	100414	RxNorm:704	{"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}	Initiate therapy with recommended starting dose.	Strong	{"CYP2D6": "Normal Metabolizer", "CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "1.5", "CYP2C19": "n/a"}	{}	{"CYP2D6": "1.5", "CYP2C19": "Intermediate Metabolizer"}	general	Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.	1	f	f	f
6726893	2405438	RxNorm:8120	{"G6PD": "Unknown risk of acute hemolytic anemia"}	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	Moderate	{"G6PD": "Indeterminate"}	{}	{}	{"G6PD": "Indeterminate"}	general	\N	1	f	f	f
6725452	100414	RxNorm:704	{"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}	Initiate therapy with recommended starting dose.	Strong	{"CYP2D6": "Normal Metabolizer", "CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "2.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "2.0", "CYP2C19": "Intermediate Metabolizer"}	general	Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.	1	f	f	f
6725453	100414	RxNorm:704	{"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}	Initiate therapy with recommended starting dose.	Strong	{"CYP2D6": "Normal Metabolizer", "CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "2.25", "CYP2C19": "n/a"}	{}	{"CYP2D6": "2.25", "CYP2C19": "Intermediate Metabolizer"}	general	Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.	1	f	f	f
6725454	100414	RxNorm:704	{"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}	Initiate therapy with recommended starting dose.	Strong	{"CYP2D6": "Normal Metabolizer", "CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "1.75", "CYP2C19": "n/a"}	{}	{"CYP2D6": "1.75", "CYP2C19": "Intermediate Metabolizer"}	general	Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.	1	f	f	f
6725455	100414	RxNorm:704	{"CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}	Avoid amitriptyline use. If a amitripyline is warranted, consider a 50% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Poor Metabolizer", "CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "0.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "0.0", "CYP2C19": "Intermediate Metabolizer"}	general	Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.	1	f	f	f
6725456	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "2.5", "CYP2C19": "n/a"}	{}	{"CYP2D6": "2.5", "CYP2C19": "Intermediate Metabolizer"}	general	Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.	1	f	f	f
6725457	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "3.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "3.0", "CYP2C19": "Intermediate Metabolizer"}	general	Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.	1	f	f	f
6725458	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "2.75", "CYP2C19": "n/a"}	{}	{"CYP2D6": "2.75", "CYP2C19": "Intermediate Metabolizer"}	general	Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.	1	f	f	f
6725459	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "4.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "4.0", "CYP2C19": "Intermediate Metabolizer"}	general	Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.	1	f	f	f
6725488	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Normal metabolism of tertiary amines"}	Avoid amitriptyline use; If amitriptyline is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.	Strong	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "≥5.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "≥5.0", "CYP2C19": "Normal Metabolizer"}	general	n/a	1	f	f	f
6725460	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "≥3.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "≥3.0", "CYP2C19": "Intermediate Metabolizer"}	general	Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.	1	f	f	f
6725461	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "≥3.25", "CYP2C19": "n/a"}	{}	{"CYP2D6": "≥3.25", "CYP2C19": "Intermediate Metabolizer"}	general	Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.	1	f	f	f
6725462	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "≥3.5", "CYP2C19": "n/a"}	{}	{"CYP2D6": "≥3.5", "CYP2C19": "Intermediate Metabolizer"}	general	Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.	1	f	f	f
6725463	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "≥4.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "≥4.0", "CYP2C19": "Intermediate Metabolizer"}	general	Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.	1	f	f	f
6725464	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "≥3.75", "CYP2C19": "n/a"}	{}	{"CYP2D6": "≥3.75", "CYP2C19": "Intermediate Metabolizer"}	general	Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.	1	f	f	f
6725465	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "≥5.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "≥5.0", "CYP2C19": "Intermediate Metabolizer"}	general	Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.	1	f	f	f
6725466	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "≥6.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "≥6.0", "CYP2C19": "Intermediate Metabolizer"}	general	Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.	1	f	f	f
6725467	100414	RxNorm:704	{"CYP2D6": "n/a", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}	No recommendation	No Recommendation	{"CYP2D6": "Indeterminate", "CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "n/a", "CYP2C19": "n/a"}	{}	{"CYP2D6": "n/a", "CYP2C19": "Intermediate Metabolizer"}	general	n/a	1	f	f	f
6725468	100414	RxNorm:704	{"CYP2D6": "n/a", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}	Initiate therapy with recommended starting dose.	Strong	{"CYP2D6": "No Result", "CYP2C19": "Intermediate Metabolizer"}	{"CYP2D6": "No Result", "CYP2C19": "n/a"}	{}	{"CYP2D6": "No Result", "CYP2C19": "Intermediate Metabolizer"}	general	Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.	1	f	f	f
6725469	100414	RxNorm:704	{"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Normal metabolism of tertiary amines"}	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	Moderate	{"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "0.25", "CYP2C19": "n/a"}	{}	{"CYP2D6": "0.25", "CYP2C19": "Normal Metabolizer"}	general	Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.	1	f	f	f
6725470	100414	RxNorm:704	{"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Normal metabolism of tertiary amines"}	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	Moderate	{"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "0.5", "CYP2C19": "n/a"}	{}	{"CYP2D6": "0.5", "CYP2C19": "Normal Metabolizer"}	general	Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.	1	f	f	f
6725471	100414	RxNorm:704	{"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Normal metabolism of tertiary amines"}	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	Moderate	{"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "0.75", "CYP2C19": "n/a"}	{}	{"CYP2D6": "0.75", "CYP2C19": "Normal Metabolizer"}	general	Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.	1	f	f	f
6725472	100414	RxNorm:704	{"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Normal metabolism of tertiary amines"}	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	Moderate	{"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "1.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "1.0", "CYP2C19": "Normal Metabolizer"}	general	Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.	1	f	f	f
6725473	100414	RxNorm:704	{"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Normal metabolism of tertiary amines"}	Initiate therapy with recommended starting dose.	Strong	{"CYP2D6": "Normal Metabolizer", "CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "1.25", "CYP2C19": "n/a"}	{}	{"CYP2D6": "1.25", "CYP2C19": "Normal Metabolizer"}	general	Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.	1	f	f	f
6725474	100414	RxNorm:704	{"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Normal metabolism of tertiary amines"}	Initiate therapy with recommended starting dose.	Strong	{"CYP2D6": "Normal Metabolizer", "CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "1.5", "CYP2C19": "n/a"}	{}	{"CYP2D6": "1.5", "CYP2C19": "Normal Metabolizer"}	general	Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.	1	f	f	f
6725475	100414	RxNorm:704	{"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Normal metabolism of tertiary amines"}	Initiate therapy with recommended starting dose.	Strong	{"CYP2D6": "Normal Metabolizer", "CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "2.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "2.0", "CYP2C19": "Normal Metabolizer"}	general	Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.	1	f	f	f
6725476	100414	RxNorm:704	{"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Normal metabolism of tertiary amines"}	Initiate therapy with recommended starting dose.	Strong	{"CYP2D6": "Normal Metabolizer", "CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "2.25", "CYP2C19": "n/a"}	{}	{"CYP2D6": "2.25", "CYP2C19": "Normal Metabolizer"}	general	Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.	1	f	f	f
6725477	100414	RxNorm:704	{"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Normal metabolism of tertiary amines"}	Initiate therapy with recommended starting dose.	Strong	{"CYP2D6": "Normal Metabolizer", "CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "1.75", "CYP2C19": "n/a"}	{}	{"CYP2D6": "1.75", "CYP2C19": "Normal Metabolizer"}	general	Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.	1	f	f	f
6725489	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Normal metabolism of tertiary amines"}	Avoid amitriptyline use; If amitriptyline is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.	Strong	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "≥6.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "≥6.0", "CYP2C19": "Normal Metabolizer"}	general	n/a	1	f	f	f
6725478	100414	RxNorm:704	{"CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Normal metabolism of tertiary amines"}	Avoid amitriptyline use. If a amitripyline is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	Strong	{"CYP2D6": "Poor Metabolizer", "CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "0.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "0.0", "CYP2C19": "Normal Metabolizer"}	general	Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.	1	f	f	f
6725479	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Normal metabolism of tertiary amines"}	Avoid amitriptyline use; If amitriptyline is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.	Strong	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "2.5", "CYP2C19": "n/a"}	{}	{"CYP2D6": "2.5", "CYP2C19": "Normal Metabolizer"}	general	n/a	1	f	f	f
6725480	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Normal metabolism of tertiary amines"}	Avoid amitriptyline use; If amitriptyline is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.	Strong	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "3.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "3.0", "CYP2C19": "Normal Metabolizer"}	general	n/a	1	f	f	f
6725481	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Normal metabolism of tertiary amines"}	Avoid amitriptyline use; If amitriptyline is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.	Strong	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "2.75", "CYP2C19": "n/a"}	{}	{"CYP2D6": "2.75", "CYP2C19": "Normal Metabolizer"}	general	n/a	1	f	f	f
6725482	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Normal metabolism of tertiary amines"}	Avoid amitriptyline use; If amitriptyline is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.	Strong	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "4.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "4.0", "CYP2C19": "Normal Metabolizer"}	general	n/a	1	f	f	f
6725483	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Normal metabolism of tertiary amines"}	Avoid amitriptyline use; If amitriptyline is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.	Strong	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "≥3.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "≥3.0", "CYP2C19": "Normal Metabolizer"}	general	n/a	1	f	f	f
6725484	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Normal metabolism of tertiary amines"}	Avoid amitriptyline use; If amitriptyline is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.	Strong	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "≥3.25", "CYP2C19": "n/a"}	{}	{"CYP2D6": "≥3.25", "CYP2C19": "Normal Metabolizer"}	general	n/a	1	f	f	f
6725485	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Normal metabolism of tertiary amines"}	Avoid amitriptyline use; If amitriptyline is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.	Strong	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "≥3.5", "CYP2C19": "n/a"}	{}	{"CYP2D6": "≥3.5", "CYP2C19": "Normal Metabolizer"}	general	n/a	1	f	f	f
6725486	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Normal metabolism of tertiary amines"}	Avoid amitriptyline use; If amitriptyline is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.	Strong	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "≥4.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "≥4.0", "CYP2C19": "Normal Metabolizer"}	general	n/a	1	f	f	f
6725487	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Normal metabolism of tertiary amines"}	Avoid amitriptyline use; If amitriptyline is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.	Strong	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "≥3.75", "CYP2C19": "n/a"}	{}	{"CYP2D6": "≥3.75", "CYP2C19": "Normal Metabolizer"}	general	n/a	1	f	f	f
6725490	100414	RxNorm:704	{"CYP2D6": "n/a", "CYP2C19": "Normal metabolism of tertiary amines"}	No recommendation	No Recommendation	{"CYP2D6": "Indeterminate", "CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "n/a", "CYP2C19": "n/a"}	{}	{"CYP2D6": "n/a", "CYP2C19": "Normal Metabolizer"}	general	n/a	1	f	f	f
6726894	2405438	RxNorm:9071	{"G6PD": "Low-to-no risk of acute hemolytic anemia"}	No reason to avoid based on G6PD status	Strong	{"G6PD": "Normal"}	{}	{}	{"G6PD": "Normal"}	general	\N	1	f	f	f
6725491	100414	RxNorm:704	{"CYP2D6": "n/a", "CYP2C19": "Normal metabolism of tertiary amines"}	Initiate therapy with recommended starting dose.	Strong	{"CYP2D6": "No Result", "CYP2C19": "Normal Metabolizer"}	{"CYP2D6": "No Result", "CYP2C19": "n/a"}	{}	{"CYP2D6": "No Result", "CYP2C19": "Normal Metabolizer"}	general	Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.	1	f	f	f
6725492	100414	RxNorm:704	{"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "0.25", "CYP2C19": "n/a"}	{}	{"CYP2D6": "0.25", "CYP2C19": "Poor Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.	1	f	f	f
6725493	100414	RxNorm:704	{"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "0.5", "CYP2C19": "n/a"}	{}	{"CYP2D6": "0.5", "CYP2C19": "Poor Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.	1	f	f	f
6725494	100414	RxNorm:704	{"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "0.75", "CYP2C19": "n/a"}	{}	{"CYP2D6": "0.75", "CYP2C19": "Poor Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.	1	f	f	f
6725495	100414	RxNorm:704	{"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "1.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "1.0", "CYP2C19": "Poor Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.	1	f	f	f
6725571	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Strong	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Indeterminate"}	{"CYP2D6": "2.5", "CYP2C19": "n/a"}	{}	{"CYP2D6": "2.5", "CYP2C19": "Indeterminate"}	general	n/a	1	f	f	f
6725496	100414	RxNorm:704	{"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid amitriptyline use. If amitripyline is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	Moderate	{"CYP2D6": "Normal Metabolizer", "CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "1.25", "CYP2C19": "n/a"}	{}	{"CYP2D6": "1.25", "CYP2C19": "Poor Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.	1	f	f	f
6725497	100414	RxNorm:704	{"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid amitriptyline use. If amitripyline is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	Moderate	{"CYP2D6": "Normal Metabolizer", "CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "1.5", "CYP2C19": "n/a"}	{}	{"CYP2D6": "1.5", "CYP2C19": "Poor Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.	1	f	f	f
6725498	100414	RxNorm:704	{"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid amitriptyline use. If amitripyline is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	Moderate	{"CYP2D6": "Normal Metabolizer", "CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "2.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "2.0", "CYP2C19": "Poor Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.	1	f	f	f
6725499	100414	RxNorm:704	{"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid amitriptyline use. If amitripyline is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	Moderate	{"CYP2D6": "Normal Metabolizer", "CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "2.25", "CYP2C19": "n/a"}	{}	{"CYP2D6": "2.25", "CYP2C19": "Poor Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.	1	f	f	f
6725500	100414	RxNorm:704	{"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid amitriptyline use. If amitripyline is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	Moderate	{"CYP2D6": "Normal Metabolizer", "CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "1.75", "CYP2C19": "n/a"}	{}	{"CYP2D6": "1.75", "CYP2C19": "Poor Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\n for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.	1	f	f	f
6725501	100414	RxNorm:704	{"CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Poor Metabolizer", "CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "0.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "0.0", "CYP2C19": "Poor Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.	1	f	f	f
6725796	2405438	RxNorm:5521	{"G6PD": "High risk of acute exacerbation of chronic hemolysis"}	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	Optional	{"G6PD": "Deficient with CNSHA"}	{}	{}	{"G6PD": "Deficient with CNSHA"}	general	There are insufficient data in patients with the G6PD Deficient with CNSHA phenotype, but the risk of using any drug should be weighed carefully against the benefits in these rare patients due to the underlying pathophysiology that confers high risk for acute on chronic hemolysis	1	f	f	f
6725502	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "2.5", "CYP2C19": "n/a"}	{}	{"CYP2D6": "2.5", "CYP2C19": "Poor Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.	1	f	f	f
6725503	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "3.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "3.0", "CYP2C19": "Poor Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.	1	f	f	f
6725504	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "2.75", "CYP2C19": "n/a"}	{}	{"CYP2D6": "2.75", "CYP2C19": "Poor Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.	1	f	f	f
6725505	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "4.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "4.0", "CYP2C19": "Poor Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.	1	f	f	f
6725506	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "≥3.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "≥3.0", "CYP2C19": "Poor Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.	1	f	f	f
6725507	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "≥3.25", "CYP2C19": "n/a"}	{}	{"CYP2D6": "≥3.25", "CYP2C19": "Poor Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.	1	f	f	f
6725508	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "≥3.5", "CYP2C19": "n/a"}	{}	{"CYP2D6": "≥3.5", "CYP2C19": "Poor Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.	1	f	f	f
6725509	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "≥4.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "≥4.0", "CYP2C19": "Poor Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.	1	f	f	f
6725510	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "≥3.75", "CYP2C19": "n/a"}	{}	{"CYP2D6": "≥3.75", "CYP2C19": "Poor Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.	1	f	f	f
6725511	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "≥5.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "≥5.0", "CYP2C19": "Poor Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.	1	f	f	f
6725512	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "≥6.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "≥6.0", "CYP2C19": "Poor Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations \nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.	1	f	f	f
6725513	100414	RxNorm:704	{"CYP2D6": "n/a", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Moderate	{"CYP2D6": "Indeterminate", "CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "n/a", "CYP2C19": "n/a"}	{}	{"CYP2D6": "n/a", "CYP2C19": "Poor Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.	1	f	f	f
6725514	100414	RxNorm:704	{"CYP2D6": "n/a", "CYP2C19": "Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Moderate	{"CYP2D6": "No Result", "CYP2C19": "Poor Metabolizer"}	{"CYP2D6": "No Result", "CYP2C19": "n/a"}	{}	{"CYP2D6": "No Result", "CYP2C19": "Poor Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.	1	f	f	f
6725515	100414	RxNorm:704	{"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}	Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "0.25", "CYP2C19": "n/a"}	{}	{"CYP2D6": "0.25", "CYP2C19": "Rapid Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.	1	f	f	f
6725516	100414	RxNorm:704	{"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}	Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "0.5", "CYP2C19": "n/a"}	{}	{"CYP2D6": "0.5", "CYP2C19": "Rapid Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.	1	f	f	f
6725517	100414	RxNorm:704	{"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}	Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "0.75", "CYP2C19": "n/a"}	{}	{"CYP2D6": "0.75", "CYP2C19": "Rapid Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.	1	f	f	f
6725518	100414	RxNorm:704	{"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}	Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "1.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "1.0", "CYP2C19": "Rapid Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.	1	f	f	f
6725572	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Strong	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Indeterminate"}	{"CYP2D6": "3.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "3.0", "CYP2C19": "Indeterminate"}	general	n/a	1	f	f	f
6725519	100414	RxNorm:704	{"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}	Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment.	Optional	{"CYP2D6": "Normal Metabolizer", "CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "1.25", "CYP2C19": "n/a"}	{}	{"CYP2D6": "1.25", "CYP2C19": "Rapid Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.	1	f	f	f
6725520	100414	RxNorm:704	{"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}	Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment.	Optional	{"CYP2D6": "Normal Metabolizer", "CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "1.5", "CYP2C19": "n/a"}	{}	{"CYP2D6": "1.5", "CYP2C19": "Rapid Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.	1	f	f	f
6725521	100414	RxNorm:704	{"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}	Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment.	Optional	{"CYP2D6": "Normal Metabolizer", "CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "2.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "2.0", "CYP2C19": "Rapid Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.	1	f	f	f
6725522	100414	RxNorm:704	{"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}	Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment.	Optional	{"CYP2D6": "Normal Metabolizer", "CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "2.25", "CYP2C19": "n/a"}	{}	{"CYP2D6": "2.25", "CYP2C19": "Rapid Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.	1	f	f	f
6725523	100414	RxNorm:704	{"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}	Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment.	Optional	{"CYP2D6": "Normal Metabolizer", "CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "1.75", "CYP2C19": "n/a"}	{}	{"CYP2D6": "1.75", "CYP2C19": "Rapid Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.	1	f	f	f
6725524	100414	RxNorm:704	{"CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Poor Metabolizer", "CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "0.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "0.0", "CYP2C19": "Rapid Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.	1	f	f	f
6725573	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Strong	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Indeterminate"}	{"CYP2D6": "2.75", "CYP2C19": "n/a"}	{}	{"CYP2D6": "2.75", "CYP2C19": "Indeterminate"}	general	n/a	1	f	f	f
6725525	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "2.5", "CYP2C19": "n/a"}	{}	{"CYP2D6": "2.5", "CYP2C19": "Rapid Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended	1	f	f	f
6725526	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "3.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "3.0", "CYP2C19": "Rapid Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended	1	f	f	f
6725527	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "2.75", "CYP2C19": "n/a"}	{}	{"CYP2D6": "2.75", "CYP2C19": "Rapid Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended	1	f	f	f
6725528	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "4.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "4.0", "CYP2C19": "Rapid Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended	1	f	f	f
6725529	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "≥3.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "≥3.0", "CYP2C19": "Rapid Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended	1	f	f	f
6725530	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "≥3.25", "CYP2C19": "n/a"}	{}	{"CYP2D6": "≥3.25", "CYP2C19": "Rapid Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended	1	f	f	f
6725531	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "≥3.5", "CYP2C19": "n/a"}	{}	{"CYP2D6": "≥3.5", "CYP2C19": "Rapid Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended	1	f	f	f
6725532	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "≥4.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "≥4.0", "CYP2C19": "Rapid Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended	1	f	f	f
6725533	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "≥3.75", "CYP2C19": "n/a"}	{}	{"CYP2D6": "≥3.75", "CYP2C19": "Rapid Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended	1	f	f	f
6725534	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "≥5.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "≥5.0", "CYP2C19": "Rapid Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended	1	f	f	f
6725535	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "≥6.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "≥6.0", "CYP2C19": "Rapid Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended	1	f	f	f
6725536	100414	RxNorm:704	{"CYP2D6": "n/a", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.	Optional	{"CYP2D6": "Indeterminate", "CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "n/a", "CYP2C19": "n/a"}	{}	{"CYP2D6": "n/a", "CYP2C19": "Rapid Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	1	f	f	f
6727202	100416	RxNorm:10689	{"CYP2D6": "Reduced O-desmethyltramadol (active metabolite) formation"}	Use tramadol label recommended age- or weight-specific dosing. If no response and opioid use is warranted, consider non-codeine opioid.	Optional	{"CYP2D6": "Intermediate Metabolizer"}	{"CYP2D6": "0.5"}	{}	{"CYP2D6": "0.5"}	general	n/a	1	f	f	f
6725537	100414	RxNorm:704	{"CYP2D6": "n/a", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.	Optional	{"CYP2D6": "No Result", "CYP2C19": "Rapid Metabolizer"}	{"CYP2D6": "No Result", "CYP2C19": "n/a"}	{}	{"CYP2D6": "No Result", "CYP2C19": "Rapid Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	1	f	f	f
6725538	100414	RxNorm:704	{"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}	Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "0.25", "CYP2C19": "n/a"}	{}	{"CYP2D6": "0.25", "CYP2C19": "Ultrarapid Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.	1	f	f	f
6725539	100414	RxNorm:704	{"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}	Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "0.5", "CYP2C19": "n/a"}	{}	{"CYP2D6": "0.5", "CYP2C19": "Ultrarapid Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.	1	f	f	f
6725540	100414	RxNorm:704	{"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}	Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "0.75", "CYP2C19": "n/a"}	{}	{"CYP2D6": "0.75", "CYP2C19": "Ultrarapid Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.	1	f	f	f
6725541	100414	RxNorm:704	{"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}	Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "1.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "1.0", "CYP2C19": "Ultrarapid Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.	1	f	f	f
6725542	100414	RxNorm:704	{"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}	Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment.	Optional	{"CYP2D6": "Normal Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "1.25", "CYP2C19": "n/a"}	{}	{"CYP2D6": "1.25", "CYP2C19": "Ultrarapid Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.	1	f	f	f
6725543	100414	RxNorm:704	{"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}	Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment.	Optional	{"CYP2D6": "Normal Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "1.5", "CYP2C19": "n/a"}	{}	{"CYP2D6": "1.5", "CYP2C19": "Ultrarapid Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.	1	f	f	f
6725544	100414	RxNorm:704	{"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}	Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment.	Optional	{"CYP2D6": "Normal Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "2.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "2.0", "CYP2C19": "Ultrarapid Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.	1	f	f	f
6725545	100414	RxNorm:704	{"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}	Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment.	Optional	{"CYP2D6": "Normal Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "2.25", "CYP2C19": "n/a"}	{}	{"CYP2D6": "2.25", "CYP2C19": "Ultrarapid Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.	1	f	f	f
6725546	100414	RxNorm:704	{"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}	Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment.	Optional	{"CYP2D6": "Normal Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "1.75", "CYP2C19": "n/a"}	{}	{"CYP2D6": "1.75", "CYP2C19": "Ultrarapid Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.	1	f	f	f
6725547	100414	RxNorm:704	{"CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Poor Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "0.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "0.0", "CYP2C19": "Ultrarapid Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.	1	f	f	f
6725548	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "2.5", "CYP2C19": "n/a"}	{}	{"CYP2D6": "2.5", "CYP2C19": "Ultrarapid Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended	1	f	f	f
6725591	100414	RxNorm:704	{"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}	Initiate therapy with recommended starting dose.	Strong	{"CYP2D6": "Normal Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "2.25", "CYP2C19": "n/a"}	{}	{"CYP2D6": "2.25", "CYP2C19": "Likely Intermediate Metabolizer"}	general	Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.	1	f	f	f
6725549	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "3.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "3.0", "CYP2C19": "Ultrarapid Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended	1	f	f	f
6725550	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "2.75", "CYP2C19": "n/a"}	{}	{"CYP2D6": "2.75", "CYP2C19": "Ultrarapid Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended	1	f	f	f
6725551	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "4.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "4.0", "CYP2C19": "Ultrarapid Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended	1	f	f	f
6725552	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "≥3.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "≥3.0", "CYP2C19": "Ultrarapid Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended	1	f	f	f
6725553	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "≥3.25", "CYP2C19": "n/a"}	{}	{"CYP2D6": "≥3.25", "CYP2C19": "Ultrarapid Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended	1	f	f	f
6725554	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "≥3.5", "CYP2C19": "n/a"}	{}	{"CYP2D6": "≥3.5", "CYP2C19": "Ultrarapid Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended	1	f	f	f
6725555	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "≥4.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "≥4.0", "CYP2C19": "Ultrarapid Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended	1	f	f	f
6725556	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "≥3.75", "CYP2C19": "n/a"}	{}	{"CYP2D6": "≥3.75", "CYP2C19": "Ultrarapid Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended	1	f	f	f
6725557	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "≥5.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "≥5.0", "CYP2C19": "Ultrarapid Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended	1	f	f	f
6725558	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "≥6.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "≥6.0", "CYP2C19": "Ultrarapid Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended	1	f	f	f
6725559	100414	RxNorm:704	{"CYP2D6": "n/a", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.	Optional	{"CYP2D6": "Indeterminate", "CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "n/a", "CYP2C19": "n/a"}	{}	{"CYP2D6": "n/a", "CYP2C19": "Ultrarapid Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	1	f	f	f
6725560	100414	RxNorm:704	{"CYP2D6": "n/a", "CYP2C19": "Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects"}	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.	Optional	{"CYP2D6": "No Result", "CYP2C19": "Ultrarapid Metabolizer"}	{"CYP2D6": "No Result", "CYP2C19": "n/a"}	{}	{"CYP2D6": "No Result", "CYP2C19": "Ultrarapid Metabolizer"}	general	Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	1	f	f	f
6725797	2405438	RxNorm:5521	{"G6PD": "Low-to-no risk of acute hemolytic anemia"}	No reason to avoid based on G6PD status at standard doses	Moderate	{"G6PD": "Variable"}	{}	{}	{"G6PD": "Variable"}	general	Due to X-linked mosaicism, individuals with more than one X chromosome (e.g., females, individuals with Klinefelter syndrome) and heterozygous for one non-deficient (class IV) and one deficient (class I–III) allele may display a normal or a deficient phenotype.	1	f	f	f
6725561	100414	RxNorm:704	{"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "n/a"}	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Moderate	{"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Indeterminate"}	{"CYP2D6": "0.25", "CYP2C19": "n/a"}	{}	{"CYP2D6": "0.25", "CYP2C19": "Indeterminate"}	general	Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.	1	f	f	f
6725562	100414	RxNorm:704	{"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "n/a"}	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Moderate	{"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Indeterminate"}	{"CYP2D6": "0.5", "CYP2C19": "n/a"}	{}	{"CYP2D6": "0.5", "CYP2C19": "Indeterminate"}	general	Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.	1	f	f	f
6725563	100414	RxNorm:704	{"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "n/a"}	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Moderate	{"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Indeterminate"}	{"CYP2D6": "0.75", "CYP2C19": "n/a"}	{}	{"CYP2D6": "0.75", "CYP2C19": "Indeterminate"}	general	Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.	1	f	f	f
6725564	100414	RxNorm:704	{"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "n/a"}	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Moderate	{"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Indeterminate"}	{"CYP2D6": "1.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "1.0", "CYP2C19": "Indeterminate"}	general	Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.	1	f	f	f
6725565	100414	RxNorm:704	{"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "n/a"}	No recommendation	No Recommendation	{"CYP2D6": "Normal Metabolizer", "CYP2C19": "Indeterminate"}	{"CYP2D6": "1.25", "CYP2C19": "n/a"}	{}	{"CYP2D6": "1.25", "CYP2C19": "Indeterminate"}	general	n/a	1	f	f	f
6725566	100414	RxNorm:704	{"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "n/a"}	No recommendation	No Recommendation	{"CYP2D6": "Normal Metabolizer", "CYP2C19": "Indeterminate"}	{"CYP2D6": "1.5", "CYP2C19": "n/a"}	{}	{"CYP2D6": "1.5", "CYP2C19": "Indeterminate"}	general	n/a	1	f	f	f
6725567	100414	RxNorm:704	{"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "n/a"}	No recommendation	No Recommendation	{"CYP2D6": "Normal Metabolizer", "CYP2C19": "Indeterminate"}	{"CYP2D6": "2.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "2.0", "CYP2C19": "Indeterminate"}	general	n/a	1	f	f	f
6725568	100414	RxNorm:704	{"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "n/a"}	No recommendation	No Recommendation	{"CYP2D6": "Normal Metabolizer", "CYP2C19": "Indeterminate"}	{"CYP2D6": "2.25", "CYP2C19": "n/a"}	{}	{"CYP2D6": "2.25", "CYP2C19": "Indeterminate"}	general	n/a	1	f	f	f
6725569	100414	RxNorm:704	{"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "n/a"}	No recommendation	No Recommendation	{"CYP2D6": "Normal Metabolizer", "CYP2C19": "Indeterminate"}	{"CYP2D6": "1.75", "CYP2C19": "n/a"}	{}	{"CYP2D6": "1.75", "CYP2C19": "Indeterminate"}	general	n/a	1	f	f	f
6725570	100414	RxNorm:704	{"CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "n/a"}	Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Strong	{"CYP2D6": "Poor Metabolizer", "CYP2C19": "Indeterminate"}	{"CYP2D6": "0.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "0.0", "CYP2C19": "Indeterminate"}	general	Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.	1	f	f	f
6725798	2405438	RxNorm:5521	{"G6PD": "Unknown risk of acute hemolytic anemia"}	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	Moderate	{"G6PD": "Indeterminate"}	{}	{}	{"G6PD": "Indeterminate"}	general	\N	1	f	f	f
6725574	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Strong	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Indeterminate"}	{"CYP2D6": "4.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "4.0", "CYP2C19": "Indeterminate"}	general	n/a	1	f	f	f
6725575	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Strong	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Indeterminate"}	{"CYP2D6": "≥3.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "≥3.0", "CYP2C19": "Indeterminate"}	general	n/a	1	f	f	f
6725576	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Strong	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Indeterminate"}	{"CYP2D6": "≥3.25", "CYP2C19": "n/a"}	{}	{"CYP2D6": "≥3.25", "CYP2C19": "Indeterminate"}	general	n/a	1	f	f	f
6725577	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Strong	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Indeterminate"}	{"CYP2D6": "≥3.5", "CYP2C19": "n/a"}	{}	{"CYP2D6": "≥3.5", "CYP2C19": "Indeterminate"}	general	n/a	1	f	f	f
6725578	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Strong	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Indeterminate"}	{"CYP2D6": "≥4.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "≥4.0", "CYP2C19": "Indeterminate"}	general	n/a	1	f	f	f
6725579	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Strong	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Indeterminate"}	{"CYP2D6": "≥3.75", "CYP2C19": "n/a"}	{}	{"CYP2D6": "≥3.75", "CYP2C19": "Indeterminate"}	general	n/a	1	f	f	f
6725580	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Strong	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Indeterminate"}	{"CYP2D6": "≥5.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "≥5.0", "CYP2C19": "Indeterminate"}	general	n/a	1	f	f	f
6725581	100414	RxNorm:704	{"CYP2D6": "Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure", "CYP2C19": "n/a"}	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	Strong	{"CYP2D6": "Ultrarapid Metabolizer", "CYP2C19": "Indeterminate"}	{"CYP2D6": "≥6.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "≥6.0", "CYP2C19": "Indeterminate"}	general	n/a	1	f	f	f
6725582	100414	RxNorm:704	{"CYP2D6": "n/a", "CYP2C19": "n/a"}	No recommendation	No Recommendation	{"CYP2D6": "Indeterminate", "CYP2C19": "Indeterminate"}	{"CYP2D6": "n/a", "CYP2C19": "n/a"}	{}	{"CYP2D6": "n/a", "CYP2C19": "Indeterminate"}	general	n/a	1	f	f	f
6725583	100414	RxNorm:704	{"CYP2D6": "n/a", "CYP2C19": "n/a"}	No recommendation	No Recommendation	{"CYP2D6": "No Result", "CYP2C19": "Indeterminate"}	{"CYP2D6": "No Result", "CYP2C19": "n/a"}	{}	{"CYP2D6": "No Result", "CYP2C19": "Indeterminate"}	general	n/a	1	f	f	f
6725592	100414	RxNorm:704	{"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}	Initiate therapy with recommended starting dose.	Strong	{"CYP2D6": "Normal Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "1.75", "CYP2C19": "n/a"}	{}	{"CYP2D6": "1.75", "CYP2C19": "Likely Intermediate Metabolizer"}	general	Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.	1	f	f	f
6725584	100414	RxNorm:704	{"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}	Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "0.25", "CYP2C19": "n/a"}	{}	{"CYP2D6": "0.25", "CYP2C19": "Likely Intermediate Metabolizer"}	general	Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.	1	f	f	f
6725585	100414	RxNorm:704	{"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}	Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "0.5", "CYP2C19": "n/a"}	{}	{"CYP2D6": "0.5", "CYP2C19": "Likely Intermediate Metabolizer"}	general	Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.	1	f	f	f
6725586	100414	RxNorm:704	{"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}	Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "0.75", "CYP2C19": "n/a"}	{}	{"CYP2D6": "0.75", "CYP2C19": "Likely Intermediate Metabolizer"}	general	Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.	1	f	f	f
6725587	100414	RxNorm:704	{"CYP2D6": "Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}	Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Intermediate Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "1.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "1.0", "CYP2C19": "Likely Intermediate Metabolizer"}	general	Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.	1	f	f	f
6725588	100414	RxNorm:704	{"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}	Initiate therapy with recommended starting dose.	Strong	{"CYP2D6": "Normal Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "1.25", "CYP2C19": "n/a"}	{}	{"CYP2D6": "1.25", "CYP2C19": "Likely Intermediate Metabolizer"}	general	Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.	1	f	f	f
6725589	100414	RxNorm:704	{"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}	Initiate therapy with recommended starting dose.	Strong	{"CYP2D6": "Normal Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "1.5", "CYP2C19": "n/a"}	{}	{"CYP2D6": "1.5", "CYP2C19": "Likely Intermediate Metabolizer"}	general	Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.	1	f	f	f
6725590	100414	RxNorm:704	{"CYP2D6": "Normal metabolism of TCAs", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}	Initiate therapy with recommended starting dose.	Strong	{"CYP2D6": "Normal Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "2.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "2.0", "CYP2C19": "Likely Intermediate Metabolizer"}	general	Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.	1	f	f	f
6725799	2405438	RxNorm:1151	{"G6PD": "Low-to-no risk of acute hemolytic anemia"}	No reason to avoid based on G6PD status	Strong	{"G6PD": "Normal"}	{}	{}	{"G6PD": "Normal"}	general	\N	1	f	f	f
6725593	100414	RxNorm:704	{"CYP2D6": "Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects", "CYP2C19": "Reduced metabolism of tertiary amines compared to normal metabolizers"}	Avoid amitriptyline use. If a amitripyline is warranted, consider a 50% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	Optional	{"CYP2D6": "Poor Metabolizer", "CYP2C19": "Likely Intermediate Metabolizer"}	{"CYP2D6": "0.0", "CYP2C19": "n/a"}	{}	{"CYP2D6": "0.0", "CYP2C19": "Likely Intermediate Metabolizer"}	general	Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.	1	f	f	f
